Non-viral DNA vectors and uses thereof for antibody and fusion protein production
Capsid-free ceDNA vectors address the limitations of AAV vectors by enabling efficient production of therapeutic antibodies and fusion proteins, improving packaging capacity and immune compatibility for effective disease treatment.
Patent Information
- Application Number
- JP2024141968
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-06-04
- Filing Date
- 2024-08-23
- Publication Date
- 2024-12-03
AI Technical Summary
Existing adeno-associated virus (AAV) vectors for gene therapy are limited by small viral packaging capacity, immune response, and slow gene expression, which restricts the delivery and expression of therapeutic antibodies and fusion proteins.
Development of capsid-free, covalently closed-ended DNA (ceDNA) vectors with symmetrical or asymmetrical inverted terminal repeats (ITRs) for expressing therapeutic antibodies and fusion proteins, allowing for efficient and controlled production in cells without viral capsids.
The ceDNA vectors enable high-yield production of therapeutic antibodies and fusion proteins, overcoming the limitations of AAV vectors by providing enhanced packaging capacity and immune compatibility, enabling treatment of diseases such as rheumatoid arthritis and Crohn's disease.
Smart Images

Figure 2024167281000001_ABST
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 62 / 630,670, filed February 14, 2018, U.S. Provisional Patent Application No. 62 / 680,087, filed June 4, 2018, U.S. Provisional Patent Application No. 62 / 630,676, filed February 14, 2018, and U.S. Provisional Patent Application No. 62 / 680,092, filed June 4, 2018, the contents of each of which are incorporated herein by reference in their entirety.
[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy created on February 13, 2019 is named 080170-091100-WOPT_SL.txt and is 128,788 bytes in size.
[0003] The present invention relates to the field of gene therapy, including the production of non-viral vectors for expressing transgenes or isolated polynucleotides in subjects or cells. The present disclosure also relates to nucleic acid constructs, promoters, vectors, and host cells containing polynucleotides, as well as methods for delivering exogenous DNA sequences to target cells, tissues, organs, or organisms. For example, the present disclosure provides a method for expressing antibodies, such as therapeutic antibodies, from cells using non-viral DNA vectors. The present disclosure also provides a method for expressing fusion proteins, such as therapeutic fusion proteins, from cells using non-viral DNA vectors. The methods and compositions can be applied, for example, to the production of commercially available antibodies or fusion proteins, or to the treatment of diseases by expressing therapeutic antibodies or fusion proteins in cells or tissues of subjects in need of treatment. [Background technology]
[0004] Gene therapy aims to improve the clinical outcomes of patients suffering from either genetic mutations or acquired diseases caused by abnormalities in gene expression profiles. Gene therapy includes the treatment or prevention of medical conditions resulting from defective genes or dysregulation or expression, e.g., underexpression or overexpression, which can lead to disorders, diseases, malignancies, etc. For example, diseases or disorders caused by defective genes can be treated, prevented, or ameliorated by delivering corrective genetic material to the patient, or by modifying or silencing the defective gene with corrective genetic material to the patient, resulting in therapeutic expression of the genetic material in the patient's body.
[0005] The basis of gene therapy is the delivery of an active gene product (sometimes referred to as a transgene) to a transcription cassette, which may result in, for example, a positive gain-of-function effect, a negative loss-of-function effect, or another outcome. Such outcomes may result from the expression of an activating antibody or fusion protein or an inhibitory (neutralizing) antibody or fusion protein. Gene therapy can also be used to treat diseases or malignancies caused by other factors. Human monogenic disorders can be treated by the delivery and expression of a normal gene into target cells. The delivery and expression of a corrective gene in a patient's target cells can be carried out through many methods, including the use of engineered viruses and viral gene delivery vectors. Among the many available virus-derived vectors (e.g., recombinant retroviruses, lentiviruses, adenoviruses, etc.), recombinant adeno-associated viruses (rAAVs) have gained popularity as versatile vectors in gene therapy.
[0006] Adeno-associated viruses (AAVs) belong to the Parvoviridae family and, more specifically, constitute the Dependoparvovirus genus. AAV-derived vectors (i.e., recombinant AAVs (rAVVs) or AAV vectors) are attractive for delivering genetic material because (i) they can infect (transduce) a wide variety of non-dividing and dividing cell types, including muscle cells and neurons; (ii) they lack viral structural genes, thereby reducing host cell responses to viral infection, such as interferon-mediated responses; (iii) wild-type viruses are considered nonpathogenic in humans; (iv) in contrast to wild-type AAVs that can integrate into host cell genomes, replication-deficient AAV vectors lack the rep gene and generally persist episomally, thus limiting the risk of insertional mutagenesis or genotoxicity; and (v) compared to other vector systems, AAV vectors are generally considered relatively poor immunogens and therefore do not elicit significant immune responses (see ii), thereby allowing sustained vector DNA and potentially long-term expression of therapeutic transgenes.
[0007] However, the use of AAV particles as gene delivery vectors presents several significant drawbacks. One significant drawback associated with rAAV is the limited viral packaging capacity of approximately 4.5 kb of heterologous DNA (Dong et al., 1996; Athanasopoulos et al., 2004; Lai et al., 2010). As a result, the use of AAV vectors is limited to protein-coding capacities of less than 150,000 Da. A second drawback is the need to screen rAAV gene therapy candidates for the presence of neutralizing antibodies that eliminate the vector from patients as a result of the prevalence of wild-type AAV infection in the population. A third drawback relates to capsid immunogenicity, which prevents re-administration in patients who were not eliminated from initial treatment. In response to vectors that effectively act as a "booster" shot, the patient's immune system may stimulate the production of high-titer anti-AAV antibodies that prevent future treatment. Several recent reports have demonstrated a relationship between immunogenicity in high-dose settings. Another notable drawback is the relatively slow onset of AAV-mediated gene expression, given that single-stranded AAV DNA must be converted to double-stranded DNA prior to heterologous gene expression.
[0008] Additionally, conventional AAV virions with capsids are produced by introducing one or more plasmids containing the AAV genome, rep gene, and cap gene (Grimm et al., 1998). However, such encapsidated AAV viral vectors have been shown to inefficiently transduce certain cell and tissue types, and the capsids also induce immune responses.
[0009] Thus, the use of adeno-associated virus (AAV) vectors for gene therapy is limited due to a single administration to the patient (due to the patient's immune response), the limited range of transgene genetic material suitable for delivery in AAV vectors due to minimal viral packaging capacity (approximately 4.5 kb), and slow AAV-mediated gene expression.
[0010] There is a need in the art for techniques that allow for the expression of therapeutic antibodies (e.g., secreted antibodies or intrabodies) or fusion proteins (e.g., receptor extracellular domain-Fc fusions) in cells, tissues, or subjects, or for the purpose of generating antibodies or fusion proteins in vitro or in vivo for purification and / or commercial production. Additionally, there remains a significant unmet need for regulatable recombinant DNA vectors with improved production and / or expression characteristics for improved production of antibodies (e.g., therapeutic antibodies) and fusion proteins (e.g., therapeutic fusion proteins) compared to existing or conventional methods or vectors. Summary of the Invention [Means for solving the problem]
[0011] The technology described herein relates to methods and compositions for the expression of antibodies and fusion proteins (such as therapeutic antibodies and fusion proteins) using capsid-free (e.g., non-viral) DNA vectors with covalently closed ends (referred to herein as "closed-end DNA vectors" or "ceDNA vectors"). These ceDNA vectors can be used to produce antibodies and fusion proteins for disease treatment, malignant tumor treatment, monitoring, and diagnosis, as well as commercially available antibodies or fusion proteins. One exemplary antibody is an anti-tumor necrosis factor antibody or antibody-binding fragment thereof, including, but not limited to, the monoclonal antibody adalimumab (Humira™), which can be expressed in a subject's cells or tissues using the ceDNA vectors described herein. Such therapeutic antibodies can be used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
[0012] Thus, the invention described herein relates to capsid-free (e.g., non-viral) DNA vectors with covalently closed ends (referred to herein as "closed-end DNA vectors" or "ceDNA vectors") that contain heterologous genes encoding antibodies (e.g., light chains, heavy chains, frameworks, Fabs', single-chain antibodies) or antigen-binding fragments thereof, to enable intracellular expression of antibodies, e.g., secreted antibodies or intrabodies. The present invention also relates to ceDNA vectors that contain heterologous genes encoding fusion proteins, to enable intracellular expression of the fusion proteins. Such expressed antibodies or fusion proteins may be therapeutic antibodies or fusion proteins, and / or the applied techniques may be used in the production of antibodies or fusion proteins for commercial purposes. In particular, the techniques described herein relate to improved production of antibodies and fusion proteins using ceDNA vectors.
[0013] The ceDNA vectors for producing the antibodies and fusion proteins described herein are non-encapsid-containing linear double-stranded DNA molecules formed from continuous strands of complementary DNA with covalently closed ends (linear, continuous, and non-encapsidated structures), and include a 5' inverted terminal repeat (ITR) sequence and a 3' ITR sequence, where the 5' ITR and 3' ITR can have the same symmetrical three-dimensional organization relative to each other (i.e., symmetric or substantially symmetric), or alternatively, the 5' ITR and 3' ITR can have different three-dimensional organizations relative to each other (i.e., asymmetric ITR). Furthermore, the ITRs can be derived from the same or different serotypes. In some embodiments, the ceDNA vectors can contain ITR sequences that have a symmetrical three-dimensional organization (i.e., they are the same or are mirror images of each other) such that their structures are the same shape in geometric space or have the same A, C-C', and B-B' loops in three-dimensional space. In some embodiments, one ITR may be derived from one AAV serotype and the other ITR may be derived from a different AAV serotype.
[0014] Thus, some aspects of the technology described herein relate to ceDNA vectors for improved expression and / or production of antibodies or fusion proteins, comprising ITR sequences selected from: (i) at least one WT ITR and at least one modified AAV inverted terminal repeat (ITR) (e.g., an asymmetric modified ITR); (ii) two modified ITRs (e.g., an asymmetric modified ITR) in which the mod-ITR pair have different three-dimensional spatial configurations relative to each other; (iii) a symmetric or substantially symmetric WT-WT ITR pair in which each WT-ITR has the same three-dimensional spatial configuration; or (iv) a symmetric or substantially symmetric modified ITR pair in which each mod-ITR has the same three-dimensional spatial configuration. The ceDNA vectors disclosed herein can be produced in eukaryotic cells and thus lack the prokaryotic DNA modifications and bacterial endotoxin contamination that insect cells experience.
[0015] The methods and compositions described herein relate, in part, to the discovery of non-viral, capsid-free DNA vectors (ceDNA vectors) with covalently closed ends that can be used to express at least one antibody and / or fusion protein, or multiple antibodies and / or fusion proteins, from cells. The methods and compositions can be applied, for example, to the production of commercially available antibodies or fusion proteins, or for the purpose of treating disease with therapeutic antibodies or fusion proteins.
[0016] Thus, in one aspect, a DNA vector (e.g., a ceDNA vector) is provided herein, comprising at least one heterologous nucleic acid encoding at least one transgene encoding an antibody or antigen-binding fragment thereof, or a fusion protein thereof, operably linked to a promoter located between two different AAV inverted terminal repeats (ITRs), one of the ITRs comprising a functional AAV terminal cleavage site and a Rep binding site, one of the ITRs comprising a deletion, insertion, or substitution relative to the other ITR, the transgene being an antibody or fragment thereof (e.g., an antigen-binding fragment thereof) or a fusion protein, wherein the DNA, when digested with a restriction enzyme having a single recognition site on the DNA vector, has the presence of a characteristic band of linear, continuous DNA compared to a linear, discontinuous DNA control when analyzed on a non-denaturing gel. Other aspects include the delivery of therapeutic antibodies or fusion proteins by in vivo expression from a ceDNA vector as described herein, and further the treatment of various diseases using such antibodies or fusion proteins. Cells comprising the ceDNA vectors described herein are also contemplated herein.
[0017] Aspects of the present invention relate to methods for producing ceDNA vectors useful for producing antibodies or fusion proteins in the cells described herein or for expressing antibodies or fusion proteins. Other embodiments relate to ceDNA vectors produced by the methods provided herein. In one embodiment, a capsid-free (e.g., non-viral) DNA vector (ceDNA vector) for producing an antibody or fusion protein is obtained from a plasmid (referred to herein as a "ceDNA-plasmid") containing a polynucleotide expression construct template comprising, in that order, an initial 5' inverted terminal repeat (e.g., AAV ITR), a heterologous nucleic acid sequence, and a 3' ITR (e.g., AAV ITR), wherein the 5' ITR and 3' ITR can be asymmetric or symmetric relative to each other (e.g., WT-ITR or modified symmetric ITR), as defined herein.
[0018] The ceDNA vectors for producing the antibodies or fusion proteins disclosed herein can be obtained by several means that will be known to those skilled in the art upon reading this disclosure. For example, the polynucleotide expression construct template used to generate the ceDNA vectors of the present invention can be a ceDNA-plasmid, a ceDNA-bacmid, and / or a ceDNA-baculovirus. In one embodiment, the ceDNA-plasmid contains, for example, a promoter operably linked to a transgene, a restriction cloning site operably positioned between the ITRs (e.g., SEQ ID NOs: 123 and / or 124) into which an expression cassette containing a nucleic acid encoding an antibody or antigen-binding fragment thereof or a fusion protein, and / or a reporter gene can be inserted. In some embodiments, the ceDNA vectors for producing antibodies or fusion proteins are produced from polynucleotide templates (e.g., ceDNA-plasmid, ceDNA-bacmid, ceDNA-baculovirus) containing symmetric or asymmetric ITRs (modified or wild-type ITRs).
[0019] In permissive host cells, for example, in the presence of Rep, a polynucleotide template having at least two ITRs replicates to produce a ceDNA vector for producing an antibody or fusion protein. ceDNA vector production involves two steps: first, Rep protein-mediated excision ("rescue") of the template from a template backbone (e.g., ceDNA-plasmid, ceDNA-bacmid, ceDNA-baculovirus genome, etc.), and second, Rep-mediated replication of the excised ceDNA vector. Rep proteins and Rep binding sites of various AAV serotypes are well known to those skilled in the art. Those skilled in the art will understand that a Rep protein is selected from a serotype that binds to and replicates a nucleic acid sequence based on at least one functional ITR. For example, if a replication-competent ITR is derived from AAV serotype 2, the corresponding Rep will be derived from an AAV serotype that cooperates with that serotype; for example, an AAV2 ITR cooperates with AAV2 or AAV4 Rep, but not with AAV5 Rep. Upon replication, the covalently closed-end ceDNA vector continues to accumulate in permissive cells, and the ceDNA vector preferably accumulates under standard replication conditions and in the presence of Rep proteins sufficiently stably over long periods of time, for example in amounts of at least 1 pg / cell, preferably at least 2 pg / cell, preferably at least 3 pg / cell, more preferably at least 4 pg / cell, and even more preferably at least 5 pg / cell.
[0020] Thus, one aspect of the present invention relates to a process for producing a ceDNA vector for antibody or fusion protein production, comprising: a) incubating a population of host cells (e.g., insect cells) harboring a polynucleotide expression construct template (e.g., ceDNA-plasmid, ceDNA-bacmid, and / or ceDNA-baculovirus) under conditions effective, and for a time sufficient, to induce production of the ceDNA vector in the host cells in the presence of Rep proteins, where the host cells lack viral capsid-encoding sequences; and b) harvesting and isolating the ceDNA vector from the host cells. The presence of Rep proteins induces replication of the vector polynucleotide with modified ITRs to produce the ceDNA vector for antibody or fusion protein production in the host cells. However, viral particles (e.g., AAV virions) are not expressed. Therefore, there is no virion-imposed size limit.
[0021] The presence of a ceDNA vector useful for producing an antibody or fusion protein isolated from a host cell can be confirmed by digesting the DNA isolated from the host cell with a restriction enzyme that has a single recognition site on the ceDNA vector and analyzing the digested DNA material on denaturing and non-denaturing gels to confirm the presence of a characteristic linear, continuous DNA band compared to linear, discontinuous DNA.
[0022] For the purposes of this disclosure, the transgene expressed by the ceDNA encodes an antibody or antibody-binding fragment or a fusion protein. Antibodies and fusion proteins are well known in the art and can bind to any protein of interest, including, but not limited to, ligands, receptors, toxins, hormones, enzymes, or cell surface proteins, or pathogen or viral proteins or antigens, as well as pre- and post-translationally modified proteins such as glycoproteins or sumoylated proteins (e.g., anti-SUMO2 / 3 antibodies). Antibodies and antigen-binding fragments also include antibodies that bind to any antigen, including, but not limited to, nucleic acids, such as DNA (e.g., anti-dsDNA antibodies), RNA (e.g., anti-RNA-binding antibodies). In some embodiments, the antibody produced by the ceDNA vector disclosed herein is a neutralizing antibody or antigen-binding fragment thereof. Exemplary target genes and proteins of interest are described in detail in the sections on uses and treatments herein.
[0023] Also provided herein are methods for expressing therapeutic antibodies or fusion proteins in cells or subjects using ceDNA vectors. Such antibodies or fusion proteins can be used to treat diseases. Accordingly, provided herein are methods for treating diseases, comprising administering a ceDNA vector encoding a therapeutic antibody or fusion protein to a subject in need thereof. In other embodiments, the therapeutic antibody or fusion protein can be used to target malignant cells, monitor specific proteins, or for diagnostic purposes.
[0024] In some embodiments, the application may be defined in any of the following paragraphs: 1. A capsid-free closed-end DNA (ceDNA) vector, comprising: A ceDNA vector comprising at least one heterologous nucleotide sequence between adjacent inverted terminal repeats (ITRs), wherein the at least one heterologous nucleotide sequence encodes at least one antibody and / or fusion protein. 1. The ceDNA vector of claim 1, wherein at least one heterologous nucleotide sequence encodes an antibody. 2. The ceDNA vector of claim 2, wherein the antibody is a full-length antibody, Fab, Fab', single-domain antibody, or single-chain antibody (scFv). 3. The ceDNA vector of claim 3, wherein at least one heterologous nucleotide sequence encodes a single domain antibody or a single chain antibody. 4. The ceDNA vector of claim 4, wherein the at least one heterologous nucleotide sequence further encodes a secretory leader sequence upstream of the single domain antibody or single chain antibody. 5. The ceDNA vector of any one of claims 1 to 3, wherein the first heterologous nucleotide sequence encodes a heavy chain variable region and the second heterologous nucleotide sequence encodes a light chain variable region. 6. The cDNA vector of claim 4, wherein the first heterologous nucleotide sequence encodes a heavy chain variable region and a heavy chain constant region or portions thereof, and the second heterologous nucleotide sequence encodes a light chain variable region and a light chain constant region or portions thereof. 7. The ceDNA vector of claim 6 or claim 7, wherein the first heterologous nucleotide sequence and / or the second heterologous nucleotide sequence further encodes a secretion leader sequence upstream of the heavy chain variable region and / or the light chain variable region. 8. The ceDNA vector of any one of claims 1 to 8, wherein the antibody is a human or humanized antibody. 9. The ceDNA vector of any one of claims 1 to 9, wherein the antibody is an IgG, IgA, IgD, IgM, or IgE antibody. 10. The ceDNA vector of claim 10, wherein the antibody is an IgG antibody. 11. The ceDNA vector of claim 11, wherein the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody. 12. The ceDNA vector of any one of claims 1 to 12, wherein the antibody binds to at least one target selected from the targets listed in Tables 1, 2, 3A, 3B, 4, and 5. 13. The ceDNA vector of claim 1, wherein at least one heterologous nucleotide sequence encodes a fusion protein. 14. The ceDNA vector of claim 14, wherein the at least one heterologous nucleotide sequence further encodes a secretory leader sequence upstream of the fusion protein. 15. The ceDNA vector of claim 14 or claim 15, wherein the fusion protein comprises at least one receptor extracellular domain fused to an Fc region. 16. The ceDNA vector of claim 16, wherein the receptor extracellular domain is the extracellular domain of a receptor selected from CTLA-4, VEGFR1, VEGFR2, LFA-3, TNFR, IL-1R1, IL-1R1, IL-1RAcP, and ACVR2A. 17. The ceDNA vector of any one of claims 1 to 17, wherein the antibody or fusion protein is selected from the antibodies and fusion proteins of Tables 1, 2, 3A, 3B, 4, or 5. 18. The ceDNA vector of any one of claims 1 to 18, wherein the ceDNA vector comprises one or more polyA sites. 19. The ceDNA vector of any one of claims 1 to 19, wherein the ceDNA vector comprises at least one promoter operably linked to at least one heterologous nucleotide sequence. 20. The ceDNA vector of any one of claims 1 to 20, wherein at least one heterologous nucleotide sequence is a cDNA. 21. The ceDNA vector of any one of claims 1 to 21, wherein at least one ITR comprises a functional terminal resolution site and a Rep binding site. 22. The ceDNA vector of any one of claims 1 to 22, wherein one or both of the ITRs are derived from a virus selected from a parvovirus, a dependovirus, and an adeno-associated virus (AAV). 23. The ceDNA vector of any one of claims 1 to 23, wherein the flanking ITRs are symmetric or asymmetric. 24. The ceDNA vector of claim 24, wherein the flanking ITRs are symmetrical or substantially symmetrical. 25. The ceDNA vector of claim 24, wherein the flanking ITRs are asymmetric. 26. The ceDNA vector of any one of claims 1 to 26, wherein one or both of the ITRs are wild-type, or both of the ITRs are wild-type. 27. The ceDNA vector of any one of claims 1 to 27, wherein the adjacent ITRs are derived from different viral serotypes. 28. The ceDNA vector of any one of claims 1 to 28, wherein the flanking ITRs are derived from pairs of viral serotypes shown in Table 6. 29. The ceDNA vector of any one of claims 1 to 29, wherein one or both of the ITRs comprises a sequence selected from the sequences in Table 7. 30. The ceDNA vector of any one of claims 1 to 30, wherein at least one of the ITRs is altered from the wild-type AAV ITR sequence by a deletion, addition, or substitution that affects the overall three-dimensional conformation of the ITR. 31. The ceDNA vector of any one of claims 1 to 31, wherein one or both of the ITRs are derived from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12. 32. The ceDNA vector of any one of claims 1 to 32, wherein one or both of the ITRs are synthetic. 33. The ceDNA vector of any one of claims 1 to 33, wherein one or both of the ITRs are not wild-type, or both of the ITRs are not wild-type. 34. The ceDNA vector of any one of claims 1 to 34, wherein one or both of the ITRs are modified by a deletion, insertion, and / or substitution in at least one of the ITR regions selected from A, A', B, B', C, C', D, and D'. 35. The ceDNA vector of claim 35, wherein the deletion, insertion, and / or substitution results in the deletion of all or part of the stem-loop structure normally formed by the A, A', B, B'C, or C' regions. 36. The ceDNA vector of any one of claims 1 to 36, wherein one or both of the ITRs have been modified by deletion, insertion, and / or substitution, resulting in the loss of all or part of the stem-loop structure normally formed by the B and B' regions. 37. The ceDNA vector of any one of claims 1 to 37, wherein one or both of the ITRs have been modified by deletion, insertion, and / or substitution, resulting in the loss of all or part of the stem-loop structure normally formed by the C and C' regions. 38. The ceDNA vector of any one of claims 1 to 38, wherein one or both of the ITRs have been modified by a deletion, insertion, and / or substitution that results in the deletion of part of the stem-loop structure normally formed by the B and B' regions and / or part of the stem-loop structure normally formed by the C and C' regions. 39. The ceDNA vector of any one of claims 1 to 39, wherein one or both of the ITRs comprises a single stem-loop structure in a region that normally comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. 40. The ceDNA vector of any one of claims 1 to 40, wherein one or both of the ITRs comprises a single stem and two loops in a region that typically comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. 41. The ceDNA vector of any one of claims 1 to 41, wherein one or both of the ITRs comprises a single stem and a single loop in a region that typically comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. 42. The ceDNA vector of any one of claims 1 to 42, wherein both ITRs are modified in a manner that results in overall three-dimensional symmetry when the ITRs are inverted relative to each other. 43. The ceDNA vector of any one of claims 1-43, wherein one or both of the ITRs comprises a sequence selected from the sequences of Tables 7, 9A, 9B, and 10. 44. The ceDNA vector of any one of claims 1 to 44, wherein at least one heterologous nucleotide sequence is under the control of at least one regulatory switch. 45. The ceDNA vector of claim 45, wherein the at least one regulatory switch is selected from a binary regulatory switch, a small molecule regulatory switch, a passcode regulatory switch, a nucleic acid-based regulatory switch, a post-transcriptional regulatory switch, a radiation- or ultrasound-controlled regulatory switch, a hypoxia-mediated regulatory switch, an inflammatory response regulatory switch, a shear-activated regulatory switch, and a kill switch. 46. A method for expressing an antibody or fusion protein in a cell, comprising contacting the cell with a ceDNA vector according to any one of claims 1 to 46. 47. The method of claim 47, wherein the contacted cell is a eukaryotic cell. 48. The method of claim 47 or claim 48, wherein the cell is in vitro or in vivo. 49. The method of any one of claims 47 to 49, wherein at least one heterologous nucleotide sequence is codon-optimized for expression in a eukaryotic cell. 50. The method of any one of claims 47 to 50, wherein the antibody or fusion protein is secreted from the cell. 51. The method of any one of claims 47 to 50, wherein the antibody or fusion protein is retained in the cell. 52. A method for treating a patient with a therapeutic antibody or a therapeutic fusion protein, comprising administering to a subject a ceDNA vector described in any one of claims 1 to 46, wherein at least one heterologous nucleotide sequence encodes a therapeutic antibody or a therapeutic fusion protein. 53. The method of claim 53, wherein the subject has a disease or disorder selected from cancer, an autoimmune disease, a neurodegenerative disorder, hypercholesterolemia, acute organ rejection, multiple sclerosis, postmenopausal osteoporosis, a skin condition, asthma, or hemophilia. 54. The method of claim 53, wherein the cancer is selected from a solid tumor, a soft tissue sarcoma, a lymphoma, and a leukemia. 55. The method of claim 53, wherein the autoimmune disease is selected from rheumatoid arthritis and Crohn's disease. 56. The method of claim 53, wherein the skin condition is selected from psoriasis and atopic dermatitis. 57. The method of claim 53, wherein the neurodegenerative disorder is Alzheimer's disease. 58. A pharmaceutical composition comprising a ceDNA vector according to any one of claims 1 to 46. 59. A cell comprising a ceDNA vector according to any one of claims 1 to 46. 60. A composition comprising a ceDNA vector according to any one of claims 1 to 46 and a lipid. 61. The composition of claim 61, wherein the lipid is a lipid nanoparticle (LNP). 62. A kit comprising a ceDNA vector according to any one of claims 1 to 46, or a composition according to claim 61 or 62, or a cell according to claim 60. 63. A method for producing an antibody or fusion protein, comprising culturing the cell of claim 60 under conditions suitable for producing the antibody or fusion protein. 64. The method of claim 64, further comprising isolating the antibody or fusion protein.
[0025] In some embodiments, one aspect of the technology described herein relates to a non-viral capsid-free DNA vector (ceDNA vector) with covalently closed ends, the ceDNA vector comprising at least one heterologous nucleotide sequence operably positioned between two inverted terminal repeats, where the ITR sequences can be asymmetric, or symmetric, or substantially symmetric, as these terms are defined herein, and at least one of the ITRs comprises a functional terminal resolution site and a Rep binding site, and optionally the heterologous nucleic acid sequence encodes a transgene (e.g., an antibody or a fusion protein), and the vector is not present in a viral capsid.
[0026] These and other aspects of the invention are described in further detail below. In certain embodiments, for example, the following are provided: (Item 1) A capsid-free closed-end DNA (ceDNA) vector, A ceDNA vector comprising at least one heterologous nucleotide sequence between adjacent inverted terminal repeats (ITRs), wherein the at least one heterologous nucleotide sequence encodes at least one antibody and / or fusion protein. (Item 2) Item 1, wherein the at least one heterologous nucleotide sequence encodes an antibody. (Item 3) 3. The ceDNA vector of item 2, wherein the antibody is a full-length antibody, Fab, Fab', single-domain antibody, or single-chain antibody (scFv). (Item 4) 4. The ceDNA vector of item 3, wherein at least one heterologous nucleotide sequence encodes a single domain antibody or a single chain antibody. (Item 5) 5. The ceDNA vector of item 4, wherein the at least one heterologous nucleotide sequence further encodes a secretory leader sequence upstream of the single domain antibody or single chain antibody. (Item 6) 4. The ceDNA vector of any one of items 1 to 3, wherein the first heterologous nucleotide sequence encodes a heavy chain variable region and the second heterologous nucleotide sequence encodes a light chain variable region. (Item 7) 5. The cDNA vector of item 4, wherein the first heterologous nucleotide sequence encodes a heavy chain variable region and a heavy chain constant region or a portion thereof, and the second heterologous nucleotide sequence encodes a light chain variable region and a light chain constant region or a portion thereof. (Item 8) 8. The ceDNA vector of claim 6 or 7, wherein the first heterologous nucleotide sequence and / or the second heterologous nucleotide sequence further encodes a secretory leader sequence upstream of the heavy chain variable region and / or the light chain variable region. (Item 9) 9. The ceDNA vector of any one of items 1 to 8, wherein the antibody is a human or humanized antibody. (Item 10) 10. The ceDNA vector of any one of items 1 to 9, wherein the antibody is an IgG, IgA, IgD, IgM, or IgE antibody. (Item 11) 11. The ceDNA vector of item 10, wherein the antibody is an IgG antibody. (Item 12) 12. The ceDNA vector of item 11, wherein the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody. (Item 13) 13. The ceDNA vector of any one of items 1 to 12, wherein the antibody binds to at least one target selected from the targets listed in Tables 2, 3A, 3B, 4, and 5. (Item 14) Item 1, wherein the at least one heterologous nucleotide sequence encodes a fusion protein. (Item 15) 15. The ceDNA vector of item 14, wherein the at least one heterologous nucleotide sequence further encodes a secretory leader sequence upstream of the fusion protein. (Item 16) 16. The ceDNA vector of claim 14 or 15, wherein the fusion protein comprises at least one receptor extracellular domain fused to an Fc region. (Item 17) 17. The ceDNA vector of item 16, wherein the receptor extracellular domain is the extracellular domain of a receptor selected from CTLA-4, VEGFR1, VEGFR2, LFA-3, TNFR, IL-1R1, IL-1R1, IL-1RAcP, and ACVR2A. (Item 18) 18. The ceDNA vector of any one of items 1 to 17, wherein the antibody or fusion protein is selected from the antibodies and fusion proteins of Tables 1, 2, 3A, 3B, 4, or 5. (Item 19) 19. The ceDNA vector of any one of items 1 to 18, wherein the ceDNA vector comprises one or more polyA sites. (Item 20) 20. The ceDNA vector of any one of items 1 to 19, wherein the ceDNA vector comprises at least one promoter operably linked to at least one heterologous nucleotide sequence. (Item 21) 21. The ceDNA vector of any one of items 1 to 20, wherein at least one heterologous nucleotide sequence is a cDNA. (Item 22) 22. The ceDNA vector of any one of items 1 to 21, wherein at least one ITR comprises a functional terminal resolution site and a Rep binding site. (Item 23) 23. The ceDNA vector of any one of items 1 to 22, wherein one or both of the ITRs are derived from a virus selected from a parvovirus, a dependovirus, and an adeno-associated virus (AAV). (Item 24) 24. The ceDNA vector of any one of items 1 to 23, wherein the flanking ITRs are symmetric or asymmetric. (Item 25) 25. The ceDNA vector of item 24, wherein the flanking ITRs are symmetrical or substantially symmetrical. (Item 26) 25. The ceDNA vector of item 24, wherein the flanking ITRs are asymmetric. (Item 27) 27. The ceDNA vector of any one of items 1 to 26, wherein one or both of the ITRs are wild-type, or both of the ITRs are wild-type. (Item 28) 28. The ceDNA vector of any one of items 1 to 27, wherein the flanking ITRs are derived from different viral serotypes. (Item 29) 29. The ceDNA vector of any one of items 1 to 28, wherein the flanking ITRs are derived from a pair of viral serotypes shown in Table 6. (Item 30) 30. The ceDNA vector of any one of items 1 to 29, wherein one or both of the ITRs comprises a sequence selected from the sequences in Table 7. (Item 31) 31. The ceDNA vector of any one of items 1 to 30, wherein at least one of the ITRs is altered from the wild-type AAV ITR sequence by a deletion, addition, or substitution that affects the overall three-dimensional conformation of the ITR. (Item 32) 32. The ceDNA vector of any one of items 1 to 31, wherein one or both of the ITRs are derived from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12. (Item 33) 33. The ceDNA vector of any one of items 1 to 32, wherein one or both of the ITRs are synthetic. (Item 34) 34. The ceDNA vector of any one of items 1 to 33, wherein one or both of the ITRs are not wild-type, or both of the ITRs are not wild-type. (Item 35) 35. The ceDNA vector of any one of items 1 to 34, wherein one or both of the ITRs are modified by a deletion, insertion, and / or substitution in at least one of the ITR regions selected from A, A', B, B', C, C', D, and D'. (Item 36) 36. The ceDNA vector of item 35, wherein the deletion, insertion, and / or substitution results in the deletion of all or part of the stem-loop structure normally formed by the A, A', B, B' C, or C' region. (Item 37) 37. The ceDNA vector of any one of items 1 to 36, wherein one or both of the ITRs are modified by deletion, insertion, and / or substitution, resulting in the loss of all or part of the stem-loop structure normally formed by the B and B' regions. (Item 38) 38. The ceDNA vector of any one of items 1 to 37, wherein one or both of the ITRs are modified by deletion, insertion, and / or substitution, resulting in the loss of all or part of the stem-loop structure normally formed by the C and C' regions. (Item 39) 39. The ceDNA vector of any one of items 1 to 38, wherein one or both of the ITRs is modified by a deletion, insertion, and / or substitution that results in the loss of part of the stem-loop structure normally formed by the B and B' regions and / or part of the stem-loop structure normally formed by the C and C' regions. (Item 40) 40. The ceDNA vector of any one of items 1 to 39, wherein one or both of the ITRs comprises a single stem-loop structure in a region that normally comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. (Item 41) 41. The ceDNA vector of any one of items 1 to 40, wherein one or both of the ITRs comprises a single stem and two loops in a region that typically comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. (Item 42) 42. The ceDNA vector of any one of items 1 to 41, wherein one or both of the ITRs comprises a single stem and a single loop in a region that typically comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. (Item 43) 43. The ceDNA vector of any one of items 1 to 42, wherein both ITRs are modified in such a manner as to result in overall three-dimensional symmetry when the ITRs are inverted relative to each other. (Item 44) 44. The ceDNA vector of any one of items 1 to 43, wherein one or both of the ITRs comprises a sequence selected from the sequences of Tables 7, 9A, 9B, and 10. (Item 45) 45. The ceDNA vector of any one of items 1 to 44, wherein at least one heterologous nucleotide sequence is under the control of at least one regulatory switch. (Item 46) 46. The ceDNA vector of item 45, wherein the at least one regulatory switch is selected from a binary regulatory switch, a small molecule regulatory switch, a passcode regulatory switch, a nucleic acid-based regulatory switch, a post-transcriptional regulatory switch, a radiation- or ultrasound-controlled regulatory switch, a hypoxia-mediated regulatory switch, an inflammatory response regulatory switch, a shear-activated regulatory switch, and a kill switch. (Item 47) 47. A method for expressing an antibody or fusion protein in a cell, comprising contacting the cell with a ceDNA vector according to any one of items 1 to 46. (Item 48) 48. The method of claim 47, wherein the contacted cell is a eukaryotic cell. (Item 49) 49. The method of claim 47 or 48, wherein the cell is in vitro or in vivo. (Item 50) 50. The method of any one of items 47 to 49, wherein at least one heterologous nucleotide sequence is codon-optimized for expression in said eukaryotic cell. (Item 51) 51. The method of any one of items 47 to 50, wherein the antibody or fusion protein is secreted from the cell. (Item 52) 51. The method according to any one of items 47 to 50, wherein the antibody or fusion protein is retained in the cell. (Item 53) 47. A method for treating a subject with a therapeutic antibody or a therapeutic fusion protein, the method comprising administering to the subject a ceDNA vector according to any one of items 1 to 46, wherein at least one heterologous nucleotide sequence encodes the therapeutic antibody or therapeutic fusion protein. (Item 54) 54. The method of claim 53, wherein the subject has a disease or disorder selected from cancer, an autoimmune disease, a neurodegenerative disorder, hypercholesterolemia, acute organ rejection, multiple sclerosis, postmenopausal osteoporosis, a skin condition, asthma, or hemophilia. (Item 55) 54. The method of claim 53, wherein the cancer is selected from a solid tumor, a soft tissue sarcoma, a lymphoma, and a leukemia. (Item 56) 54. The method of claim 53, wherein the autoimmune disease is selected from rheumatoid arthritis and Crohn's disease. (Item 57) 54. The method of claim 53, wherein the skin condition is selected from psoriasis and atopic dermatitis. (Item 58) 54. The method of claim 53, wherein the neurodegenerative disorder is Alzheimer's disease. (Item 59) 47. A pharmaceutical composition comprising the ceDNA vector of any one of items 1 to 46. (Item 60) A cell comprising the ceDNA vector according to any one of items 1 to 46. (Item 61) 47. A composition comprising the ceDNA vector according to any one of items 1 to 46 and a lipid. (Item 62) 62. The composition of claim 61, wherein the lipid is a lipid nanoparticle (LNP). (Item 63) A kit comprising the ceDNA vector according to any one of items 1 to 46, or the composition according to item 61 or 62, or the cell according to item 60. (Item 64) 61. A method for producing an antibody or fusion protein, comprising culturing the cell of item 60 under conditions suitable for producing the antibody or fusion protein. (Item 65) 65. The method of claim 64, further comprising isolating the antibody or fusion protein. [Brief explanation of the drawings]
[0027] Embodiments of the present disclosure, briefly summarized above and discussed in more detail below, can be understood by reference to exemplary embodiments of the present disclosure, which are depicted in the accompanying drawings. However, the accompanying drawings illustrate only typical embodiments of the present disclosure and therefore should not be considered limiting in scope, as the present disclosure may admit of other equally effective embodiments.
[0028] Embodiments of the present disclosure, briefly summarized above and discussed in more detail below, can be understood by reference to exemplary embodiments of the present disclosure, which are depicted in the accompanying drawings. However, the accompanying drawings illustrate only typical embodiments of the present disclosure and therefore should not be considered limiting in scope, as the present disclosure may admit of other equally effective embodiments.
[0029] [Figure 1A] Illustrated is an exemplary structure of a ceDNA vector for producing an antibody or fusion protein disclosed herein, comprising asymmetric ITRs. In this embodiment, the exemplary ceDNA vector comprises an expression cassette containing a CAG promoter, a WPRE, and BGHpA. An open reading frame (ORF) encoding a transgene, such as a nucleic acid encoding an antibody or fusion protein, can be inserted into the cloning site (R3 / R4) between the CAG promoter and the WPRE. The expression cassette is flanked by two inverted terminal repeats (ITRs)—wild-type AAV2 ITRs upstream (5' end) of the expression cassette and modified ITRs downstream (3' end), and therefore the two ITRs flanking the expression cassette are asymmetric with respect to each other. [Figure 1B] 1 shows an exemplary structure of a ceDNA vector for producing an antibody or fusion protein disclosed herein, comprising a CAG promoter, a WPRE, and an asymmetric ITR with an expression cassette comprising BGHpA. An open reading frame (ORF) encoding a transgene, such as a nucleic acid encoding an antibody or fusion protein, can be inserted into the cloning site between the CAG promoter and the WPRE. The expression cassette is flanked by two inverted terminal repeats (ITRs)—a modified ITR upstream (5' end) of the expression cassette and a wild-type ITR downstream (3' end). [Figure 1C] 1 shows an exemplary structure of a ceDNA vector for producing an antibody or fusion protein disclosed herein, comprising an asymmetric ITR with an expression cassette containing an enhancer / promoter, a transgene, a post-transcriptional element (WPRE), and a polyA signal. An open reading frame (ORF) allows insertion of a nucleic acid encoding a transgene, such as an antibody or fusion protein, into the cloning site between the CAG promoter and the WPRE. The expression cassette is flanked by two inverted terminal repeats (ITRs) that are asymmetric with respect to each other: a modified ITR upstream (5' end) and a modified ITR downstream (3' end) of the expression cassette, where both the 5' and 3' ITRs are modified ITRs but have different modifications (i.e., do not have the same modifications). [Figure 1D] 1 shows an exemplary structure of a ceDNA vector for producing an antibody or fusion protein disclosed herein, comprising a symmetrically modified ITR or a substantially symmetrically modified ITR as defined herein, with an expression cassette comprising a CAG promoter, a WPRE, and BGHpA. An open reading frame (ORF) encoding a transgene, such as a nucleic acid encoding an antibody or fusion protein, is inserted into the cloning site between the CAG promoter and the WPRE. The expression cassette is flanked by two modified inverted terminal repeats (ITRs), in which the 5'-modified ITR and the 3'-modified ITR are symmetrical or substantially symmetrical. [Figure 1E]1 shows an exemplary structure of a ceDNA vector for producing an antibody or fusion protein disclosed herein, comprising a symmetric or substantially symmetric modified ITR as defined herein, with an expression cassette comprising an enhancer / promoter, a transgene, a post-transcriptional element (WPRE), and a polyA signal. An open reading frame (ORF) allows insertion of a nucleic acid encoding a transgene, e.g., an antibody or fusion protein, into the cloning site between the CAG promoter and the WPRE. The expression cassette is flanked by two modified inverted terminal repeats (ITRs), in which the 5'-modified ITR and the 3'-modified ITR are symmetric or substantially symmetric. [Figure 1F] 1 shows an exemplary structure of a ceDNA vector for producing an antibody or fusion protein disclosed herein, comprising a symmetric or substantially symmetric WT-ITR as defined herein, with an expression cassette comprising a CAG promoter, a WPRE, and BGHpA. An open reading frame (ORF) encoding a transgene, such as a nucleic acid encoding an antibody or fusion protein, is inserted into the cloning site between the CAG promoter and the WPRE. The expression cassette is flanked by two wild-type inverted terminal repeats (WT-ITR), with symmetric or substantially symmetric 5'WT-ITR and 3'WT-ITR. [Figure 1G] 1 shows an exemplary structure of a ceDNA vector for producing an antibody or fusion protein disclosed herein, comprising a symmetric or substantially symmetric modified ITR as defined herein, with an expression cassette comprising an enhancer / promoter, a transgene, a post-transcriptional element (WPRE), and a polyA signal. An open reading frame (ORF) allows insertion of a nucleic acid encoding a transgene, e.g., an antibody or fusion protein, into the cloning site between the CAG promoter and the WPRE. The expression cassette is flanked by two wild-type inverted terminal repeats (WT-ITR), with the 5'WT-ITR and 3'WT-ITR being symmetric or substantially symmetric. [Figure 2A]The T-shaped stem-loop structure of the wild-type left ITR of AAV2 (SEQ ID NO: 52) is provided, with the A-A', B-B', and C-C' arms, and the identification of two Rep binding sites (RBE and RBE'), and the terminal resolution site (trs) is also shown. The RBE contains a series of four double tetramers that are thought to interact with either Rep78 or Rep68. Furthermore, the RBE' is also thought to interact with the Rep complex assembled on the wild-type or mutant ITR in the construct. The D and D' regions contain transcription factor binding sites and other conserved structures. [Figure 2B] 1 shows the proposed Rep catalytic nicking and ligation activity in the wild-type ITR (SEQ ID NO: 53), including the T-shaped stem-loop structure of the wild-type left ITR of AAV2, with identification of the A-A' arm, the B-B' arm, the C-C' arm, two Rep binding sites (RBE and RBE'), and the terminal resolution site (trs), and also shows the D and D' regions, which contain several transcription factor binding sites, and other conserved structures. [Figure 3A] 1 provides the primary structure (polynucleotide sequence) (left) and secondary structure (right) of the A-A' arm and the RBE-containing portions of the C-C' and B-B' arms of the wild-type left AAV2 ITR (SEQ ID NO: 54). [Figure 3B] 1 shows an exemplary mutant ITR (also referred to as a modified ITR) sequence for the left ITR. The primary structure (left) and predicted secondary structure (right) of the RBE portions of the A-A', C, and B-B' arms of an exemplary mutant left ITR (ITR-1, left) (SEQ ID NO: 113) are shown. [Figure 3C] The primary structure (left) and secondary structure (right) of the A-A' loop and the RBE-containing portions of the B-B' and C-C' arms of the wild-type right AAV2 ITR (SEQ ID NO: 55) are shown. [Figure 3D]An exemplary right-modified ITR is shown. The primary structure (left) and predicted secondary structure (right) of the A-A' arm and the RBE-containing portion of the B-B' and C arms of an exemplary mutant right ITR (ITR-1, right) (SEQ ID NO: 114) are shown. Any combination of left and right ITRs (e.g., AAV2 ITRs or other viral serotype or synthetic ITRs) can be used as taught herein. Each of the polynucleotide sequences in Figures 3A-3D refers to the sequence used in the plasmid or bacmid / baculovirus genome used to produce ceDNA as described herein. The corresponding ceDNA secondary structure, predicted from the ceDNA vector configuration in the plasmid or bacmid / baculovirus genome and the predicted Gibbs free energy value, is also included in each of Figures 3A-3D. [Figure 4A] FIG. 4C is a schematic diagram showing the upstream process for generating baculovirus-infected insect cells (BIICs), which are useful for producing ceDNA for the production of antibodies or fusion proteins disclosed herein, in the process described in the schematic diagram of FIG. 4B. [Figure 4B] FIG. 4B is a schematic diagram of an exemplary method for the production of ceDNA, and FIG. 4C shows the biochemical methods and processes for confirming the production of ceDNA vectors. [Figure 4C] FIG. 4B is a schematic diagram of an exemplary method for the production of ceDNA, and FIG. 4C shows the biochemical methods and processes for confirming the production of ceDNA vectors. [Figure 4D]Figures 4D and 4E are schematic diagrams illustrating a process for identifying the presence of ceDNA in DNA harvested from cell pellets obtained during the ceDNA production process of Figure 4B. Figure 4D shows, on the left, the schematic expected bands of an exemplary ceDNA that is uncut or digested with a restriction endonuclease and then subjected to electrophoresis on either a native or denaturing gel. The leftmost schematic is a native gel, showing multiple bands suggesting that in its duplex and uncut form, the ceDNA exists in at least a monomeric and dimeric state, appearing as a faster-migrating, smaller monomer and a slower-migrating dimer that is twice the size of the monomer. The second schematic from the left shows that when the ceDNA is cut with a restriction endonuclease, the original band disappears and a faster-migrating (e.g., smaller) band appears, corresponding to the expected fragment size remaining after cleavage. Under denaturing conditions, the original double-stranded DNA is single-stranded and migrates as a species twice as large as that observed on a native gel due to the covalent attachment of the complementary strand. Thus, in the second-to-the-right schematic, digested ceDNA exhibits a banding distribution similar to that observed on a native gel, but the bands migrate as fragments twice the size of their native counterparts. The rightmost schematic shows that uncut ceDNA under denaturing conditions migrates as a single-stranded open circle, and thus the observed bands are twice the size of those observed under native conditions where the circle is not open. In this figure, "kb" is used to indicate the relative size of nucleotide molecules based on the length of the nucleotide chain (e.g., for single-stranded molecules observed under denaturing conditions) or the number of base pairs (e.g., for double-stranded molecules observed under native conditions), depending on the context. Figure 4E shows DNA with a discontinuous structure. ceDNA can be cleaved by a restriction endonuclease with a single recognition site on the ceDNA vector, generating two DNA fragments with different sizes (1 kb and 2 kb) under both neutral and denaturing conditions. Figure 4E also shows ceDNA with a linear and continuous structure.The ceDNA vector can be cleaved by restriction endonucleases to generate two DNA fragments that migrate as 1 kb and 2 kb in neutral but not denaturing conditions, and the strands remain connected, producing single strands that migrate as 2 kb and 4 kb. [Figure 4E]Figures 4D and 4E are schematic diagrams illustrating a process for identifying the presence of ceDNA in DNA harvested from cell pellets obtained during the ceDNA production process of Figure 4B. Figure 4D shows, on the left, the schematic expected bands of an exemplary ceDNA that is uncut or digested with a restriction endonuclease and then subjected to electrophoresis on either a native or denaturing gel. The leftmost schematic is a native gel, showing multiple bands suggesting that in its duplex and uncut form, the ceDNA exists in at least a monomeric and dimeric state, appearing as a faster-migrating, smaller monomer and a slower-migrating dimer that is twice the size of the monomer. The second schematic from the left shows that when the ceDNA is cut with a restriction endonuclease, the original band disappears and a faster-migrating (e.g., smaller) band appears, corresponding to the expected fragment size remaining after cleavage. Under denaturing conditions, the original double-stranded DNA is single-stranded and migrates as a species twice as large as that observed on a native gel due to the covalent attachment of the complementary strand. Thus, in the second-to-the-right schematic, digested ceDNA exhibits a banding distribution similar to that observed on a native gel, but the bands migrate as fragments twice the size of their native counterparts. The rightmost schematic shows that uncut ceDNA under denaturing conditions migrates as a single-stranded open circle, and thus the observed bands are twice the size of those observed under native conditions where the circle is not open. In this figure, "kb" is used to indicate the relative size of nucleotide molecules based on the length of the nucleotide chain (e.g., for single-stranded molecules observed under denaturing conditions) or the number of base pairs (e.g., for double-stranded molecules observed under native conditions), depending on the context. Figure 4E shows DNA with a discontinuous structure. ceDNA can be cleaved by a restriction endonuclease with a single recognition site on the ceDNA vector, generating two DNA fragments with different sizes (1 kb and 2 kb) under both neutral and denaturing conditions. Figure 4E also shows ceDNA with a linear and continuous structure.The ceDNA vector can be cleaved by restriction endonucleases to generate two DNA fragments that migrate as 1 kb and 2 kb in neutral but not denaturing conditions, and the strands remain connected, producing single strands that migrate as 2 kb and 4 kb. [Figure 5] Figure 1 shows an illustrative diagram of an example denaturing gel flow of ceDNA vectors with (+) or without (-) digestion with endonucleases (EcoRI for ceDNA constructs 1 and 2, BamH1 for ceDNA constructs 3 and 4, SpeI for ceDNA constructs 5 and 6, and XhoI for ceDNA vectors 7 and 8). Constructs 1-8 are described in Example 1 of International Application No. PCTPCT / US18 / 49996, which is incorporated by reference herein in its entirety. The sizes of the bands highlighted with asterisks were determined and are indicated below the figure. [Figure 6A]Figures 6A-6C show exemplary constructs and plasmids for generating ceDNA vectors for antibody or fusion protein production, and for illustrative purposes, a ceDNA vector encoding aducanumab is shown. One skilled in the art can easily replace the nucleic acid encoding aducanumab with any other nucleic acid encoding a different antibody or fusion protein. Figure 6A shows an exemplary ceDNA plasmid (pFBdual-ceDNA-aducanumab, SEQ ID NO: 56) for generating a ceDNA vector expressing aducanumab (full IgG1). This ceDNA plasmid contains a nucleic acid sequence for expressing aducanumab that is codon-optimized and flanked by an asymmetric ITR pair (i.e., a wild-type 5' ITR (wt ITR) and a 3' mod-ITR (R-asym ITR). This ITR pair can be readily replaced with another asymmetric or symmetric ITR pair, as described herein. Additionally, this plasmid contains, flanked by, from 5' to 3' between the ITR pair, an SV40 enhancer (SEQ ID NO: 126), a human EF1α promoter (SEQ ID NO: 77) or a fragment thereof (SEQ ID NO: 78), and a VH1-02 secretion leader sequence (SEQ ID NO: 88), an optimized aducanumab heavy chain (HC) nucleic acid sequence (SEQ ID NO: 57), an SV40 polyA sequence (SEQ ID NO: 86), and, upstream of the aducanumab light chain (LC) sequence, a CMV enhancer (SEQ ID NO: 83), a rEF1 promoter (SEQ ID NO: 85 or SEQ ID NO: 150), a VK Figure 6B is an exemplary insert that can be used as a modular component to be inserted into a desired ceDNA vector to generate a plasmid as in Figure 6A. Figure 6C is a linearized representation of the region of the ceDNA-Adu-full-IgG1 plasmid containing the sequence for generating aducanumab. [Figure 6B] Figures 6A-6C show exemplary constructs and plasmids for generating ceDNA vectors for antibody or fusion protein production, and for illustrative purposes, a ceDNA vector encoding aducanumab is shown. One skilled in the art can easily replace the nucleic acid encoding aducanumab with any other nucleic acid encoding a different antibody or fusion protein. Figure 6A shows an exemplary ceDNA plasmid (pFBdual-ceDNA-aducanumab, SEQ ID NO: 56) for generating a ceDNA vector expressing aducanumab (full IgG1). This ceDNA plasmid contains a nucleic acid sequence for expressing aducanumab that is codon-optimized and flanked by an asymmetric ITR pair (i.e., a wild-type 5' ITR (wt ITR) and a 3' mod-ITR (R-asym ITR). This ITR pair can be readily replaced with another asymmetric or symmetric ITR pair, as described herein. Additionally, this plasmid contains, flanked by, from 5' to 3' between the ITR pair, an SV40 enhancer (SEQ ID NO: 126), a human EF1α promoter (SEQ ID NO: 77) or a fragment thereof (SEQ ID NO: 78), and a VH1-02 secretion leader sequence (SEQ ID NO: 88), an optimized aducanumab heavy chain (HC) nucleic acid sequence (SEQ ID NO: 57), an SV40 polyA sequence (SEQ ID NO: 86), and, upstream of the aducanumab light chain (LC) sequence, a CMV enhancer (SEQ ID NO: 83), a rEF1 promoter (SEQ ID NO: 85 or SEQ ID NO: 150), a VK Figure 6B is an exemplary insert that can be used as a modular component to be inserted into a desired ceDNA vector to generate a plasmid as in Figure 6A. Figure 6C is a linearized representation of the region of the ceDNA-Adu-full-IgG1 plasmid containing the sequence for generating aducanumab. [Figure 6C]Figures 6A-6C show exemplary constructs and plasmids for generating ceDNA vectors for antibody or fusion protein production, and for illustrative purposes, a ceDNA vector encoding aducanumab is shown. One skilled in the art can easily replace the nucleic acid encoding aducanumab with any other nucleic acid encoding a different antibody or fusion protein. Figure 6A shows an exemplary ceDNA plasmid (pFBdual-ceDNA-aducanumab, SEQ ID NO: 56) for generating a ceDNA vector expressing aducanumab (full IgG1). This ceDNA plasmid contains a nucleic acid sequence for expressing aducanumab that is codon-optimized and flanked by an asymmetric ITR pair (i.e., a wild-type 5' ITR (wt ITR) and a 3' mod-ITR (R-asym ITR). This ITR pair can be readily replaced with another asymmetric or symmetric ITR pair, as described herein. Additionally, this plasmid contains, flanked by, from 5' to 3' between the ITR pair, an SV40 enhancer (SEQ ID NO: 126), a human EF1α promoter (SEQ ID NO: 77) or a fragment thereof (SEQ ID NO: 78), and a VH1-02 secretion leader sequence (SEQ ID NO: 88), an optimized aducanumab heavy chain (HC) nucleic acid sequence (SEQ ID NO: 57), an SV40 polyA sequence (SEQ ID NO: 86), and, upstream of the aducanumab light chain (LC) sequence, a CMV enhancer (SEQ ID NO: 83), a rEF1 promoter (SEQ ID NO: 85 or SEQ ID NO: 150), a VK Figure 6B is an exemplary insert that can be used as a modular component to be inserted into a desired ceDNA vector to generate a plasmid as in Figure 6A. Figure 6C is a linearized representation of the region of the ceDNA-Adu-full-IgG1 plasmid containing the sequence for generating aducanumab. [Figure 7A]Figures 7A-7G show exemplary ceDNA vectors capable of expressing a variety of different antibodies or antigen-binding fragments or fusion proteins disclosed herein. The illustrated ceDNA vectors also show multiple configurations for the use of IRES, promoter, enhancer, linker, and polyadenylation sequences. Figure 7A shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an optional enhancer upstream of the light chain nucleic acid sequence. Figure 7B shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an IRES upstream of the light chain nucleic acid sequence. Figure 7C shows an embodiment of a ceDNA vector construct for producing an antibody fragment (e.g., an antigen-binding fragment) similar to Figure 7A, but including a polyA sequence after the heavy chain Fab fragment sequence and an optional enhancer upstream of the light chain fragment nucleic acid sequence. Figure 7D shows an embodiment of a ceDNA vector construct for producing an antibody disclosed herein, including one with a polyA sequence after the light chain sequence. Figure 7E shows embodiments of ceDNA vector constructs for producing antibodies disclosed herein, including those with a polyA sequence after the heavy chain sequence. Figure 7F shows embodiments of ceDNA vector constructs for producing single-domain antibodies (dAbs) disclosed herein, including those with a polyA sequence after the dAb sequence. Figure 7G shows embodiments of ceDNA vector constructs for producing antibody fragments, such as single-chain variable fragment fusion proteins (scFvs) or single-chain antibodies, disclosed herein, including those with a polyA sequence after the scFv sequence of the single-chain antibody sequence. As those skilled in the art will appreciate, the ceDNA vectors for antibody production described herein can be used in a modular manner, allowing desired regulatory sequences or heterologous nucleic acids encoding antibodies or fragments thereof to be exchanged for other desired sequences. That is, the ceDNA vectors can be customized for desired applications. Also shown in Figures 7A-7G are embodiments in which the nucleic acid sequences for the variable chains (VH and VL) and constant chains (CH and CL) and the Fc sequence are located proximal to each other, or alternatively, the Fc can be linked to the VH and VL encoding sequences via a linker sequence as disclosed herein. [Figure 7B]Figures 7A-7G show exemplary ceDNA vectors capable of expressing a variety of different antibodies or antigen-binding fragments or fusion proteins disclosed herein. The illustrated ceDNA vectors also show multiple configurations for the use of IRES, promoter, enhancer, linker, and polyadenylation sequences. Figure 7A shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an optional enhancer upstream of the light chain nucleic acid sequence. Figure 7B shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an IRES upstream of the light chain nucleic acid sequence. Figure 7C shows an embodiment of a ceDNA vector construct for producing an antibody fragment (e.g., an antigen-binding fragment) similar to Figure 7A, but including a polyA sequence after the heavy chain Fab fragment sequence and an optional enhancer upstream of the light chain fragment nucleic acid sequence. Figure 7D shows an embodiment of a ceDNA vector construct for producing an antibody disclosed herein, including one with a polyA sequence after the light chain sequence. Figure 7E shows embodiments of ceDNA vector constructs for producing antibodies disclosed herein, including those with a polyA sequence after the heavy chain sequence. Figure 7F shows embodiments of ceDNA vector constructs for producing single-domain antibodies (dAbs) disclosed herein, including those with a polyA sequence after the dAb sequence. Figure 7G shows embodiments of ceDNA vector constructs for producing antibody fragments, such as single-chain variable fragment fusion proteins (scFvs) or single-chain antibodies, disclosed herein, including those with a polyA sequence after the scFv sequence of the single-chain antibody sequence. As those skilled in the art will appreciate, the ceDNA vectors for antibody production described herein can be used in a modular manner, allowing desired regulatory sequences or heterologous nucleic acids encoding antibodies or fragments thereof to be exchanged for other desired sequences. That is, the ceDNA vectors can be customized for desired applications. Also shown in Figures 7A-7G are embodiments in which the nucleic acid sequences for the variable chains (VH and VL) and constant chains (CH and CL) and the Fc sequence are located proximal to each other, or alternatively, the Fc can be linked to the VH and VL encoding sequences via a linker sequence as disclosed herein. [Figure 7C]Figures 7A-7G show exemplary ceDNA vectors capable of expressing a variety of different antibodies or antigen-binding fragments or fusion proteins disclosed herein. The illustrated ceDNA vectors also show multiple configurations for the use of IRES, promoter, enhancer, linker, and polyadenylation sequences. Figure 7A shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an optional enhancer upstream of the light chain nucleic acid sequence. Figure 7B shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an IRES upstream of the light chain nucleic acid sequence. Figure 7C shows an embodiment of a ceDNA vector construct for producing an antibody fragment (e.g., an antigen-binding fragment) similar to Figure 7A, but including a polyA sequence after the heavy chain Fab fragment sequence and an optional enhancer upstream of the light chain fragment nucleic acid sequence. Figure 7D shows an embodiment of a ceDNA vector construct for producing an antibody disclosed herein, including one with a polyA sequence after the light chain sequence. Figure 7E shows embodiments of ceDNA vector constructs for producing antibodies disclosed herein, including those with a polyA sequence after the heavy chain sequence. Figure 7F shows embodiments of ceDNA vector constructs for producing single-domain antibodies (dAbs) disclosed herein, including those with a polyA sequence after the dAb sequence. Figure 7G shows embodiments of ceDNA vector constructs for producing antibody fragments, such as single-chain variable fragment fusion proteins (scFvs) or single-chain antibodies, disclosed herein, including those with a polyA sequence after the scFv sequence of the single-chain antibody sequence. As those skilled in the art will appreciate, the ceDNA vectors for antibody production described herein can be used in a modular manner, allowing desired regulatory sequences or heterologous nucleic acids encoding antibodies or fragments thereof to be exchanged for other desired sequences. That is, the ceDNA vectors can be customized for desired applications. Also shown in Figures 7A-7G are embodiments in which the nucleic acid sequences for the variable chains (VH and VL) and constant chains (CH and CL) and the Fc sequence are located proximal to each other, or alternatively, the Fc can be linked to the VH and VL encoding sequences via a linker sequence as disclosed herein. [Figure 7D]Figures 7A-7G show exemplary ceDNA vectors capable of expressing a variety of different antibodies or antigen-binding fragments or fusion proteins disclosed herein. The illustrated ceDNA vectors also show multiple configurations for the use of IRES, promoter, enhancer, linker, and polyadenylation sequences. Figure 7A shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an optional enhancer upstream of the light chain nucleic acid sequence. Figure 7B shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an IRES upstream of the light chain nucleic acid sequence. Figure 7C shows an embodiment of a ceDNA vector construct for producing an antibody fragment (e.g., an antigen-binding fragment) similar to Figure 7A, but including a polyA sequence after the heavy chain Fab fragment sequence and an optional enhancer upstream of the light chain fragment nucleic acid sequence. Figure 7D shows an embodiment of a ceDNA vector construct for producing an antibody disclosed herein, including one with a polyA sequence after the light chain sequence. Figure 7E shows embodiments of ceDNA vector constructs for producing antibodies disclosed herein, including those with a polyA sequence after the heavy chain sequence. Figure 7F shows embodiments of ceDNA vector constructs for producing single-domain antibodies (dAbs) disclosed herein, including those with a polyA sequence after the dAb sequence. Figure 7G shows embodiments of ceDNA vector constructs for producing antibody fragments, such as single-chain variable fragment fusion proteins (scFvs) or single-chain antibodies, disclosed herein, including those with a polyA sequence after the scFv sequence of the single-chain antibody sequence. As those skilled in the art will appreciate, the ceDNA vectors for antibody production described herein can be used in a modular manner, allowing desired regulatory sequences or heterologous nucleic acids encoding antibodies or fragments thereof to be exchanged for other desired sequences. That is, the ceDNA vectors can be customized for desired applications. Also shown in Figures 7A-7G are embodiments in which the nucleic acid sequences for the variable chains (VH and VL) and constant chains (CH and CL) and the Fc sequence are located proximal to each other, or alternatively, the Fc can be linked to the VH and VL encoding sequences via a linker sequence as disclosed herein. [Figure 7E]Figures 7A-7G show exemplary ceDNA vectors capable of expressing a variety of different antibodies or antigen-binding fragments or fusion proteins disclosed herein. The illustrated ceDNA vectors also show multiple configurations for the use of IRES, promoter, enhancer, linker, and polyadenylation sequences. Figure 7A shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an optional enhancer upstream of the light chain nucleic acid sequence. Figure 7B shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an IRES upstream of the light chain nucleic acid sequence. Figure 7C shows an embodiment of a ceDNA vector construct for producing an antibody fragment (e.g., an antigen-binding fragment) similar to Figure 7A, but including a polyA sequence after the heavy chain Fab fragment sequence and an optional enhancer upstream of the light chain fragment nucleic acid sequence. Figure 7D shows an embodiment of a ceDNA vector construct for producing an antibody disclosed herein, including one with a polyA sequence after the light chain sequence. Figure 7E shows embodiments of ceDNA vector constructs for producing antibodies disclosed herein, including those with a polyA sequence after the heavy chain sequence. Figure 7F shows embodiments of ceDNA vector constructs for producing single-domain antibodies (dAbs) disclosed herein, including those with a polyA sequence after the dAb sequence. Figure 7G shows embodiments of ceDNA vector constructs for producing antibody fragments, such as single-chain variable fragment fusion proteins (scFvs) or single-chain antibodies, disclosed herein, including those with a polyA sequence after the scFv sequence of the single-chain antibody sequence. As those skilled in the art will appreciate, the ceDNA vectors for antibody production described herein can be used in a modular manner, allowing desired regulatory sequences or heterologous nucleic acids encoding antibodies or fragments thereof to be exchanged for other desired sequences. That is, the ceDNA vectors can be customized for desired applications. Also shown in Figures 7A-7G are embodiments in which the nucleic acid sequences for the variable chains (VH and VL) and constant chains (CH and CL) and the Fc sequence are located proximal to each other, or alternatively, the Fc can be linked to the VH and VL encoding sequences via a linker sequence as disclosed herein. [Figure 7F]Figures 7A-7G show exemplary ceDNA vectors capable of expressing a variety of different antibodies or antigen-binding fragments or fusion proteins disclosed herein. The illustrated ceDNA vectors also show multiple configurations for the use of IRES, promoter, enhancer, linker, and polyadenylation sequences. Figure 7A shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an optional enhancer upstream of the light chain nucleic acid sequence. Figure 7B shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an IRES upstream of the light chain nucleic acid sequence. Figure 7C shows an embodiment of a ceDNA vector construct for producing an antibody fragment (e.g., an antigen-binding fragment) similar to Figure 7A, but including a polyA sequence after the heavy chain Fab fragment sequence and an optional enhancer upstream of the light chain fragment nucleic acid sequence. Figure 7D shows an embodiment of a ceDNA vector construct for producing an antibody disclosed herein, including one with a polyA sequence after the light chain sequence. Figure 7E shows embodiments of ceDNA vector constructs for producing antibodies disclosed herein, including those with a polyA sequence after the heavy chain sequence. Figure 7F shows embodiments of ceDNA vector constructs for producing single-domain antibodies (dAbs) disclosed herein, including those with a polyA sequence after the dAb sequence. Figure 7G shows embodiments of ceDNA vector constructs for producing antibody fragments, such as single-chain variable fragment fusion proteins (scFvs) or single-chain antibodies, disclosed herein, including those with a polyA sequence after the scFv sequence of the single-chain antibody sequence. As those skilled in the art will appreciate, the ceDNA vectors for antibody production described herein can be used in a modular manner, allowing desired regulatory sequences or heterologous nucleic acids encoding antibodies or fragments thereof to be exchanged for other desired sequences. That is, the ceDNA vectors can be customized for desired applications. Also shown in Figures 7A-7G are embodiments in which the nucleic acid sequences for the variable chains (VH and VL) and constant chains (CH and CL) and the Fc sequence are located proximal to each other, or alternatively, the Fc can be linked to the VH and VL encoding sequences via a linker sequence as disclosed herein. [Figure 7G]Figures 7A-7G show exemplary ceDNA vectors capable of expressing a variety of different antibodies or antigen-binding fragments or fusion proteins disclosed herein. The illustrated ceDNA vectors also show multiple configurations for the use of IRES, promoter, enhancer, linker, and polyadenylation sequences. Figure 7A shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an optional enhancer upstream of the light chain nucleic acid sequence. Figure 7B shows an embodiment of a ceDNA vector construct for producing an antibody with a polyA sequence after the heavy chain sequence and an IRES upstream of the light chain nucleic acid sequence. Figure 7C shows an embodiment of a ceDNA vector construct for producing an antibody fragment (e.g., an antigen-binding fragment) similar to Figure 7A, but including a polyA sequence after the heavy chain Fab fragment sequence and an optional enhancer upstream of the light chain fragment nucleic acid sequence. Figure 7D shows an embodiment of a ceDNA vector construct for producing an antibody disclosed herein, including one with a polyA sequence after the light chain sequence. Figure 7E shows embodiments of ceDNA vector constructs for producing antibodies disclosed herein, including those with a polyA sequence after the heavy chain sequence. Figure 7F shows embodiments of ceDNA vector constructs for producing single-domain antibodies (dAbs) disclosed herein, including those with a polyA sequence after the dAb sequence. Figure 7G shows embodiments of ceDNA vector constructs for producing antibody fragments, such as single-chain variable fragment fusion proteins (scFvs) or single-chain antibodies, disclosed herein, including those with a polyA sequence after the scFv sequence of the single-chain antibody sequence. As those skilled in the art will appreciate, the ceDNA vectors for antibody production described herein can be used in a modular manner, allowing desired regulatory sequences or heterologous nucleic acids encoding antibodies or fragments thereof to be exchanged for other desired sequences. That is, the ceDNA vectors can be customized for desired applications. Also shown in Figures 7A-7G are embodiments in which the nucleic acid sequences for the variable chains (VH and VL) and constant chains (CH and CL) and the Fc sequence are located proximal to each other, or alternatively, the Fc can be linked to the VH and VL encoding sequences via a linker sequence as disclosed herein. [Figure 8A] Figures 8A-8B show exemplary SDS-Page (Figure 8A) and Western blot (Figure 8B) analyses of the expression of aducanumab (full IgG1) antibody expressed from the ceDNA-IgG1-Adu construct as described in Example 9, following one-step purification of the expressed protein. Figure 8A shows an SDS-PAGE gel image of the expressed antibody. The lanes are as follows: M1 is a protein marker (Takara, catalog number 3452), and purified aducanumab is shown under reducing (lane 1) and non-reducing (lane 2) conditions. The presence of two bands under reducing conditions and only a single band under non-reducing conditions is consistent with the protein being an antibody with heavy and light chains, which migrates as a single band under non-reducing conditions and as the heavy and light chains of the construct under reducing conditions. Figure 8B shows a Western blot image immunostained with an anti-human IgG antibody. The lanes are as follows: M1 is a protein marker (Takara, catalog number 3452), and purified aducanumab is shown under reducing (lane 1) and non-reducing (lane 2) conditions. The presence of two bands under reducing conditions and only a single band under non-reducing conditions is consistent with the protein being an antibody with heavy and light chains, which migrates as a single band under non-reducing conditions and as the heavy and light chains of the construct under reducing conditions. M2 is a protein marker (GenScript, catalog number M00521) and P is a positive control human IgG1 antibody (Sigma). [Figure 8B] Figures 8A-8B show exemplary SDS-Page (Figure 8A) and Western blot (Figure 8B) analyses of the expression of aducanumab (full IgG1) antibody expressed from the ceDNA-IgG1-Adu construct as described in Example 9, following one-step purification of the expressed protein. Figure 8A shows an SDS-PAGE gel image of the expressed antibody. The lanes are as follows: M1 is a protein marker (Takara, catalog number 3452), and purified aducanumab is shown under reducing (lane 1) and non-reducing (lane 2) conditions. The presence of two bands under reducing conditions and only a single band under non-reducing conditions is consistent with the protein being an antibody with heavy and light chains, which migrates as a single band under non-reducing conditions and as the heavy and light chains of the construct under reducing conditions. Figure 8B shows a Western blot image immunostained with an anti-human IgG antibody. The lanes are as follows: M1 is a protein marker (Takara, catalog number 3452), and purified aducanumab is shown under reducing (lane 1) and non-reducing (lane 2) conditions. The presence of two bands under reducing conditions and only a single band under non-reducing conditions is consistent with the protein being an antibody with heavy and light chains, which migrates as a single band under non-reducing conditions and as the heavy and light chains of the construct under reducing conditions. M2 is a protein marker (GenScript, catalog number M00521) and P is a positive control human IgG1 antibody (Sigma). [Figure 9A] Figures 9A-9B show the expression of GFP expressed from the ceDNA-IgG1-Adu vector or ceDNA expressing the aducanumab (full IgG1) antibody. Figure 9A provides fluorescence microscopy images of HEK293T cells transfected with the ceDNA-GFP plasmid (upper panel) and the ceDNA-GFP vector (lower panel) as described in Example 8. The presence of abundant fluorescence in both images indicates significant transfection and expression of the transgene GFP in cells treated with either ceDNA. Figure 9B provides two different images of the same membrane transfer of a cell sample electrophoretically separated by SDS-PAGE as described in Example 8. The lower panel is a Ponceau-stained membrane showing total protein content. The upper panel is a Western blot in which visible bands reflect the presence of human antibody. In lanes 7-10, the antibody heavy chain migrates at approximately 50 kDa, and the antibody light chain migrates at approximately 25 kDa. Both chains are visible in all four lanes. [Figure 9B] Figures 9A-9B show the expression of GFP expressed from the ceDNA-IgG1-Adu vector or ceDNA expressing the aducanumab (full IgG1) antibody. Figure 9A provides fluorescence microscopy images of HEK293T cells transfected with the ceDNA-GFP plasmid (upper panel) and the ceDNA-GFP vector (lower panel) as described in Example 8. The presence of abundant fluorescence in both images indicates significant transfection and expression of the transgene GFP in cells treated with either ceDNA. Figure 9B provides two different images of the same membrane transfer of a cell sample electrophoretically separated by SDS-PAGE as described in Example 8. The lower panel is a Ponceau-stained membrane showing total protein content. The upper panel is a Western blot in which visible bands reflect the presence of human antibody. In lanes 7-10, the antibody heavy chain migrates at approximately 50 kDa, and the antibody light chain migrates at approximately 25 kDa. Both chains are visible in all four lanes. [Figure 10A]Figures 10A-10B show the characteristics of ceDNA-produced aducanumab antibodies. Figure 10A shows the results of an HPLC analysis described in Example 9, demonstrating a single peak corresponding to ceDNA-produced aducanumab. Figure 10B shows the results of an ELISA analysis evaluating the ability of purified aducanumab antibodies to recognize immobilized β-amyloid (1-42) ligand, as described in Example 9. [Figure 10B] Figures 10A-10B show the characteristics of ceDNA-produced aducanumab antibodies. Figure 10A shows the results of an HPLC analysis described in Example 9, demonstrating a single peak corresponding to ceDNA-produced aducanumab. Figure 10B shows the results of an ELISA analysis evaluating the ability of purified aducanumab antibodies to recognize immobilized β-amyloid (1-42) ligand, as described in Example 9. [Figure 11] 10 graphically depicts the results of the experiment described in Example 10. Negative control samples from mice treated with a ceDNA construct lacking the aducanumab transgene (labeled as ceDNA negative control) were below the lower limit of quantitation of the assay. In contrast, high levels of human immunoglobulins were present in the serum of mice treated with the ceDNA-IgG construct at both day 3 and day 7. [Figure 12] Two different time exposures of the same membrane transfer of a cell sample electrophoretically separated by SDS-PAGE, as described in Example 12, are provided. The top panel was taken after a 6-second exposure, and the bottom panel was taken after a 20-second exposure. Bands corresponding to intact antibody are seen at the top of the gel (limited amounts of reduced heavy and light chains migrating at approximately 50 kDa and 25 kDa, respectively) in lanes 5, 7 (both aducanumab), and 11 (bevacizumab) (see arrows). In lane 9, the presence of the Fc fusion protein is observed near the top of the lane; as expected, no lower molecular weight constructs are observed. DETAILED DESCRIPTION OF THE INVENTION
[0030] Provided herein are ceDNA vectors for producing the antibodies described herein, comprising one or more heterologous nucleic acids encoding the antibody (e.g., heavy chain, light chain, framework, Fab', scAb). Also provided herein are ceDNA vectors for producing the fusion proteins described herein, comprising one or more heterologous nucleic acids encoding the fusion protein. Such vectors can be used in the production of commercial antibodies or fusion proteins or in the delivery of therapeutic antibodies or fusion proteins described herein by intracellular expression from the ceDNA vector. In some embodiments, expression of the antibody or fusion protein can include secretion of the antibody or fusion protein from the cell in which it is expressed, or alternatively, in some embodiments, the expressed antibody or fusion protein can target a protein within the cell in which it is expressed (e.g., the antibody is an intrabody). In some embodiments, the ceDNA vector expresses the antibody or antigen-binding fragment thereof or fusion protein in the muscle of a subject (e.g., skeletal muscle), which can act as a depot for the production and secretion of the antibody or fusion protein to many systemic compartments.
[0031] I. Definition Unless otherwise defined herein, scientific and technical terms used in connection with this application shall have the meanings commonly understood by one of ordinary skill in the art to which this disclosure belongs. It is to be understood that the present invention is not limited to the particular methodology, protocols, and reagents, etc., described herein, and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims. Definitions of common terms in immunology and molecular biology can be found in The Merck Manual of Diagnosis and Therapy, 19th Edition, published by Merck Sharp&Dohme Corp.,2011(ISBN 978-0-911910-19-3)、Robert S.Porter et al.(eds.),Fields Virology,6 th Edition,published by Lippincott Williams&Wilkins,Philadelphia,PA,USA(2013),Knipe,D.M.and Howley,P.M.(ed.),The Encyclopedia of Molecular Cell Biology and Molecular Medicine,published by Blackwell Science Ltd.,1999-2012(ISBN 9783527600908)、およびRobert A.Meyers(ed.),Molecular Biology and Biotechnology:a Comprehensive Desk Reference,published by VCH Publishers,Inc.,1995(ISBN 1-56081-569-8)、Immunology by Werner Luttmann,published by Elsevier,2006、Janeway‘s Immunobiology,Kenneth Murphy,Allan Mowat,Casey Weaver(eds.),Taylor&Francis Limited,2014(ISBN 0815345305,9780815345305)、Lewin’s Genes XI,published by Jones&Bartlett Publishers,2014(ISBN-1449659055)、Michael Richard Green and Joseph Sambrook,Molecular Cloning:A Laboratory Manual,4 th ed.,Cold Spring Harbor Laboratory Press,Cold Spring Harbor,NY,USA(2012)(ISBN 1936113414), Davis et al.,Basic Methods in Molecular Biology,Elsevier Science Publishing,Inc.,New York,USA(2012)(ISBN 044460149X),Laboratory Methods in Enzymology:DNA,Jon Lorsch(ed.)Elsevier,2013(ISBN Current Protocols in Protein Science (CPPS), John E. Coligan (ed.), John Wiley and Sons, Inc., 2005, and Current Protocols in Immunology (CPI) (John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of all of which are incorporated herein by reference in their entireties.
[0032] As used herein, "heterologous nucleotide sequence" and "transgene" are used interchangeably and refer to a nucleic acid of interest (other than a nucleic acid encoding a capsid polypeptide) that can be incorporated into, delivered and expressed by, the ceDNA vectors disclosed herein.
[0033] As used herein, the terms "expression cassette" and "transcription cassette" are used interchangeably and refer to a linear stretch of nucleic acid that includes a transgene operably linked to one or more promoters or other regulatory sequences sufficient to direct transcription of the transgene, but does not include capsid-encoding sequences, other vector sequences, or inverted terminal repeat regions. An expression cassette may additionally include one or more cis-acting sequences (e.g., promoters, enhancers, or repressors), one or more introns, and one or more post-transcriptional regulatory elements.
[0034] The terms "polynucleotide" and "nucleic acid," used interchangeably herein, refer to polymeric forms of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, the terms include single-stranded, double-stranded, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. An "oligonucleotide" generally refers to a polynucleotide of about 5 to about 100 nucleotides, either single-stranded or double-stranded DNA. However, for purposes of this disclosure, there is no upper limit to the length of an oligonucleotide. Oligonucleotides, also known as "oligomers" or "oligos," can be isolated from genes or chemically synthesized by methods known in the art. The terms "polynucleotide" and "nucleic acid" should be understood to include single-stranded (e.g., sense or antisense) and double-stranded polynucleotides, as applicable to the described embodiments.
[0035] As used herein, the term "nucleic acid construct" refers to a single- or double-stranded nucleic acid molecule that is isolated from a naturally occurring gene, or that is modified to contain a segment of nucleic acid in a manner that does not otherwise occur in nature, or that is synthetic. The term nucleic acid construct is synonymous with the term "expression cassette" when the nucleic acid construct contains the control sequences necessary for expression of the coding sequence of the present disclosure. An "expression cassette" contains a DNA coding sequence operably linked to a promoter.
[0036] "Hybridizable" or "complementary" or "substantially complementary" means that a nucleic acid (e.g., RNA) contains a sequence of nucleotides that allows it to "anneal" or "hybridize" to another nucleic acid (i.e., the nucleic acid specifically binds to a complementary nucleic acid) in a sequence-specific, antiparallel manner under appropriate in vitro and / or in vivo conditions of temperature and solution ionic strength, forming non-covalently bound Watson-Crick base pairs and / or G / U base pairs. As known in the art, standard Watson-Crick base pairings include adenine (A) pairing with thymidine (T), adenine (A) pairing with uracil (U), and guanine (G) pairing with cytosine (C). Additionally, it is known in the art that guanine (G) bases pair with uracil (U) for hybridization between two RNA molecules (e.g., dsRNA). For example, G / U base pairing is partially responsible for the degeneracy (i.e., redundancy) of the genetic code in the context of tRNA anticodon base pairing with codons in mRNA. In the context of this disclosure, guanine (G) of the protein-binding segment (dsRNA duplex) of a subject DNA-targeting RNA molecule is considered to be complementary to uracil (U), and vice versa. Therefore, if a G / U base pair can be made at a given nucleotide position of the protein-binding segment (dsRNA duplex) of a subject DNA-targeting RNA molecule, that position is not considered to be non-complementary, but instead is considered to be complementary.
[0037] The terms "peptide," "polypeptide," and "protein" are used interchangeably herein to refer to polymeric forms of amino acids of any length, which may include coded and non-coded amino acids, amino acids that are chemically or biochemically modified or derivatized, and polypeptides with modified peptide backbones.
[0038] As used herein, the term "antibody" encompasses any antibody or antibody fragment (i.e., functional antibody fragment), or antigen-binding fragment that retains antigen-binding activity for a desired antigen or epitope. In one embodiment, an antibody or antigen-binding fragment thereof comprises an immunoglobulin chain or fragment thereof and at least one immunoglobulin variable domain sequence. Examples of antibodies include, but are not limited to, scFv, Fab fragment, Fab', F(ab')2, single-domain antibodies (dAbs), heavy chain, light chain, heavy and light chain, complete antibodies (e.g., including each of Fc, Fab, heavy chain, light chain, variable region, etc.), bispecific antibodies, diabodies, linear antibodies, single-chain antibodies, intrabodies, monoclonal antibodies, chimeric antibodies, or multimeric antibodies. Furthermore, antibodies can be derived from any mammal, e.g., primates, humans, rats, mice, horses, goats, etc. In one embodiment, the antibodies are human or humanized. In some embodiments, the antibodies are modified antibodies. In some embodiments, the components of the antibody can be expressed separately, such that the antibody self-assembles after expression of the protein components. In some embodiments, the antibody has a desired function, e.g., interacts with and inhibits a desired protein, for the purpose of treating a disease or disease symptom. In one embodiment, an antibody or antigen-binding fragment thereof comprises a framework region or F domain. cThe antibody fragment may comprise a region. An antibody fragment can retain 10-99% of the activity of the complete antibody (e.g., 10-90%, 10-80%, 10-70%, 10-60%, 10-50%, 10-40%, 10-30%, 10-20%, 50-99%, 50-90%, 50-80%, 50-70%, 50-60%, 20-99%, 30-99%, 40-99%, 60-99%, 70-99%, 80-99%, 90-99%, or any activity therebetween). Also contemplated herein is a functional antibody fragment that comprises an activity that is greater (e.g., at least 2-fold greater) than the activity of the intact antibody. In another embodiment, the antibody fragment comprises an affinity for a target (e.g., epitope) that is substantially similar to the affinity of the intact antibody for the same target. An antibody can be "activating," such that it increases the activity of a target protein, or "inhibiting," such that it decreases the activity of a target protein (e.g., a neutralizing or blocking antibody).
[0039] As used herein, the term "antigen-binding domain" of an antibody molecule refers to the portion of an antibody molecule, e.g., an immunoglobulin (Ig) molecule, that is involved in antigen binding. In embodiments, the antigen-binding site is formed by amino acid residues in the variable (V) regions of the heavy (H) and light (L) chains. Three highly divergent stretches within the variable regions of the heavy and light chains are called hypervariable regions and are located between more conserved adjacent stretches called "framework regions" (FRs). FRs are amino acid sequences naturally found between and adjacent to the hypervariable regions of immunoglobulins. In embodiments, in an antibody molecule, the three hypervariable regions of the light chain and the three hypervariable regions of the heavy chain are positioned relative to each other in three-dimensional space to form an antigen-binding surface that is complementary to the three-dimensional surface of a bound antigen. The three hypervariable regions of each of the heavy and light chains are referred to as "complementarity-determining regions" or "CDRs." Framework regions and CDRs are defined and described, for example, in Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDepartment of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917. Each variable chain (e.g., variable heavy chain and variable light chain) typically consists of three CDRs and four FRs, arranged in the following amino acid order from amino terminus to carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. As used herein, the terms "complementarity-determining region" and "CDR" refer to the amino acid sequence in an antibody variable region that confers antigen specificity and binding affinity. Generally, each heavy chain variable region has three CDRs (HCDR1, HCDR2, and HCDR3), and each light chain variable region has three CDRs (LCDR1, LCDR2, and LCDR3). The precise amino acid sequence boundaries of a given CDR are described in Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. ("Kabat" numbering scheme); Al-Lazikani et al., (1997) JMB 273, 927-948 ("Chothia" numbering scheme). As used herein, CDRs defined according to the "Chothia" numbering scheme are sometimes referred to as "hypervariable loops." For example, under Kabat, the CDR amino acid residues of the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3), and the CDR amino acid residues of the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Under Chothia, the CDR amino acids of a VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3), and the amino acid residues of a VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3). Each VH and VL typically contains three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0040] As used herein, the term "full length antibody" refers to an immunoglobulin (Ig) molecule (e.g., IgG, IgE, IgM antibody), e.g., that occurs in nature and that is formed by recombinant processes of conventional immunoglobulin gene fragments.
[0041] As used herein, the terms "functional antibody fragment" or "antigen-binding fragment" are used interchangeably and refer to an antibody fragment that binds to the same antigen or epitope recognized by an intact (e.g., full-length) antibody. The terms "antibody fragment" or "functional fragment" also include isolated fragments consisting of the variable regions, such as an "Fv" fragment consisting of the variable regions of the heavy and light chains, or a recombinant single-chain polypeptide molecule ("scFv protein") in which the light and heavy chain variable regions are connected by a peptide linker. In some embodiments, an antibody fragment does not include a portion of an antibody without antigen-binding activity, such as an Fc fragment or a single amino acid residue. In some embodiments, a functional antibody fragment retains at least 20% of the activity of an intact or full-length antibody, as assessed, for example, by measuring the degree of activation or inhibition of a target protein. In other embodiments, a functional antibody fragment retains at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% (i.e., substantially similar) activity relative to an intact antibody. Also contemplated herein are functional antibody fragments that include increased activity (e.g., at least 1-fold, at least 2-fold, at least 5-fold, at least 10-fold, at least 100 or more) compared to an intact antibody.
[0042] As used herein, "immunoglobulin variable domain sequence" refers to an amino acid sequence capable of forming the structure of an immunoglobulin variable domain. For example, the sequence may include all or part of the amino acid sequence of a naturally occurring variable domain. For example, the sequence may or may not include one, two, or more N- or C-terminal amino acids, or may include other alterations compatible with forming a protein structure.
[0043] As used herein, the term "framework" or "framework sequence" refers to the remaining sequence of the variable region minus the CDRs. Because the exact definition of a CDR sequence can be determined by different systems, the meaning of a framework sequence is subject to correspondingly different interpretations. The six CDRs (CDR-L1, CDR-L2, CDR-L3 of the light chain and CDR-H1, CDR-H2, CDR-H3 of the heavy chain) also divide the framework regions on the light and heavy chains into four subregions (FR1, FR2, FR3, FR4) on each chain, with CDR1 located between FR1 and FR2, CDR2 located between FR2 and FR3, and CDR3 located between FR3 and FR4. Framework regions referred to by others without specifying a particular subregion as FR1, FR2, FR3, or FR4 represent the composite FRs within the variable region of a single naturally occurring immunoglobulin chain. As used herein, FR refers to one of the four subregions, and FR refers to two or more of the four subregions that make up a framework region.
[0044] A DNA sequence that "encodes" a particular antibody or antigen-binding fragment is a DNA nucleic acid sequence that is transcribed into a specific RNA and / or protein. The DNA polynucleotide may encode an RNA (mRNA) that is translated into a protein, or the DNA polynucleotide may encode an RNA that is not translated into a protein (e.g., tRNA, rRNA, or DNA-targeting RNA, also called "non-coding" RNA or "ncRNA").
[0045] As used herein, the term "fusion protein" refers to a polypeptide comprising protein domains from at least two different proteins. For example, a fusion protein may comprise (i) an antibody or fragment thereof (e.g., an antigen-binding portion or antigen-binding fragment of an antibody) or a ligand-binding domain and (ii) at least one non-antibody protein. Fusion proteins encompassed herein include, but are not limited to, an antibody or the Fc or antigen-binding fragment of an antibody fused to the extracellular domain of a protein of interest, such as a receptor, ligand, enzyme, or peptide. The antibody or antigen-binding fragment thereof that is part of the fusion protein may be a monospecific antibody or a bispecific or multispecific antibody.
[0046] As used herein, the term "genomic safe harbor gene" or "safe harbor gene" refers to a gene or locus into which a nucleic acid sequence can be inserted such that the sequence can integrate and function in a predictable manner (e.g., express a protein of interest) without significantly adversely affecting endogenous gene activity or promoting cancer. In some embodiments, a safe harbor gene is also a locus or gene where the inserted nucleic acid sequence can be expressed more efficiently and at higher levels than at a non-safe harbor site.
[0047] As used herein, the term "gene delivery" refers to the process by which foreign DNA is introduced into host cells for gene therapy applications.
[0048] As used herein, the term "terminal repeat" or "TR" includes any viral or synthetic terminal sequence that contains at least one minimally necessary origin of replication and a region containing a palindromic hairpin structure. The Rep binding sequence ("RBS") (also referred to as an RBE (Rep binding element)) and terminal resolution site ("TRS") together constitute the "minimally necessary origin of replication," and thus a TR contains at least one RBS and at least one TRS. TRs that are reverse complements of each other within a given stretch of a polynucleotide sequence are typically referred to as "inverted terminal repeats" or "ITRs," respectively. In the context of viruses, ITRs mediate replication, viral packaging, integration, and proviral rescue. As unexpectedly found in the present invention, TRs that are not reverse complements over their entire length can still perform the traditional functions of ITRs, and therefore the term ITR is used herein to refer to TRs in a ceDNA genome or ceDNA vector that are capable of mediating replication of the ceDNA vector. It will be understood by those skilled in the art that there may be more than two ITRs or asymmetric ITR pairs in a composite ceDNA vector construct. ITRs may be AAV ITRs or non-AAV ITRs. ITRs can be ITRs, or can be derived from AAV ITRs or non-AAV ITRs. For example, ITRs can be derived from the Parvoviridae family, including parvoviruses and dependoviruses (e.g., canine parvovirus, bovine parvovirus, mouse parvovirus, porcine parvovirus, human parvovirus B-19), or the SV40 hairpin that serves as the origin of SV40 replication can be used as an ITR, which can be further modified by truncation, substitution, deletion, insertion, and / or addition. The Parvoviridae family of viruses is composed of two subfamilies: Parvovirinae, which infect vertebrates, and Densovirinae, which infect invertebrates. Dependoparvoviruses include the adeno-associated virus (AAV) family of viruses, which can replicate in vertebrate hosts, including but not limited to humans, primates, bovine, canine, equine, and ovine species. For convenience herein, an ITR located 5' to (upstream of) an expression cassette in a ceDNA vector is referred to as the "5' ITR" or "left ITR," and an ITR located 3' to (downstream of) an expression cassette in a ceDNA vector is referred to as the "3' ITR" or "right ITR."
[0049] "Wild-type ITR" or "WT-ITR" refers to the sequence of a naturally occurring ITR sequence in an AAV or other dependant virus, e.g., that retains Rep binding activity and Rep nicking ability. The nucleotide sequence of a WT-ITR from any AAV serotype may differ slightly from the naturally occurring canonical sequence due to degeneracy of the genetic code or drift; therefore, WT-ITR sequences encompassed for use herein include WT-ITR sequences that result from naturally occurring variations (e.g., replication errors) that occur during the production process.
[0050] As used herein, the term "substantially symmetric WT-ITR" or "substantially symmetric WT-ITR pair" refers to a pair of WT-ITRs within a single ceDNA genome or ceDNA vector, both of which are wild-type ITRs with reverse-complementary sequences throughout their entire length. For example, an ITR can be considered to have a wild-type sequence even if it has one or more nucleotides that deviate from the naturally occurring canonical sequence, as long as the changes do not affect the sequence's characteristics and overall three-dimensional structure. In some embodiments, the deviating nucleotides represent conservative sequence changes. As a non-limiting example, a sequence has at least 95%, 96%, 97%, 98%, or 99% sequence identity (e.g., as measured using BLAST with default settings) to the canonical sequence and has a symmetric three-dimensional spatial organization relative to the other WT-ITR, such that their three-dimensional structures have the same shape in geometric space. A substantially symmetric WT-ITR has the same A, C-C', and B-B' loops in three-dimensional space. Substantially symmetric WT ITRs can be functionally confirmed as WT by determining that they have an operable Rep binding site (RBE or RBE') and terminal resolution site (trs) that pair with the appropriate Rep protein. Optionally, other functions can be tested, including transgene expression under permissive conditions.
[0051] As used herein, the phrases "modified ITR" or "mod-ITR" or "mutant ITR" are used interchangeably herein and refer to an ITR that has a mutation in at least one or more nucleotides compared to a WT-ITR from the same serotype. The mutation may result in a change in one or more of the A, C, C', B, and B' regions of the ITR, resulting in a change in its three-dimensional spatial configuration (i.e., its three-dimensional structure in geometric space) compared to the three-dimensional spatial configuration of a WT-ITR from the same serotype.
[0052] As used herein, the term "asymmetric ITR," also referred to as an "asymmetric ITR pair," refers to a pair of ITRs within a single ceDNA genome or ceDNA vector that are not reverse-complementary across their entire length. As a non-limiting example, an asymmetric ITR pair does not have a symmetrical three-dimensional spatial configuration relative to its cognate ITR, such that their three-dimensional structures are different shapes in geometric space. In other words, an asymmetric ITR pair differs in overall geometric structure, i.e., the configuration of their A, C-C', and B-B' loops in three-dimensional space (e.g., compared to the cognate ITR), differs. The sequence difference between the two ITRs may be due to one or more nucleotide additions, deletions, truncations, or point mutations. In one embodiment, one ITR of the asymmetric ITR pair may be a wild-type AAV ITR sequence, and the other ITR may be a modified ITR (e.g., a non-wild-type or synthetic ITR sequence) as defined herein. In another embodiment, neither ITR of the asymmetric ITR pair is a wild-type AAV sequence, but rather the two ITRs are modified ITRs that have different shapes in geometric space (i.e., different overall geometric structures). In some embodiments, one mod-ITR of the asymmetric ITR pair can have a short C-C' arm, and the other ITR can have a different modification (e.g., a single arm, or a short B-B' arm, etc.) such that it has a different three-dimensional spatial organization compared to its cognate asymmetric mod-ITR.
[0053] As used herein, the term "symmetric ITRs" refers to a pair of ITRs within a single ceDNA genome or ceDNA vector that are mutated or modified relative to the wild-type Dependvirus ITR sequence and are reverse complements across their entire length. Neither ITR is the wild-type AAV2 ITR sequence (i.e., they are modified ITRs, also referred to as mutant ITRs), and their sequence may differ from the wild-type ITR due to nucleotide additions, deletions, substitutions, truncations, or point mutations. For convenience, the ITR located 5' (upstream) of the expression cassette in the ceDNA vector is referred to as the "5' ITR" or "left ITR," and the ITR located 3' (downstream) of the expression cassette in the ceDNA vector is referred to as the "3' ITR" or "right ITR."
[0054] As used herein, the term "substantially symmetric modified ITR" or "substantially symmetric mod-ITR pair" refers to a pair of modified ITRs within a single ceDNA genome or ceDNA vector, both of which have reverse-complementary sequences throughout their entire length. For example, modified ITRs can be considered substantially symmetric even if there are some nucleotide sequence deviations from the reverse-complementary sequence, as long as the changes do not affect the properties and overall shape. As a non-limiting example, the sequences have at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity (measured using BLAST with default settings) to the canonical sequence and also have a symmetric three-dimensional spatial organization relative to their cognate modified ITR, such that their three-dimensional structures have the same shape in geometric space. In other words, a substantially symmetric modified ITR pair has the same A, C-C', and B-B' loops organized in three-dimensional space. In some embodiments, the ITRs from a mod-ITR pair may have different reverse-complementary nucleotide sequences but still have the same symmetrical three-dimensional spatial organization. That is, both ITRs have mutations that result in the same overall three-dimensional shape. For example, one ITR (e.g., the 5' ITR) of a mod-ITR pair may be derived from one serotype, and the other ITR (e.g., the 3' ITR) may be derived from a different serotype, but both may have the same corresponding mutation (e.g., if the 5' ITR has a deletion in the C region, the cognate modified 3' ITR of the different serotype will have a deletion in the corresponding position in the C' region), thereby resulting in the modified ITR pair having the same symmetrical three-dimensional spatial organization. In such embodiments, each ITR of a modified ITR pair can be derived from a different serotype (e.g., AAV1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12), such as a combination of AAV2 and AAV6, and modifications of one ITR are reflected in the corresponding position of the cognate ITR of the different serotype. In one embodiment, a substantially symmetric modified ITR pair refers to a pair of modified ITRs (mod-ITRs), so long as the nucleotide sequence differences between the ITRs do not affect their properties or overall shape and they have substantially the same shape in three-dimensional space.As a non-limiting example, a mod-ITR has at least 95%, 96%, 97%, 98%, or 99% sequence identity to a canonical mod-ITR, as determined by standard means well known in the art, such as BLAST (Basic Local Alignment Search Tool) or BLASTN with default settings, and has a symmetrical three-dimensional spatial organization such that their three-dimensional structures have the same shape in geometric space. A substantially symmetric mod-ITR pair will have the same A, C-C', and B-B' loops in three-dimensional space. For example, if the modified ITR of a substantially symmetric mod-ITR pair has a deletion of the C-C' arm, the cognate mod-ITR will have a corresponding deletion of the C-C' loop and a similar three-dimensional structure of the remaining A and B-B' loops that are the same shape in geometric space as its cognate mod-ITR.
[0055] The term "flanking" refers to the relative position of one nucleic acid sequence with respect to another. Generally, in the sequence ABC, B is flanked on either side by A and C. The same is true for the arrangement AxBxC. Thus, a flanking sequence may precede or follow the flanked sequence, but need not be contiguous with or immediately adjacent to the flanked sequence. In one embodiment, the term flanking refers to the terminal repeats at each end of a linear, double-stranded ceDNA vector.
[0056] As used herein, the term "ceDNA genome" refers to an expression cassette that further incorporates at least one inverted terminal repeat region. The ceDNA genome may further comprise one or more spacer regions. In some embodiments, the ceDNA genome is incorporated into a plasmid or viral genome as an intermolecular double-stranded polynucleotide of DNA.
[0057] As used herein, the term "ceDNA spacer region" refers to an intervening sequence that separates functional elements in a ceDNA vector or ceDNA genome. In some embodiments, a ceDNA spacer region maintains two functional elements in a desired arrangement for optimal functionality. In some embodiments, a ceDNA spacer region provides or increases the genetic stability of a ceDNA genome, for example, within a plasmid or baculovirus. In some embodiments, a ceDNA spacer region facilitates easy genetic manipulation of a ceDNA genome by providing a convenient location for cloning sites, etc. For example, in certain aspects, an oligonucleotide "polylinker" containing several restriction endonuclease sites, or a non-open reading frame sequence designed to lack known protein (e.g., transcription factor) binding sites, can be positioned in a ceDNA genome to separate cis-acting elements, e.g., inserting a 6-mer, 12-mer, 18-mer, 24-mer, 48-mer, 86-mer, 176-mer, etc., between the terminal resolution site and the upstream transcriptional regulatory element. Similarly, a spacer can be incorporated between a polyadenylation signal sequence and a 3' terminal resolution site.
[0058] As used herein, "Rep binding site," "Rep binding element," "RBE," and "RBS" are used interchangeably and refer to the binding site of a Rep protein (e.g., AAV Rep78 or AAV Rep68) that, upon binding by the Rep protein, enables the Rep protein to carry out its site-specific endonuclease activity on the sequence incorporating the RBS. An RBS sequence and its reverse complement together form a single RBS. RBS sequences are known in the art and include, for example, the RBS sequence specified in AAV2, 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 60). Any known RBS sequence may be used in embodiments of the present invention, including other known AAV RBS sequences and other naturally occurring or synthetic RBS sequences. Without being bound by theory, it is believed that the nuclease domain of the Rep protein binds to the double-stranded nucleotide sequence GCTC, and thus two known AAV Rep proteins directly bind and stably assemble to the double-stranded oligonucleotide 5'-(GCGC)(GCTC)(GCTC)(GCTC)-3' (SEQ ID NO: 60). In addition, soluble aggregated conformers (i.e., an indefinite number of interrelated Rep proteins) dissociate and bind to oligonucleotides containing the Rep binding site. Each Rep protein interacts with both the nitrogenous bases and the phosphodiester backbone on each strand. The interactions with the nitrogenous bases provide sequence specificity, while the interactions with the phosphodiester backbone are non- or low-sequence specific, stabilizing the protein-DNA complex.
[0059] As used herein, the terms "terminal resolution site" and "TRS" are used interchangeably herein and refer to the region where Rep forms a tyrosine-phosphodiester bond with the 5'-thymidine, generating a 3'-OH that serves as a substrate for DNA elongation via a cellular DNA polymerase, such as DNA pol δ or DNA pol ε. Alternatively, the Rep-thymidine complex can participate in a coordinate ligation reaction. In some embodiments, the TRS minimally includes a non-base-paired thymidine. In some embodiments, the nicking efficiency of the TRS can be controlled, at least in part, by its distance from the RBS within the same molecule. When the acceptor substrate is a complementary ITR, the resulting product is an intermolecular duplex. TRS sequences are known in the art and include, for example, the hexanucleotide sequence 5'-GGTTGA-3' (SEQ ID NO: 61) identified in AAV2. Any known TRS sequence can be used in embodiments of the invention, including other known AAV TRS sequences, other naturally occurring or synthetic TRS sequences such as AGTT (SEQ ID NO: 62), GGTTGG (SEQ ID NO: 63), AGTTGG (SEQ ID NO: 64), AGTTGA (SEQ ID NO: 65), and other motifs such as RRTTRR (SEQ ID NO: 66).
[0060] As used herein, the term "ceDNA-plasmid" refers to a plasmid that contains a ceDNA genome as an intermolecular duplex.
[0061] As used herein, the term "ceDNA-bacmid" refers to an infectious baculovirus genome that contains a ceDNA genome as an intermolecular duplex that can be propagated as a plasmid in E. coli, thereby manipulating it as a baculovirus shuttle vector.
[0062] As used herein, the term "ceDNA-baculovirus" refers to a baculovirus that contains a ceDNA genome as an intermolecular duplex within the baculovirus genome.
[0063] As used herein, the terms "ceDNA-baculovirus-infected insect cells" and "ceDNA-BIIC" are used interchangeably and refer to invertebrate host cells (including but not limited to insect cells (e.g., Sf9 cells)) infected with a ceDNA-baculovirus.
[0064] As used herein, the term "closed-end DNA vector" refers to a capsid-free DNA vector that has at least one covalently closed end and at least a portion of the vector has an intramolecular double-stranded structure.
[0065] As used herein, the terms "ceDNA vector" and "ceDNA" are used interchangeably and refer to a closed-end DNA vector containing at least one terminal palindrome. In some embodiments, the ceDNA contains two covalently closed ends.
[0066] As defined herein, a "reporter" refers to a protein that can be used to provide a detectable readout. Reporters generally produce a measurable signal, such as fluorescence, color, or luminescence. A reporter protein coding sequence encodes a protein whose presence in a cell or organism is easily observed. For example, fluorescent proteins cause cells to fluoresce when excited with light of a particular wavelength, luciferase causes cells to catalyze a light-producing reaction, and enzymes such as β-galactosidase convert a substrate into a colored product. Exemplary reporter polypeptides useful for experimental or diagnostic purposes include, but are not limited to, β-lactamase, β-galactosidase (LacZ), alkaline phosphatase (AP), thymidine kinase (TK), green fluorescent protein (GFP) and other fluorescent proteins, chloramphenicol acetyltransferase (CAT), luciferase, and others well known in the art.
[0067] As used herein, the term "effector protein" refers to a polypeptide that provides a detectable readout, for example, as a reporter polypeptide, or more appropriately, as a cell-killing polypeptide, such as a toxin or a drug that renders cells susceptible to killing by a selected agent or its deletion. Effector proteins include any protein or peptide that directly targets or damages host cell DNA and / or RNA. For example, effector proteins include, but are not limited to, restriction endonucleases (whether genomic or extrachromosomal) that target host cell DNA sequences, proteases that target polypeptides required for cell survival, DNA gyrase inhibitors, and ribonuclease-type toxins. In some embodiments, the expression of an effector protein controlled by a synthetic biological circuit described herein can participate as a factor in another synthetic biological circuit, thereby expanding the scope and complexity of the reactivity of the biological circuit system.
[0068] Transcriptional regulators refer to transcriptional activators and repressors that activate or suppress the transcription of a gene of interest. A promoter is a region of nucleic acid that initiates the transcription of a specific gene. A transcriptional activator typically binds near the transcriptional promoter and recruits RNA polymerase to directly initiate transcription. A repressor binds to the transcriptional promoter and sterically hinders the initiation of transcription by RNA polymerase. Other transcriptional regulators can serve as either activators or repressors depending on where they bind and on cellular and environmental conditions. Non-limiting examples of transcriptional regulator classes include, but are not limited to, homeodomain proteins, zinc finger proteins, winged helix (forkhead) proteins, and leucine zipper proteins.
[0069] As used herein, a "repressor protein" or an "inducer protein" is a protein that binds to a regulatory sequence element and represses or activates the transcription of a sequence operably linked to the regulatory sequence element, respectively. Preferred repressor and inducer proteins described herein are sensitive to the presence or absence of at least one input agent or environmental input. Preferred proteins described herein are modular in form, for example, containing separable DNA binding and input agent binding or reactive elements or domains.
[0070] As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Supplementary active ingredients can also be incorporated into the composition. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce toxic, allergic, or similar untoward reactions when administered to a host.
[0071] As used herein, an "input agent-responsive domain" is a domain of a transcription factor that binds to or otherwise responds to a condition or input agent in such a manner as to render the linked DNA-binding fusion domain responsive to the presence of that condition or input. In one embodiment, the presence of the condition or input results in a conformational change in the input agent-responsive domain or the protein to which it is fused, which modifies the transcriptional regulatory activity of the transcription factor.
[0072] The term "in vivo" refers to an assay or process that occurs in or within an organism, such as a multicellular animal. In some of the embodiments described herein, a method or use may be said to occur "in vivo" when a unicellular organism, such as a bacterium, is used. The term "ex vivo" refers to methods and uses carried out using living cells with intact membranes outside the body of a multicellular animal or plant, such as explants, cultured cells (including primary cells and cell lines), transformed cell lines, and extracted tissues or cells (including blood cells), among others. The term "in vitro" refers to assays and methods that do not require the presence of cells with intact membranes, such as cell extracts, and can refer to introducing a programmable synthetic biological circuit into a non-cellular system, e.g., a medium that does not contain cells or cell systems, such as a cell extract.
[0073] As used herein, the term "promoter" refers to any nucleic acid sequence that regulates the expression of another nucleic acid sequence by driving the transcription of that nucleic acid sequence, which may be a heterologous target gene encoding a protein or RNA. A promoter can be constitutive, inducible, repressible, tissue-specific, or any combination thereof. A promoter is a control region of a nucleic acid sequence that controls the initiation and rate of transcription of the remainder of the nucleic acid sequence. A promoter can also contain genetic elements to which regulatory proteins and molecules, such as RNA polymerase and other transcription factors, can bind. In some embodiments of the aspects described herein, a promoter can drive the expression of transcription factors that regulate its own expression. Within the promoter sequence, one will find a transcription initiation site, as well as protein binding domains involved in the binding of RNA polymerase. Eukaryotic promoters often, but not necessarily, contain "TATA" and "CAT" boxes. A variety of promoters, including inducible promoters, can be used to drive the expression of transgenes in the ceDNA vectors disclosed herein. The promoter sequence is bounded at its 3' end by a transcription initiation site and extends upstream (5' orientation) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.
[0074] As used herein, the term "enhancer" refers to a cis-acting regulatory sequence (e.g., 50 to 1,500 base pairs) that binds to one or more proteins (e.g., activator proteins or transcription factors) to increase transcriptional activation of a nucleic acid sequence. Enhancers can be located up to 1,000,000 base pairs upstream of the start site of the gene they regulate or downstream of the start site of the gene. Enhancers can be located within intronic or exon regions of unrelated genes.
[0075] A promoter can be said to drive the expression or transcription of the nucleic acid sequence it regulates. The phrases "operably linked," "operably positioned," "operably linked," "under control," and "under transcriptional control" indicate that the promoter is in the correct functional location and / or orientation with respect to a nucleic acid sequence and regulates to control transcription initiation and / or expression of that sequence. As used herein, an "inverted promoter" refers to a promoter in which a nucleic acid sequence is in an inverted orientation, whereby what was the coding strand is now the non-coding strand, and vice versa. Inverted promoter sequences are used in various embodiments to regulate the state of a switch. Additionally, in various embodiments, a promoter can be used in conjunction with an enhancer.
[0076] A promoter can be one that is naturally associated with a gene or sequence, which can be obtained by isolating the 5' non-coding sequence located upstream of the coding segment and / or exon of a given gene or sequence. Such a promoter can be referred to as "endogenous." Similarly, in some embodiments, an enhancer can be one that is naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence.
[0077] In some embodiments, a coding nucleic acid segment is placed under the control of a "recombinant promoter" or "heterologous promoter," both of which refer to a promoter that is not normally associated with an operably linked encoded nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer refers to an enhancer that is not normally associated with a given nucleic acid sequence in its natural environment. Such promoters or enhancers can include promoters or enhancers of other genes, promoters or enhancers isolated from any other prokaryotic, viral, or eukaryotic cell, and synthetic promoters or enhancers that are not "naturally occurring," i.e., may contain different elements of different transcriptional regulatory regions and / or mutations that alter expression through methods of genetic engineering known in the art. In addition to synthetically producing promoter and enhancer nucleic acid sequences, promoter sequences can be produced using recombinant cloning and / or nucleic acid amplification techniques, including PCR, for the synthetic biological circuits and modules disclosed herein (see, e.g., U.S. Pat. Nos. 4,683,202 and 5,928,906, each of which is incorporated herein by reference). Furthermore, it is contemplated that regulatory sequences that direct transcription and / or expression of sequences within non-nuclear organelles, such as mitochondria, chloroplasts, etc., can be similarly employed.
[0078] As described herein, an "inducible promoter" is characterized by initiating or enhancing transcriptional activity when in the presence of, affected by, or contacted by an inducer or inducer agent. As defined herein, an "inducer" or "inducing agent" can be endogenous or can be a compound or protein, usually exogenous, administered in such a way that it is active in inducing transcriptional activity from an inducible promoter. In some embodiments, the inducer or inducer, i.e., a chemical, compound, or protein, can itself be the result of transcription or expression of a nucleic acid sequence (i.e., the inducer can be an inducer protein expressed by another component or module) and can itself be under the control of an inducible promoter. In some embodiments, an inducible promoter is induced in the absence of certain agents, such as repressors. Examples of inducible promoters include, but are not limited to, tetracycline, metallothionine, ecdysone, mammalian viruses (e.g., adenovirus late promoter and mouse mammary tumor virus long terminal repeat (MMTV-LTR)), as well as other steroid-responsive promoters, rapamycin-responsive promoters, and the like.
[0079] The terms "DNA regulatory sequence," "control element," and "regulatory element," used interchangeably herein, refer to transcriptional and translational control sequences, such as promoters, enhancers, polyadenylation signals, terminators, proteolysis signals, etc., that provide for and / or regulate the transcription of a non-coding sequence (e.g., a DNA-targeting RNA) or a coding sequence (e.g., a site-directed modifying polypeptide or a Cas9 / Csn1 polypeptide) and / or regulate the translation of the encoded polypeptide.
[0080] "Operably linked" refers to a juxtaposition of the components described in such a way that they function in their intended manner. For example, a promoter is operably linked to a coding sequence if it affects its transcription or expression. An "expression cassette" comprises a heterologous DNA sequence operably linked to a promoter or other regulatory sequence sufficient to direct the transcription of a transgene in a ceDNA vector. Suitable promoters include, for example, tissue-specific promoters. The promoter may also be of AAV origin.
[0081] As used herein, the term "subject" refers to a human or animal to which treatment, including preventive treatment, with the ceDNA vector of the present invention is provided. Typically, the animal is a vertebrate, such as, but not limited to, a primate, a rodent, a domestic animal, or a game animal. Primates include, but are not limited to, chimpanzees, cynomolgus monkeys, spider monkeys, and macaques, such as rhesus monkeys. Rodents include mice, rats, woodchucks, ferrets, rabbits, and hamsters. Domestic and game animals include, but are not limited to, cattle, horses, pigs, deer, bison, buffalo, feline species, such as domestic cats, canine species, such as dogs, foxes, wolves, avian species, such as chickens, emus, ostriches, and fish, such as trout, catfish, and salmon. In certain embodiments of the aspects described herein, the subject is a mammal, such as a primate or human. The subject may be male or female. Additionally, the subject may be an infant or child. In some embodiments, the subject may be a newborn or fetal subject, e.g., the subject is present in utero. Preferably, the subject is a mammal. The mammal may be, but is not limited to, a human, non-human primate, mouse, rat, dog, cat, horse, or cow. Non-human mammals may be advantageously used as subjects representing animal models of diseases and disorders. Additionally, the methods and compositions described herein may be used with domestic animals and / or pets. The human subject may be of any age, sex, race, or ethnic group, e.g., Caucasian (white), Asian, African, Black, African-American, Afro-European, Hispanic, Middle Eastern, etc. In some embodiments, the subject may be a patient or other subject in a clinical setting. In some embodiments, the subject has already received treatment. In some embodiments, the subject is an embryo, fetus, newborn, infant, child, adolescent, or adult. In some embodiments, the subject is a human fetus, human newborn, human infant, human child, human adolescent, or human adult. In some embodiments, the subject is an animal embryo, or a non-human embryo or a non-human primate embryo, hi some embodiments, the subject is a human embryo.
[0082] As used herein, the term "host cell" includes any cell type that is amenable to transformation, transfection, transduction, etc. with a nucleic acid construct or ceDNA expression vector of the present disclosure. By way of non-limiting example, host cells include isolated primary cells, pluripotent stem cells, CD34 + Host cells can be either human stem cells, induced pluripotent stem cells, or any of several immortalized cell lines (e.g., HepG2 cells). Alternatively, host cells can be cells in situ or in vivo in a tissue, organ, or organism.
[0083] The term "exogenous" refers to a substance present in a cell other than its natural source. As used herein, the term "exogenous" can refer to a nucleic acid (e.g., a nucleic acid encoding a polypeptide) or polypeptide that is not normally found and that has been introduced into a biological system, such as a cell or organism, by a process involving the hand of man, where it is desired to introduce the nucleic acid or polypeptide into such a cell or organism. Alternatively, "exogenous" can refer to a nucleic acid or polypeptide that is found in relatively low amounts and that has been introduced into a biological system, such as a cell or organism, by a process involving the hand of man, where it is desired to increase the amount of the nucleic acid or polypeptide in the cell or organism, e.g., to result in ectopic expression or levels. In contrast, the term "endogenous" refers to a substance that is native to a biological system or cell.
[0084] The term "sequence identity" refers to the relatedness between two nucleotide sequences. For purposes of this disclosure, the degree of sequence identity between two deoxyribonucleotide sequences is measured using the Needleman-Wunsch algorithm (Needleman) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, supra), preferably version 3.0.0 or later. and Wunsch, 1970, supra). Optional parameters used are a gap open penalty of 10, a gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The Needle output labeled "Longest Identity" (obtained using the -nobrief option) is used as the percent identity, calculated as follows: (identical deoxyribonucleotides × 100) / length of alignment - total number of gaps in the alignment. The length of the alignment is preferably at least 10 nucleotides, preferably at least 25 nucleotides, more preferably at least 50 nucleotides, and most preferably at least 100 nucleotides.
[0085] As used herein, the term "homology" or "homology" is defined as the percentage of nucleotide residues that are identical to the nucleotide residues of the corresponding sequence on the target chromosome, after aligning the sequences as necessary and introducing gaps to achieve the maximum sequence identity percentage. Alignment for the purpose of determining the percentage of nucleotide sequence homology can be achieved in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ClustalW2, or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment across the entire length of the sequences being compared. In some embodiments, for example, a nucleic acid sequence (e.g., a DNA sequence) of a homology arm is considered "homologous" if the sequence is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more identical to the corresponding native or unedited nucleic acid sequence (e.g., genomic sequence) of the host cell.
[0086] As used herein, the term "heterologous" refers to a nucleotide or polypeptide sequence that is not found in a naturally occurring nucleic acid or protein, respectively. A heterologous nucleic acid sequence can be linked (e.g., by genetic engineering) to a naturally occurring nucleic acid sequence (or a variant thereof) to generate a chimeric nucleotide sequence that encodes a chimeric polypeptide. A heterologous nucleic acid sequence can be linked (e.g., by genetic engineering) to a variant polypeptide to generate a nucleotide sequence that encodes a fusion variant polypeptide.
[0087] A "vector" or "expression vector" is a replicon, such as a plasmid, bacmid, phage, virus, virion, or cosmid, to which another DNA segment, i.e., an "insert," can be attached to effect replication of the attached segment in a cell. A vector can be a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. As used herein, a vector can be viral or non-viral in origin and / or final form, but for purposes of this disclosure, "vector," as the term is used herein, generally refers to a ceDNA vector. The term "vector" encompasses any genetic element that, when associated with the appropriate control elements, is capable of replicating and transferring gene sequences to a cell. In some embodiments, the vector can be an expression vector or a recombinant vector.
[0088] As used herein, the term "expression vector" refers to a vector that directs the expression of RNA or polypeptides from sequences linked to transcriptional regulatory sequences on the vector. The expressed sequences are often, but not necessarily, heterologous to the cell. Expression vectors can contain additional elements; for example, an expression vector can have two replication systems, allowing it to be maintained in two organisms, such as human cells for expression and prokaryotic hosts for cloning and amplification. The term "expression" refers to the cellular processes involved in the production of RNA and proteins, and, where appropriate, secreted proteins, including, but not limited to, transcription, transcription processing, translation, and protein folding, modification, and processing. "Expression product" includes RNA transcribed from a gene and polypeptides obtained by translation of mRNA transcribed from a gene. The term "gene" refers to a nucleic acid sequence (DNA) that is transcribed into RNA in vitro or in vivo when operably linked to appropriate regulatory sequences. A gene may or may not include regions preceding and following the coding region, such as 5' untranslated (5'UTR) or "leader" sequence and 3'UTR or "trailer" sequence, as well as intervening sequences (introns) between individual coding segments (exons).
[0089] "Recombinant vector" refers to a vector containing a heterologous nucleic acid sequence or a "transgene" that can be expressed in vivo. It should be understood that in some embodiments, the vectors described herein can be combined with other suitable compositions and therapeutic methods. In some embodiments, the vector is episomal. The use of a suitable episomal vector provides a means for maintaining the nucleotide of interest in a subject in high copy number extrachromosomal DNA, thereby eliminating the potential effects of chromosomal integration.
[0090] As used herein, the phrase "genetic disease" refers to a disease caused, directly or indirectly, in part or in whole by one or more abnormalities in the genome, particularly conditions present from birth. The abnormality may be a mutation, insertion, or deletion. The abnormality may affect the coding sequence of a gene or its regulatory sequence. The genetic disease may be, but is not limited to, DMD, hemophilia, cystic fibrosis, Huntington's disease, familial hypercholesterolemia (LDL receptor deficiency), hepatoblastoma, Wilson's disease, congenital hepatic porphyria, inherited disorders of liver metabolism, Lesch-Nyhan syndrome, sickle cell anemia, thalassemia, xeroderma pigmentosum, Fanconi anemia, retinitis pigmentosa, ataxia-telangiectasia, Bloom's syndrome, retinoblastoma, and Tay-Sachs disease.
[0091] As used herein, the terms "comprising" or "comprises" are used in reference to compositions, methods, and their respective component(s) that are essential to the method or composition, but are open to the inclusion of unspecified elements, whether essential or not.
[0092] As used herein, the term "consisting essentially of" refers to elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic and novel or functional characteristic(s) of the embodiment. The use of "comprises" indicates inclusion rather than limitation.
[0093] The term "consisting of" refers to compositions, methods, and their respective components described herein, excluding any element not recited in the description of the embodiment.
[0094] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a "method" includes one or more methods, and / or steps of the type described herein and / or that will become apparent to those of ordinary skill in the art upon reading this disclosure. Similarly, the word "or" is intended to include "and" unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The abbreviation "eg" is derived from the Latin "exempli gratia" and is used herein to indicate a non-limiting example. Thus, the abbreviation "eg" is synonymous with "for example."
[0095] Except in working examples or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood to be modified in all instances by the term "about." The term "about," when used in connection with percentages, may mean ±1%. The present invention is further illustrated by the following examples, but the scope of the present invention should not be limited thereto.
[0096] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limiting. Each group member may be referenced and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group may be included in, or deleted from, a group for reasons of convenience and / or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to include the modified group, thus satisfying all Markush group descriptions used in the appended claims.
[0097] In some embodiments of any aspect, the disclosure described herein does not pertain to human cloning processes, processes for correcting the genetic identity of human germ lines, the use of human embryos for industrial or commercial purposes, or animals that are likely to cause suffering without providing any substantial medical benefit to humans or animals, and processes for correcting the genetic identity of animals resulting from such processes.
[0098] Other terms are defined herein within the description of various aspects of the invention.
[0099] All patents and other publications cited throughout this application, including literature references, issued patents, published patent applications, and pending patent applications, are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that may be used in connection with the technology described herein. These publications are provided solely for their disclosure prior to the filing date of this application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the accuracy of the dates or contents of these documents.
[0100] The description of the embodiments of the present disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific embodiments and examples of the present disclosure have been described herein for illustrative purposes, those skilled in the art will recognize that various equivalent modifications are possible within the scope of the present disclosure. For example, while method steps or functions may be presented in a given order, alternative embodiments may perform the functions in a different order, or the functions may be performed substantially simultaneously. The teachings of the disclosure provided herein can be applied to other procedures or methods as appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the present disclosure can be modified, as appropriate, to employ the structure, function, and concepts of the above-mentioned references and applications to provide further embodiments of the present disclosure. Furthermore, due to considerations of biological functional equivalence, some changes can be made to protein structure without affecting the type or amount of biological or chemical activity. These and other changes can be made to the present disclosure in light of the detailed description. All such modifications are intended to be within the scope of the appended claims.
[0101] Specific elements of any of the foregoing embodiments can be combined with or substituted for elements of other embodiments. Additionally, although advantages associated with certain embodiments of the present disclosure have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments necessarily exhibit such advantages, to be within the scope of the present disclosure.
[0102] The techniques described herein are further illustrated by the following examples, which should not be construed as further limiting in any way. It is understood that the present invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention, which is defined solely by the claims.
[0103] II. Expression of antibodies or fusion proteins from ceDNA vectors The technology described herein generally relates to the expression and / or production of antibodies or fusion proteins in cells from non-viral DNA vectors, such as the ceDNA vectors described herein. ceDNA vectors for the production of antibodies or fusion proteins are described herein in the section entitled "ceDNA Vectors Generally." In particular, ceDNA vectors for the production of antibodies or fusion proteins include a pair of ITRs (e.g., symmetric or asymmetric as described herein) and a nucleic acid encoding the antibody or fusion protein described herein, operably linked to a promoter or regulatory sequence between the ITR pair. A distinct advantage of ceDNA vectors for the production of antibodies or fusion proteins over traditional AAV vectors and even lentiviral vectors is that there are no size constraints on the heterologous nucleic acid sequence encoding the desired protein. Thus, for example, even a full-length antibody containing two heavy chain Fc regions, a linker, and a Fab fragment can be expressed from a single ceDNA vector. Given their size, especially for antibody expression and / or production, ceDNA vectors are advantageous over conventional vectors due to their ease of use, and the lack of size constraints makes it easy to express antibodies with different domain structures (including multimeric antibodies) in a controlled manner. Furthermore, multiple administrations can be performed, allowing for the administration of a cocktail of different ceDNA vectors expressing different antibodies or fusion proteins. Thus, the ceDNA vectors described herein can be used to express therapeutic antibodies or fusion proteins in subjects in need thereof. Alternatively, ceDNA vectors can be used to produce antibodies or fusion proteins in commercial settings, for example, using bioreactors or for production in desired hosts.
[0104] As will be understood, the ceDNA vector technology described herein can be adapted to any level of complexity, or can be used in a modular manner, whereby the expression of different components of an antibody or fusion protein can be controlled independently. For example, the ceDNA vector technology designed herein can be as simple as using a single ceDNA vector to express a single heterologous gene sequence (e.g., the heavy or light chain of a desired antibody), or as complex as using multiple ceDNA vectors, each expressing multiple antibodies or antibody components, each independently controlled by a different promoter. The following embodiments are specifically contemplated herein and can be adapted by those skilled in the art as needed.
[0105] In embodiments, a single ceDNA vector can be used to express a single component of an antibody or fusion protein, e.g., a heavy chain or a light chain. Alternatively, a single ceDNA vector can be used to express multiple components (e.g., at least two) of an antibody or fusion protein under the control of a single promoter (e.g., a strong promoter), optionally using IRES sequence(s) to ensure proper expression of each component.
[0106] Also contemplated herein, in another embodiment, is a single ceDNA vector containing at least two inserts (e.g., expressing a heavy chain or a light chain), with the expression of each insert being under the control of its own promoter. The promoter may include multiple copies of the same promoter, multiple different promoters, or any combination thereof. As one skilled in the art will appreciate, it is often desirable to express components of an antibody at different expression levels, thus controlling the stoichiometry of the individual components expressed to ensure efficient antibody folding and combination in the cell.
[0107] Further variations of ceDNA vector technology can be envisioned by those skilled in the art or can be adapted from antibody production methods using conventional vectors.
[0108] A. Heterologous Sequences for Expression of Antibodies or Fusion Proteins Essentially any antibody or antigen-binding fragment (e.g., functional fragment) or fusion protein thereof can be expressed from a ceDNA vector as described herein. Those skilled in the art will understand that an antibody fragment includes at least the amino acids necessary for antigen or epitope binding (e.g., scAb, Fab, F(ab')2, dAb, and Fv). For example, an antibody molecule can include a heavy (H) chain variable domain sequence (abbreviated herein as VH) and a light (L) chain variable domain sequence (abbreviated herein as VL). In one embodiment, an antibody molecule comprises or consists of a heavy chain and a light chain (referred to herein as a half antibody). In another example, an antibody molecule contains two heavy (H) chain variable domain sequences and two light (L) chain variable domain sequences, thereby forming two antigen-binding sites, e.g., Fab, Fab', F(ab')2, Fc, Fd, Fd', Fv, single-chain antibodies (e.g., scFv), single variable domain antibodies, diabodies (Dab) (bivalent and bispecific), and chimeric (e.g., humanized) antibodies, which can be produced by modification of whole antibodies or those synthesized de novo using recombinant DNA technology. Such functional antibody fragments retain the ability to selectively bind with their respective antigens or epitopes and activate or inhibit target proteins.
[0109] Also included herein are ceDNA vectors that express fusion proteins. In some embodiments, the fusion protein is a biofunctional fusion protein. In some embodiments, the fusion protein is useful for trapping technology, e.g., antibody-ligand trapping, where the fusion protein comprises an antibody (e.g., a monospecific or bispecific antibody) or antibody fragment (e.g., an antigen-binding fragment) fused to a peptide, or a ligand-binding domain or receptor domain that captures a ligand and thereby inhibits its activity. Thus, in some embodiments, the ceDNA vector can encode and express a fusion protein, referred to in the art as a trap or Y-trap. In some embodiments, the ceDNA vectors described herein are used to express fusion proteins, e.g., a VEGF-trap fusion protein, an IGF-trap fusion protein (see Vaniotis et al., Sci Rep, 2018, 8(1), 17361), or a TGFβ-trap fusion protein. An exemplary TGFβ-trap is a bifunctional antibody-ligand trap (Y-trap), comprising, for example, a Y-trap, an antibody targeting CTLA-4 and / or PD-L1 fused to a TGFβ receptor II ectodomain sequence (a-CTLA4-TGFβRIIecd and a-PDL1-TGFβRIIecd), which simultaneously disables autocrine / paracrine TGFβ in the target cell microenvironment (e.g., Ravi et al., Nat Comm 2018, 9(1);741). In some embodiments, the fusion proteins encompassed for use herein and expressed by the ceDNA vectors are antibody-ligand traps, wherein the fusion protein comprises an antibody or antibody fragment (e.g., an antigen-binding fragment) fused to a ligand-binding domain or receptor domain (e.g., an extracellular receptor domain) that traps the ligand, and the ligand is selected from any commonly known growth factor or ligand, including, but not limited to, IGF, VEGF, TGFβ, TNFα, EGF, NGF, PDGF, LFA-3, CTLA-4, IL-1, TPO.
[0110] Exemplary fusion proteins include etanercept (ENBREL®), which comprises the 75 kDa soluble extracellular domain (ECD) of tumor necrosis factor (TNF) receptor II fused to human IgG1 Fc; alefacept (AMEVIVE®), which comprises the first ECD of lymphocyte function-associated antigen 3 (LFA-3) fused to human IgG1 Fc; abatacept (ORENCIA®), which comprises the ECD of human cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) fused to human IgG1 Fc; rilonacept (ARCALYST®), which comprises two chains, each comprising the C-terminus of the IL-1R accessory protein ligand binding region fused to the N-terminus of the IL-1RI ECD fused to human IgG1 Fc; romiplostim (NPLATE®), which comprises a peptide thrombopoietin (TPO) mimetic fused to the C-terminus of aglycosylated human IgG1 Fc; These include, but are not limited to, belatacept (NULOJIX®), which comprises the ECD of CTLA-4 fused to Fc and differs from abatacept by two amino acid substitutions in the CTLA-4 region (L104E, A29Y).
[0111] Antibodies and antibody fragments can be from any class of antibody, including, but not limited to, IgG, IgA, IgM, IgD, and IgE, and from any subclass of antibody (e.g., IgG1, IgG2, IgG3, and IgG4). Antibodies can be monoclonal. Antibodies produced using the methods described herein can be human, humanized, CDR-grafted, or in vitro generated. Antibodies can have a heavy chain constant region selected from, for example, IgG1, IgG2, IgG3, or IgG4. Antibodies can also have a light chain selected from, for example, kappa or lambda. The term "immunoglobulin" (Ig) is used interchangeably with the term "antibody" herein. Virtually any antibody can be produced by inserting the coding sequence of such an antibody into a ceDNA vector. In one embodiment, the light and heavy chain genes are under the control of a regulatory switch. In the same or alternative embodiment, the light and heavy chain genes are connected with an IRES sequence (e.g., SEQ ID NO: 190).
[0112] Typically, the antibody or fusion protein gene also encodes a secretory sequence that targets the antibody to the Golgi apparatus and endoplasmic reticulum, where it is folded into the correct conformation by chaperone molecules as it passes through the ER and exits the cell. Exemplary secretory sequences include VH-02 (SEQ ID NO: 88) and VK-A26 (SEQ ID NO: 89) and Ig K These include, but are not limited to, a signal sequence (SEQ ID NO: 126), as well as a Gluc secretion signal (SEQ ID NO: 188) that enables the tagged protein to be secreted from the cytosol, and a TMD-ST secretion sequence (SEQ ID NO: 189) that targets the tagged protein to the Golgi apparatus.
[0113] If an intrabody is desired, the nucleic acid or gene encoding the antibody typically does not encode a secretory sequence. In some instances, it may encode a secretory sequence, but also have an intended targeting sequence, such as, but not limited to, a KDEL sequence, to keep it intracellular. In other embodiments, the intrabody gene encodes another intracellular targeting sequence, such as a nuclear localization sequence.
[0114] Regulatory switches can be used to fine-tune expression of antibodies (including intrabodies) or fusion proteins so that the antibody is expressed as needed (including, but not limited to, expression of the antibody or fusion protein at a desired expression level or amount) or in the presence or absence of a particular signal, including a cell signaling event. For example, as described herein, expression of an antibody or fusion protein from a ceDNA vector can be turned on or off when a particular condition occurs, as described herein in the section entitled "Regulatory Switches."
[0115] For example, and for illustrative purposes only, antibodies or fusion proteins can be used to block undesired reactions, as in the case of anti-TNFα antibodies such as adalimumab. In other cases, antibodies or fusion proteins can help enhance immune responses. For example, in the context of malignant cells, such as tumors. The antibody gene may include a tumor-associated marker to direct the antibody to the desired cells. However, in either situation, it may be desirable to regulate the expression of the antibody or fusion protein. ceDNA vectors readily accommodate the use of regulatory switches with antibodies. ceDNA vectors also allow for control of the stoichiometry of the heavy and light chains. Examples of fusion proteins include, but are not limited to, VEGF-trap and TGFβ-trap technologies.
[0116] Antibody molecules include intact molecules as well as antigen-binding and functional fragments thereof. The constant regions of an antibody molecule can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of Fc receptor binding, the number of cysteine residues, etc.). Examples of antigen-binding fragments of antibody molecules include, but are not limited to, (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) an F(ab')2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a diabody (dAb) fragment consisting of a VH domain; (vi) a camel or camelized variable domain; (vii) a single-chain Fv (scFv) (see, e.g., Bird et al. (1988) Science 242:423-426 and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883); and (viii) a single-domain antibody. These antibody fragments can be obtained using ceDNA vectors and screened for utility in the same manner as intact antibodies.
[0117] A distinct advantage of ceDNA vectors over traditional AAV vectors and even lentiviral vectors is that there are no size constraints on the heterologous nucleic acid sequence encoding the desired protein. Thus, even a full-length antibody containing two heavy chain Fc regions, a linker, and a Fab fragment can be expressed from a single ceDNA vector. Furthermore, depending on the required atomic chemistry, multiple segments (e.g., light and heavy chains) of the same antibody or fusion protein can be expressed, using the same or different promoters, and regulatory switches can be used to fine-tune the expression of each region. For example, as shown in the Examples, ceDNA vectors containing dual-promoter systems can be used, whereby different promoters are used for each of the heavy and light chains of the aducanumab antibody. The use of ceDNA plasmids to produce antibodies or fusion proteins involves a unique combination of promoters for heavy and light chain expression, resulting in the appropriate ratio of heavy and light chains for the formation of a functional antibody or fusion protein. Thus, in some embodiments, ceDNA vectors can be used to express different regions of an antibody or fusion protein separately (e.g., under the control of different promoters). In some embodiments, the nucleic acid encoding the heavy chain can be operably linked to a first promoter or a first regulatory switch, and the nucleic acid encoding the light chain can be operably linked to a second promoter or a second regulatory switch, thus allowing for controlled or tunable expression of the heavy and light chains, independent of each other, and allowing for control of the ratio of heavy to light chains for production of a functional antibody or fusion protein.
[0118] Expression of the antibody or fusion protein from the ceDNA vector can be achieved spatially and temporally using one or more inducible or repressible promoters.
[0119] The antibody molecule may also be a single domain antibody. A single domain antibody may include an antibody whose complementarity-determining region is part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies that naturally lack light chains, single domain antibodies derived from traditional four-chain antibodies, engineered antibodies, and single domain scaffolds other than those derived from antibodies. A single domain antibody may be any single domain antibody currently available or in the future. A single domain antibody may be derived from any species, including, but not limited to, mouse, human, camel, llama, fish, shark, goat, rabbit, and cow.
[0120] In some embodiments, the antibody is a multispecific antibody, comprising two or more variable regions that, for example, bind to at least two different epitopes on the same target protein or simultaneously target at least two different proteins, i.e., the epitopes recognized by the multispecific antibody can be on the same or different targets.
[0121] In other embodiments, the antibody is a bispecific antibody, capable of recognizing and binding to at least two different epitopes or targets (see, e.g., Riethmuller, G Cancer Immunity (2012) 12:12-18; Schaefer w et al. PNAS (2011) 108(27):11187-92 for exemplary bispecific antibody structures). Second-generation bispecific antibodies, e.g., "trifunctional bispecific" antibodies, are also contemplated in the methods and compositions described herein.
[0122] In certain embodiments, the provided antibody is a multispecific antibody, including a bispecific antibody. A multispecific antibody is a monoclonal antibody that has binding specificities for at least two different sites. An exemplary bispecific antibody has one binding specificity for Aβ and the other for any other antigen. In certain embodiments, the bispecific antibody can bind to two different epitopes of Aβ. Bispecific antibodies can also be used to localize cytotoxic agents in cells. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.
[0123] In some embodiments, ceDNA vectors for producing multispecific antibodies include the co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein and Cuello, Nature 305:537 (1983)), WO 93 / 08829, and Traunecker et al., EMBOJ. 10:3655 (1991)) and "knobs-in-holes" engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can also be produced by creating antibody Fc heterodimeric molecules (WO2009 / 089004A1), cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980 and Brennan et al., Science, 229:81 (1985)), using leucine zippers to produce bispecific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)), using "diabody" technology to create bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)), and using single-chain Fv (sFv) dimers (see, e.g., Gruber et al. al., J. Immunol., 152:5368 (1994)), for example, by manipulating electrostatic steering effects to prepare trispecific antibodies as described in Tutt et al. J. Immunol. 147:60 (1991).
[0124] In some embodiments, the ceDNA vector encodes an engineered antibody with three or more functional antigen binding sites, including an "octopus antibody," also included herein (see, e.g., US2006 / 0025576A1). In some embodiments, the ceDNA vector encodes an antibody or fusion protein that is a "dual-acting FAb" or "DAF," which contains antigen binding sites that bind to Aβ and another distinct antigen (see, e.g., US2008 / 0069820).
[0125] In one embodiment, the antibody is an "antibody variant," which refers to an antibody that has an altered amino acid sequence, composition, or structure compared to the corresponding native antibody. For example, the antibody variant may contain a non-native secretory signal that enables the antibody to be secreted from host cells.
[0126] In certain embodiments, the ceDNA vector encodes a cysteine-engineered antibody variant, e.g., a "thioMAb," in which one or more residues of the antibody are substituted with a cysteine residue. In certain embodiments, the substituted residues occur at accessible sites of the antibody. By substituting these residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody, which can be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create immunoconjugates, as further described herein. In certain embodiments, any one or more of the following residues can be substituted with cysteine: V205 (Kabat numbering) of the light chain, A118 (EU numbering) of the heavy chain, and S400 (EU numbering) of the heavy chain Fc region. Cysteine-engineered antibodies can be generated, for example, as described in U.S. Pat. No. 7,521,541.
[0127] In another embodiment, the antibody may be a miniaturized antibody, which is a monovalent or bivalent antibody comprising a variable light chain, a variable heavy antigen-binding domain, and optionally one or more effector domains (e.g., tissue-specific targets). While the use of miniaturized antibodies is specifically contemplated herein, ceDNA vectors have the advantage that they are not size-constrained with respect to heterologous nucleic acid sequences and therefore allow the expression of even full-length antibodies.
[0128] In another embodiment, the antibody or fusion protein expressed from the ceDNA vector further comprises additional functionality, such as fluorescence, enzymatic activity, a secretion signal, or an immune cell activator.
[0129] In some embodiments, the antibody encoded by the ceDNA vector comprises a diabody (a bispecific single-chain antibody) or a unibody (an IgG4 molecule lacking the hinge region to reduce the risk of immune activation).
[0130] The ceDNA vectors for antibody production described herein are also useful for expressing fusion proteins or intrabodies (i.e., intracellular antibodies) that can target intracellular proteins that affect cellular functions (e.g., metabolism, cell division, transcription, translation, etc.). Intrabodies can be scFvs. Intrabodies can be directed to specific cellular compartments by incorporating signaling motifs such as a C-terminal ER retention signal (e.g., KDEL), a mitochondrial targeting sequence, or a nuclear localization sequence.
[0131] Intrabodies are particularly suitable for the treatment of diseases associated with misfolded proteins, such as Alzheimer's disease, Parkinson's disease, prion diseases, Huntington's disease, and the like.
[0132] In some embodiments, the antibody or fusion protein can further comprise, for example, a linker domain. As used herein, "linker domain" refers to an oligo- or polypeptide region, approximately 2 to 100 amino acids in length, that links together any of the antibody domains / regions described herein. In some embodiments, the linker can comprise or consist of flexible residues, such as glycine and serine, to allow adjacent protein domains to move freely relative to one another. Longer linkers can be used if it is desirable to prevent two adjacent domains from sterically interfering with one another. The linker can be cleavable or non-cleavable. Examples of cleavable linkers include a 2A linker (e.g., T2A), a 2A-like linker, or functional equivalents thereof, and combinations thereof. The linker can be a linker region that is T2A derived from the Thosea asigna virus.
[0133] It is well within the ability of one of ordinary skill in the art to take known and / or publicly available protein sequences, for example, fusion proteins, heavy chains, light chains, variable regions, etc., and reverse engineer cDNA sequences to encode such proteins (e.g., fusion proteins) or antibodies. The cDNA can then be codon-optimized to be compatible with the intended host cell and inserted into a ceDNA vector as described herein.
[0134] In one embodiment, the antibody encoding sequence may be derived from an existing hybridoma cell line, for example, by reverse transcribing mRNA obtained from the hybridoma cell line and amplifying the sequence using PCR.
[0135] B. ceDNA Vectors Expressing Antibodies or Fusion Proteins A ceDNA vector for producing an antibody or fusion protein having one or more sequences encoding a desired antibody can include regulatory sequences such as a promoter, secretion signal, polyA region, and enhancer. At a minimum, the ceDNA vector contains one or more heterologous sequences encoding the antibody or fusion protein. Exemplary ceDNA vectors for producing an antibody or fusion protein are shown in Figures 7A-7G.
[0136] To achieve highly efficient and accurate antibody or fusion protein assembly, in some embodiments, the antibody, fusion protein, or individual antibody domain contains an endoplasmic reticulum (ER) leader sequence that directs it to the ER where protein folding occurs, e.g., a sequence that targets the expressed protein(s) to the ER for folding.
[0137] In some embodiments, a cellular or extracellular localization signal (e.g., a secretory signal, a nuclear localization signal, a mitochondrial localization signal, etc.) is included in the ceDNA vector (see, e.g., Figure 10G) to direct the secretion or desired subcellular localization of the antibody or fusion protein, thereby enabling the antibody or fusion protein to bind to an intracellular target(s) (e.g., an intrabody) or an extracellular target(s).
[0138] In certain embodiments, the ceDNA vector for antibody production can encode intrabody, and in some embodiments, the intrabody can be a full-length antibody and a single chain.Intrabody can be used in a wide range of fields, including treating viral diseases and cellular diseases such as cancer.See, for example, U.S. Patent No. 6,004,940.
[0139] In some embodiments, the ceDNA vectors for antibody or fusion protein production described herein (see, e.g., the exemplary ceDNA vector depicted in Figure 6A) allow for the assembly and expression of any desired antibody or fusion protein in a modular manner. As used herein, the term "module" refers to an element in a ceDNA expression plasmid that can be easily removed from the construct. For example, modular elements in ceDNA production plasmids contain unique pairs of restriction sites flanking each element within the construct, allowing for exclusive manipulation of individual elements (see, e.g., Figures 7A-7G). Thus, the ceDNA vector platform can enable the expression and assembly of any desired antibody or fusion protein construct. Provided herein, in various embodiments, are ceDNA plasmid vectors that can reduce and / or minimize the amount of manipulation required to assemble a desired ceDNA vector encoding an antibody or fusion protein.
[0140] C. Exemplary Antibodies and Fusion Proteins Expressed by ceDNA Vectors In particular, the ceDNA vectors for the production of antibodies or fusion proteins disclosed herein can encode, for example, but are not limited to, antibodies, antigen-binding fragments, fusion proteins, and variants and / or active fragments thereof for use in the treatment, prevention, and / or amelioration of one or more symptoms of a disease, dysfunction, injury, and / or disorder. In one embodiment, the disease, dysfunction, injury, injury, and / or disorder is a human disease, dysfunction, injury, injury, and / or disorder.
[0141] In some embodiments, ceDNA vectors for production of antibodies or fusion proteins disclosed herein can also encode cofactors or other polypeptides, sense or antisense oligonucleotides, or RNA (coding or non-coding, e.g., siRNA, shRNA, microRNA, antisense counterparts (e.g., antagoMiR) that can be used in combination with antibodies or fusion proteins expressed from ceDNA). Additionally, expression cassettes containing sequences encoding antibodies or fusion proteins can also include exogenous sequences encoding reporter proteins used for experimental or diagnostic purposes, such as β-lactamase, β-galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), luciferase, and others well known in the art.
[0142] In certain embodiments, multiple different antibodies and / or fusion proteins can be administered using one or more ceDNA vectors, and it is specifically contemplated that a desired number of antibodies and / or fusion proteins can thus be expressed in a "cocktail" of cells, tissues, or subjects.
[0143] The ceDNA vectors described herein can be used to deliver antibodies and fusion proteins for the treatment of, for example, cancer, autoimmune diseases (e.g., rheumatoid arthritis, Crohn's disease), Alzheimer's disease, hypercholesterolemia, acute organ rejection, multiple sclerosis, postmenopausal osteoporosis, skin conditions (e.g., psoriasis, atopic dermatitis), asthma, or hemophilia.
[0144] The ceDNA vectors described herein can be used to express any desired therapeutic antibody or fusion protein. Exemplary therapeutic antibodies and fusion proteins include abciximab, abaloparatide, adalimumab, adalimumab-atto, ado-trastuzumab emtansine, aducanumab, alemtuzumab, alirocumab, atezolizumab, avelumab, bapineuzumab, basiliximab, belimumab, bevacizumab, bezlotoxumab, blinatumomab, brosozumab, bococizumab, brentuximab vedotin, brodalumab, canakinumab, capromab pedragonfly ... ndetide, certolizumab pegol, cetuximab, concizumab, daclizumab, daratumumab, denosumab, dinutuximab, dupilumab, durvalumab, ecallantide, eculizumab, elotuzumab, emtansine, emicizumab, evolocumab, evinacumab, factor IX-Fc antibody, factor VIII-Fc antibody, golimumab, ibritumomab tiuxetan, idarucizumab, inlacumab, infliximab, infliximab-abda, Infliximab-dyyb, ipilimumab, ixekizumab, lanadelumab, roderucizumab, mepolizumab, natalizumab, necitumumab, nivolumab, obilutoxaximab, obinutuzumab, ocrelizumab, ofatumumab, olaratumab, omalizumab, olticumab, palivizumab, panitumumab, pembrolizumab, pertuzumab, pexelizumab, ralpancizumab, ramucirumab, ranibizumab, raxibacumab, reslizumab, rituximab These include, but are not limited to, ximab, lorezumab, romosozumab, secukinumab, siltuximab, solanezumab, sotatercept, tadocizumab, tocilizumab, trastuzumab, ustekinumab, vedolizumab, sarilumab, rituximab, guselkumab, inotuzumab ozogamicin, adalimumab-adbm, gemtuzumab ozogamicin, bevacizumab-awwb, benralizumab, emicizumab-kxwh, and trastuzumab-dkst.
[0145] In one embodiment, the ceDNA vector contains a nucleic acid sequence for expressing a therapeutic antibody or fusion protein that is functional for the treatment of a disease. In a preferred embodiment, the therapeutic antibody or fusion protein does not provoke an immune system response unless desired.
[0146] In one embodiment, the antibody is a therapeutic antibody or fusion protein expressed by a ceDNA vector that targets an immune checkpoint inhibitor (e.g., PDL1), and may be used, for example, to treat cancer (e.g., solid tumors, breast cancer, lymphoma, liver cancer, ovarian cancer, lung cancer, colorectal cancer, leukemia, blood cancer, skin cancer, multiple myeloma, etc.).In one embodiment, the therapeutic antibody or fusion protein is selected from the group consisting of checkpoint inhibitors, such as PDL1, CD47, mesothelin, gangloside 2 (GD2), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PMSA), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), Ron kinase, c-Met, immature laminin receptor, TAG-72, BING-4, calcium-activated chloride channel 2, cyclin-B1, 9D7, Ep-CAM, EphA3, Her2 / neu, and tetanus. Romeroase, SAP-1, survivin, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A / MART-1, Gp100 / pmel17, tyrosinase, TRP-1 / -2, MC1R, β-catenin, BRCA1 / 2, CDK4, CML66, fibronectin, p53, Ras, TGF-B receptor, AFP, ETA, MAGE, MUC-1, CA-125, BAGE, GAGE, NY-ESO-1, β-catenin, CDK4, CDC27, CD47, α-actin leukemia-4, TRP1 / gp75, TRP2, gp100, Melan-A / MART1, gangliosides, WT1, EphA3, epithelial intestinal factor receptor (EGFR), CD20, MART-2, MART-1, MUC1, MUC2, MUC16, MUM1, MUM2, MUMS, NA88-1, NPM, OA1, OGT, RCC, RUI1, RUI2, SAGE, TRG, TRP1, TSTA, folate receptor α, L1-CAM, CAIX, EGFRvIII, gpA33, GD3, GM2, VEG Targeting FR, integrins (integrin αVβ3, integrin α5β1), carbohydrates (Le), IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL, fibroblast-activating protease (FAP), TGF-β, hyaluronic acid, collagen (e.g., collagen IV, tenascin-C, or tenascin-W), CD19, CD33, CD47, CD123, CD20, CD99, CD30, BCMA, CD38, CD22, SLAMF7, or NY-ESO1.
[0147] In one embodiment, the ceDNA vector expresses the evolocumab monoclonal antibody and is used to treat hyperlipidemia. Evolocumab inhibits proprotein convertase subtilisin / kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation, reducing the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood. Evolocumab is further described in US 8,999,341, the entire contents of which are incorporated herein by reference.
[0148] Exemplary antibodies and fusion proteins expressed from ceDNA vectors for use in the methods and compositions disclosed herein can be any antibody or fusion protein listed in Table 1, Table 2, Table 3A, Table 3B, Table 4, or Table 5 herein. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 3A] [Table 3B] [Table 4-1] [Table 4-2] [Table 5-1] [Table 5-2]
[0149] Additional exemplary antibodies and fusion proteins expressed by ceDNA vectors include, but are not limited to, those described below.
[0150] Brodalumab (SILIQ®, LUMICEF®, KYNTHEUM®, AMG-827) is a human IgG2 antibody that targets IL-17 receptor A (IL-17RA) and prevents the inflammatory signaling of the pro-inflammatory cytokines IL-17A, IL-17F, and IL-17C through IL-17RA. Brodalumab is approved in the United States (SILIQ®), the EU (KYNTHEUM®), and Japan (LUMICEF®). Brodalumab is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have not responded or have stopped responding to other systemic therapies.
[0151] Dupilumab (DUPIXENT®, REGN668 / SAR231893) is a human IgG4 mAb that targets the IL-4 receptor (IL4R), thus blocking IL-4- and IL-13-mediated inflammatory responses. The mAb has been approved in the US and EU for patients with atopic dermatitis.
[0152] Ocrelizumab (OCREVUS®) is a humanized IgG1 antibody that targets CD20-positive B cells, which play a role in myelin damage and the pathogenesis of multiple sclerosis.
[0153] Ocrelizumab is approved in the United States for the treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
[0154] Sarilumab (KEVZARA®, SAR153191, REGN88) is a human IgG1 antibody that targets the IL-6 receptor (IL-6R) and is approved in Canada, the United States, and the EU for patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).
[0155] Benralizumab (FASENRA®, MEDI-563) is an afucosylated IgG1 mAb that targets the α subunit of the IL-5R found on eosinophils and is FDA-approved for add-on maintenance treatment of patients aged 12 years and older with severe asthma.
[0156] Emicizumab (HEMLIBRA®, emicizumab-kxwh, ACE910, RO5534262) is a bispecific IgG4 mAb targeting factor IXa and factor X and has been approved by the FDA. This drug was approved to prevent or reduce the frequency of bleeding episodes in adult and pediatric hemophilia A patients with a developed factor VIII inhibitor. As of December 1, 2017, a total of nine antibody therapeutics were under regulatory review in either the United States or the EU. Of these, eight (ibalizumab, burosumab, tildrakizumab, caplacizumab, erenumab, fremanezumab, galcanezumab, and romosozumab) have not yet received marketing approval. Mogamulizumab was the first globally approved in Japan on March 20, 2012.
[0157] Ibalizumab is an IgG4 mAb that targets CD4 and is being evaluated by the FDA for the treatment of multidrug-resistant human immunodeficiency virus (HIV) infection.
[0158] Burosumab (KRN23) is a human IgG1 mAb that targets fibroblast growth factor 23 (FGF23), a hormone that regulates phosphate excretion and active vitamin D production by the kidney.
[0159] Tildrakizumab (SCH900222 / MK-3222) is a humanized IgG1 mAb that targets IL-23p19. Marketing authorization applications for tildrakizumab for the treatment of moderate to severe plaque psoriasis have been submitted in the EU and the US.
[0160] Caplacizumab (ALX-0081), a bivalent single-domain antibody (Nanobody®) targeting von Willebrand factor, is under regulatory review for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a rare, life-threatening blood clot disorder associated with the formation of microthrombi that lead to low platelet counts, tissue ischemia, and organ dysfunction in patients with aTTP.
[0161] Aimovig (AMG 334) is an IgG2 mAb that targets the receptor for calcitonin gene-related peptide (CGRP), which is involved in the development of sensitized nociceptive neurons. Marketing authorization applications for Aimovig have been submitted in the EU and the US for the prevention of migraine in patients experiencing four or more migraine days per month.
[0162] Fremanezumab (TEV-48125) is an IgG2 mAb targeting CGRP that is under regulatory review for the preventive treatment of migraine.
[0163] Galcanezumab (LY2951742) is an IgG4 mAb targeting CGRP that is undergoing regulatory review for the prevention of episodic and chronic migraine headaches in adults.
[0164] Romosozumab (EVENITY™, AMG785) is a humanized IgG2 mAb that targets sclerostin and is being evaluated for the treatment of osteoporosis in women and men.
[0165] Mogamulizumab (KW-0761, POTELIGEo®) is an IgG1 afucosylated humanized mAb that targets CC chemokine receptor 4 (CCR4) expressed on tumor cells in patients with cutaneous T-cell leukemia-lymphoma (CTCL), including mycosis fungoides and Sézary syndrome.
[0166] Lanadelumab (SHP643, DX-2930) is a human IgG1 mAb that targets plasma kallikrein, thereby preventing the production of bradykinin.
[0167] Crizanlizumab (SEG101) is a humanized mAb targeting P-selectin (also known as CD62) that is being evaluated for the treatment of sickle cell-related pain crisis (SCPC), which is caused by vaso-occlusion in patients with sickle cell disease.
[0168] Ravulizumab (ALXN1210) is a humanized mAb targeting complement component 5 (C5) that is undergoing evaluation in two phase 3 trials in patients with paroxysmal nocturnal hemoglobinuria (PNH).
[0169] Eptinezumab (ALD403) is an IgG1 mAb targeting calcitonin gene-related peptide (CGRP) that is being evaluated for migraine prevention.
[0170] Risankizumab (ABBV066, BI655066) is an IgG1 mAb that targets the p19 subunit of IL-23, which is involved in the pathogenesis of psoriasis.
[0171] Satralizumab (SA237) is a humanized IgG2 that targets the IL-6R and is undergoing evaluation in two phase 3 trials in patients with neuromyelitis optica (NMO) or NMO spectrum disorders.
[0172] Brolucizumab (RTH258) is a single-chain variable fragment (scFv) that targets vascular endothelial growth factor (VEGF)-A.
[0173] PRO140 is a humanized IgG4 mAb that blocks the human immunodeficiency virus (HIV) co-receptor CCR5 on T cells, thereby preventing viral entry.
[0174] Lampalizumab (RG7417, FCFD4514S) is a humanized antigen-binding fragment (Fab) that inhibits activation and amplification of the alternative pathway by binding complement factor D.
[0175] Lorezumab (LFB-R593) is a human IgG1 anti-rhesus (Rh) D mAb derived from LFB SA's EMABLING® technology platform, which alters fucosylation, resulting in more effective binding of the antibody to effector cells. The antibody is designed to prevent several maternal-fetal alloimmunization conditions, namely in RhD-negative pregnant women carrying RhD-positive fetuses.
[0176] Fasinumab (REGN475) is a human IgG4 mAb targeting nerve growth factor that is being evaluated in a number of late-stage studies for the treatment of moderate to severe osteoarthritis pain of the hip or knee, and chronic low back pain.
[0177] Etrolizumab (RH7413) is a humanized mAb that binds to the β7 subunit of the α4β7 and αEβ7 integrin heterodimers, thereby inhibiting their interaction with the ligands MAdCAM-1 and E-cadherin, respectively.
[0178] NEOD001 is a humanized IgG1 mAb that targets soluble and insoluble light chain aggregates that cause amyloid light chain (AL) amyloidosis, a disease characterized by excessive accumulation of protein aggregates in tissues and organs, including the heart, kidneys, and liver.
[0179] Gantenerumab (RO4909832) is a human mAb targeting fibrillar amyloid-β that is under investigation as a treatment for Alzheimer's disease.
[0180] Anifrolumab (MEDI-546) is a human IgG1 mAb targeting type I interferon (IFN) receptor subunit 1 that is being evaluated for the treatment of SLE.
[0181] Moxetumomab passudotox (HA22, CAT-8015) is a recombinant immunotoxin containing the 38 kDa cytotoxic portion of Pseudomonas exotoxin A fused to an antibody variable fragment that targets CD22.
[0182] Cemiplimab (REGN2810, SAR439684), a human antibody targeting programmed death-1 (PD1), is being evaluated as a treatment for metastatic or unresectable cutaneous squamous cell carcinoma (CSCC).
[0183] Ublituximab (LFB-R603, TGT-1101, TGTX-1101) is a glycoengineered chimeric mAb that targets CD20.
[0184] Tremelimumab (CP-675, 206) is a human IgG2 antibody that targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Under physiological conditions, CD28 interacts with B7 ligands (CD80, CD86), leading to T cell activation, proliferation, and CTLA-4 upregulation. CTLA-4 binds to B7 ligands with higher affinity than CD28 and terminates the T cell response.
[0185] Isatuximab (SAR650984) is an anti-CD38 IgG1 chimeric antibody being evaluated for the treatment of patients with relapsed and refractory multiple myeloma (MM).
[0186] BCD-100 is a human antibody that targets programmed cell death-1 (PD-1).
[0187] Carotuximab (TRC105) is a chimeric IgG1 antibody that targets endoglin (CD105), a protein highly expressed on angiogenic and proliferating endothelial cells. The mAb binds to human CD105 on proliferating endothelium with a KD of 1-2 ng / mL and induces ADCC of human umbilical vein endothelial cells.
[0188] Camrelizumab (INCSHR-1210, SHR-1210) is an IgG4κ humanized antibody that targets PD-1.
[0189] Glenbatumumab vedotin (CDX-011, CR011-vcMMAE) is an IgG2 human antibody targeting the transmembrane glycoprotein nonmetastatic gene B (gpNMB) conjugated to monomethyl auristatin E, a cytotoxic drug that can lead to tumor cell death when released into cancer cells.
[0190] Mirvetuximab soravtansine (IMGN853) is an antibody targeting the folate receptor alpha (FRα) conjugated to three to four molecules of the antimitotic maytansinoid drug DM4.
[0191] Oportuzumab monatox (VICINIUM™, VB4-845) is an anti-epithelial cell adhesion molecule (EpCAM) recombinant humanized antibody scFv fragment conjugated to Pseudomonas aeruginosa exotoxin A.
[0192] L19IL2 / L19TNF (DAROMUN) is a fusion protein composed of the scFv of the L19 antibody, which targets the extra domain B of fibronectin, fused to either human IL2 or human TNF.
[0193] Further additional exemplary antibodies and fusion proteins may be selected from any of the following: benralizumab, MEDI-8968, anifrolumab, MEDI7183, sifalimumab, MEDI-575, tralokinumab from AstraZeneca and Medimmune; BAN2401 from Biogen Idec / Eisai Co.LTD ("Eisai") / / BioArctic Neuroscience AB; CDP7657, anti-CD40L monovalent PEGylated Fab antibody fragment, STX-100 anti-avB6 mAb, BIIB059, anti-TWEAK (BIIB023), and BIIB022 from Biogen; furanumab from Janssen and Amgen; BI-204 / RG7418 from BioInvent International / Genentech; BT-062 (indatuximab ravtansine) from Biotest Pharmaceuticals Corporation; XmAb from Boehringer Ingelheim / Xencor; Bristol-Myers anti-IP10 from Squibb; J 591 Lu-177 from BZL Biologics LLC; CDX-011 (glenbatumumab vedotin), CDX-0401 from Celldex Therapeutics; foravirumab from Crucell; tigatuzumab from Daiichi Sankyo Company Limited; MORAb-004, MORAb-009 (amatuximab) from Eisai; LY2382770 from Eli Lilly; DI17E6 from EMD Serono Inc; zanolimumab from Emergent BioSolutions, Inc.; FG-3019 from FibroGen, Inc.; Fresenius Catumaxomab from SE&Co. KGaA; pateclizumab, lontalizumab from Genentech; fresolimumab from Genzyme&Sanofi; GS-6624 (simtuzumab) from Gilead; CNTO-328, bapineuzumab (AAB-001), carlumab, CNTO-136 from Janssen; KaloBios Pharmaceuticals, Inc.KB003 from; ASKP1240 from Kyowa; RN-307 from Labrys Biologics Inc.; ecloneximab from Life Science Pharmaceuticals; LY2495655, LY2928057, LY3015014, LY2951742 from Eli Lilly; MBL-HCV1 from MassBiologics; AME-133v from MENTRIK Biotech, LLC; abituzumab from Merck KGaA; MM-121 from Merrimack Pharmaceuticals, Inc.; MCS 110, QAX576, QBX258, QGE031 from Novartis, AG; HCD122 from Novartis AG and XOMA Corporation ("XOMA"); NN8555 from Novo Nordisk; bavituximab and Kotara from Peregrine Pharmaceuticals, Inc.; Progenies PSMA-ADC from Quest Pharmaceuticals, Inc.; oregovomab from Quest Pharmatech, Inc.; fasinumab (REGN475), REGN1033, SAR231893, REGN846 from Regeneron; RG7160, CIM331, RG7745 from Roche; ibalizumab (TMB-355) from TaiMed Biologics Inc.; TCN-032 from Theraclone Sciences; TRC105 from TRACON Pharmaceuticals, Inc.; UB-421 from United Biomedical Inc.; VB4-845 from Viventia Bio, Inc.; ABT-110 from AbbVie; caplacizumab and ozoralizumab from Ablynx; and PRO from CytoDyn, Inc. 140; GS-CDA1, MDX-1388 from Medarex, Inc.; AMG 827, AMG 888 from Amgen; ublituximab from TG Therapeutics Inc.; TOL101 from Tolera Therapeutics, Inc.; huN901-DM1 (lorvotuzumab mertansine) from ImmunoGen Inc.; Immunomedics, Inc.epratuzumab Y-90 / veltuzumab combination (IMMU-102) from Agenix, Limited; antifibrin mAb / 3B6 / 22 Tc-99m from Agenix, Limited; ALD403 from Alder Biopharmaceuticals, Inc.; RN6G / PF-04382923 from Pfizer; CG201 from CG Therapeutics, Inc.; KB001-A from KaloBios Pharmaceuticals / Sanofi; KRN-23 from Kyowa; Y-90 hPAM 4 from Immunomedics, Inc.; tarexizumab from Morphosys AG & OncoMed Pharmaceuticals, Inc.; LFG316 from Morphosys AG & Novartis AG; CNTO3157, CNTO6785 from Morphosys AG & Jannsen; RG6013 from Roche & Chugai; Merrimack Pharmaceuticals, Inc.MM-111 from Merrimack; GSK2862277 from GlaxoSmithKline; AMG 282, AMG 172, AMG 595, AMG 745, AMG 761 from Amgen; BVX-20 from Biocon; CT-P19, CT-P24, CT-P25, CT-P26, CT-P27, CT-P4 from Celltrion; GSK284933, GSK2398852, GSK2618960, GSK1223249, GSK933776A from GlaxoSmithKline; anetumab ravtansine from Morphosys AG & Bayer AG; BI-836845 from Morphosys AG & Boehringer Ingelheim; Morphosys AG & Novartis NOV-7, NOV-8 from AG; MM-302, MM-310, MM-141, MM-131, MM-151 from Merrimack; RG7882 from Roche & Seattle Genetics; RG7841 from Roche / Genentech; PF-06410293, PF-06438179, PF-06439535, PF-04605412, PF-05280586 from Pfizer; RG7716, RG7936, gentenerumab, RG7444 from Roche; MEDI-547, MEDI-565, MEDI1814, MEDI4920, MEDI8897, MEDI-4212, MEDI-5117, MEDI-7814 from Astrazeneca; Bristol-Myers Ulocuplumab, a PCSK9 Adnectin, from Squibb; FivePrime Therapeutics, Inc.FPA009, FPA145 from Biogen; GS-5745 from Gilead; BIW-8962, KHK4083, KHK6640 from Kyowa Hakko Kirin; MM-141 from Merck KGaA; REGN1154, REGN1193, REGN1400, REGN1500, REGN1908-1909, REGN2009, REGN2176-3, REGN728 from Regeneron; SAR307746 from Sanofi; SGN-CD70A from Seattle Genetics; ALX-0141, ALX-0171 from Ablynx; milatuzumab-DOX, milatuzumab, TF2 from Immunomedics, Inc.; MLNO264 from Millennium; ABT-981 from AbbVie; AbGenomics International AbGn-168H from Inc.; ficlatuzumab from AVEO; BI-505 from BioInvent International; CDX-1127, CDX-301 from Celldex Therapeutics; CLT-008 from Cellerant Therapeutics Inc.; VGX-100 from Circadian; U3-1565 from Daiichi Sankyo Company Limited; DKN-01 from Dekkun Corp.; framvotumab (TYRP1 protein), IL-1β antibody, IMC-CS4 from Eli Lilly; VEGFR3 mAb, IMC-TR1 (LY3022859) from Eli Lilly and ImClone, LLC; Elusys. Anthim from Therapeutics Inc.; HuL2G7 from Galaxy Biotech LLC; IMGB853, IMGN529 from ImmunoGen Inc.; CNTO-5, CNTO-5825 from Janssen; KD-247 from Kaketsuken; KB004 from KaloBios Pharmaceuticals; MGA271, MGAH22 from MacroGenics, Inc.; XmAb5574 from MorphoSys AG / Xencor; ensituximab (NPC-1C) from Neogenix Oncology, Inc.; LFA102 from Novartis AG and XOMA; ATI355 from Novartis AG; SAN-300 from Santarus Inc.; SelG1 from Selexys; HuM195 / rGel from Targa Therapeutics, Corp.; Teva Pharmaceuticals, Industries Ltd. ("Teva") and Vaccinex VX15 from Inc.; TCN-202 from Theraclone Sciences; XmAb2513, XmAb5872 from Xencor; and XOMA from XOMA and the National Institute of Allergy and Infectious Diseases. 3AB; a neuroblastoma antibody vaccine from MabVax Therapeutics; Cytolin from CytoDyn, Inc.; Thravixa from Emergent BioSolutions Inc.; and FB 301 from Cytovance Biologics; a rabies mAb from Janssen and Sanofi; a flu mAb from Janssen and funded in part by the National Institute of Allergy and Infectious Diseases; MB-003 and ZMapp from Mapp Biopharmaceutical, Inc.; and ZMAb from Defyrus IncG.
[0194] III. General ceDNA Vectors for Use in Antibody and Fusion Protein Production Embodiments of the present invention are based on methods and compositions comprising closed-end linear double-stranded (ceDNA) vectors capable of expressing a transgene (e.g., an antibody or fusion protein). In some embodiments, the transgene is a sequence encoding an antibody or fusion protein. The ceDNA vectors for producing antibodies or fusion proteins described herein are not limited by size, thereby allowing, for example, expression of all components necessary for transgene expression from a single vector. The ceDNA vectors for producing antibodies or fusion proteins are preferably double-stranded, e.g., self-complementary, over at least a portion of the molecule, such as an expression cassette (e.g., the ceDNA is not a double-stranded circular molecule). The ceDNA vectors have covalently closed ends and are therefore resistant to exonuclease digestion (e.g., exonuclease I or exonuclease III), for example, at 37°C for 1 hour or more.
[0195] Generally, ceDNA vectors for producing antibodies or fusion proteins disclosed herein comprise, in the 5' to 3' direction, a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest (e.g., an expression cassette described herein), and a second AAV ITR. The ITR sequences are selected from: (i) at least one WT ITR and at least one modified AAV inverted terminal repeat (mod-ITR) (e.g., an asymmetric modified ITR), (ii) two modified ITRs (e.g., an asymmetric modified ITR) in which the mod-ITR pair has a different three-dimensional spatial configuration relative to each other, or (iii) a symmetric or substantially symmetric WT-WT ITR pair in which each WT-ITR has the same three-dimensional spatial configuration, or (iv) a symmetric or substantially symmetric modified ITR pair in which each mod-ITR has the same three-dimensional spatial configuration.
[0196] The present disclosure includes methods and compositions for producing antibodies or fusion proteins, including ceDNA vectors, and may further include delivery systems, such as, but not limited to, liposomal nanoparticle delivery systems. Non-limiting exemplary liposomal nanoparticle systems that can be used are disclosed herein. In some embodiments, the present disclosure provides lipid nanoparticles comprising ceDNA and ionized lipids. For example, lipid nanoparticle formulations prepared and loaded with ceDNA obtained by the process are disclosed in International Application No. PCT / US2018 / 050042, filed September 7, 2018, and are incorporated herein.
[0197] The ceDNA vectors for producing antibodies or fusion proteins disclosed herein do not have the packaging constraints imposed by the limited space within the viral capsid. In contrast to the enclosed AAV genome, ceDNA vectors represent a versatile eukaryotic alternative to prokaryotically produced plasmid DNA vectors. This allows the insertion of control elements, such as the regulatory switches disclosed herein, large transgenes, multiple transgenes, etc.
[0198] 1A-1E show schematic diagrams of non-limiting exemplary ceDNA vectors for antibody or fusion protein production, or the sequences of corresponding ceDNA plasmids. The ceDNA vectors for antibody or fusion protein production do not contain a capsid and can be derived from a plasmid encoding, in that order, a first ITR, an expression cassette containing a transgene, and a second ITR. The expression cassette can include one or more regulatory sequences that enable and / or control expression of the transgene. For example, the expression cassette can include, in that order, one or more of an enhancer / promoter, an ORF reporter (transgene), a post-transcriptional regulatory element (e.g., WPRE), and a polyadenylation and termination signal (e.g., BGH polyA).
[0199] The expression cassette may also contain an internal ribosome entry site (IRES) and / or a 2A element. Cis-regulatory elements include, but are not limited to, promoters, riboswitches, insulators, mir regulatory elements, post-transcriptional regulatory elements, tissue- and cell-type-specific promoters, and enhancers. In some embodiments, the ITRs can act as promoters for transgenes, such as antibodies or fusion proteins. In some embodiments, the ceDNA vectors contain additional components for regulating the expression of the transgene, such as regulatory switches for controlling and regulating the expression of antibodies or fusion proteins, as described herein in the section entitled "Regulatory Switches," and, if desired, a kill switch that enables controlled cell death of cells containing the ceDNA vector.
[0200] An expression cassette can comprise more than 4000 nucleotides, 5000 nucleotides, 10,000 nucleotides, 20,000 nucleotides, 30,000 nucleotides, 40,000 nucleotides, or 50,000 nucleotides, or any range between about 4000 and 10,000 nucleotides, or 10,000 and 50,000 nucleotides, or greater than 50,000 nucleotides. In some embodiments, an expression cassette can comprise a transgene in the range of 500 to 50,000 nucleotides in length. In some embodiments, an expression cassette can comprise a transgene in the range of 500 to 75,000 nucleotides in length. In some embodiments, an expression cassette can comprise a transgene that is in the range of 500 to 10,000 nucleotides in length. In some embodiments, an expression cassette can comprise a transgene that is in the range of 1000 to 10,000 nucleotides in length. In some embodiments, an expression cassette can comprise a transgene that is in the range of 500 to 5,000 nucleotides in length. ceDNA vectors do not have the size limitations of encapsidated AAV vectors, and therefore can deliver large expression cassettes resulting in efficient transgene expression. In some embodiments, ceDNA vectors lack prokaryotic cell-specific methylation.
[0201] The ceDNA expression cassette may contain, for example, an expressible exogenous sequence (e.g., an open reading frame) or transgene encoding a protein that is absent, inactive, or insufficiently active in the recipient subject, or a gene encoding a protein with a desired biological or therapeutic effect. The transgene may encode a gene product that can function to correct the expression of a defective gene or transcript. In principle, the expression cassette may contain any gene that encodes a protein, polypeptide, or RNA that is reduced or absent due to a mutation, or that provides a therapeutic effect if overexpression is considered within the scope of the present disclosure.
[0202] The expression cassette can include any transgene (e.g., encoding an antibody or fusion protein), such as an antibody or fusion protein useful for treating a disease or disorder in a subject, i.e., a therapeutic antibody or fusion protein. The ceDNA vector can be used alone or in combination with exogenous genes and nucleotide sequences, including polypeptide-encoding or non-coding nucleic acids (e.g., RNAi, miR, etc.), and viral sequences in the subject's genome, such as HIV viral sequences, to deliver and express any antibody or fusion protein of interest to a subject. Preferably, the ceDNA vectors disclosed herein are used for therapeutic purposes (e.g., medical, diagnostic, or veterinary use) or immunogenic polypeptides. In certain embodiments, the ceDNA vector is useful for expressing any gene of interest in a subject, including one or more polypeptides, peptides, ribozymes, peptide nucleic acids, siRNAs, RNAis, antisense oligonucleotides, antisense polynucleotides, or RNAs (coding or non-coding; e.g., siRNAs, shRNAs, microRNAs, and their antisense counterparts (e.g., antagoMiRs)), antibodies, fusion proteins, or any combination thereof.
[0203] Expression cassettes may also encode polypeptides, sense or antisense oligonucleotides, or RNA (coding or non-coding; e.g., siRNA, shRNA, microRNA, and their antisense counterparts (e.g., antagoMiR)). Expression cassettes may also include exogenous sequences encoding reporter proteins used for experimental or diagnostic purposes, such as β-lactamase, β-galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), luciferase, and others known in the art.
[0204] The sequences provided in the expression cassettes, expression constructs of ceDNA vectors for producing the antibodies or fusion proteins described herein may be codon-optimized for the target host cell. As used herein, the term "codon-optimized" or "codon optimization" refers to the process of modifying a nucleic acid sequence by replacing at least one, two, or a substantial number of codons in a native sequence (e.g., a prokaryotic sequence) with codons more frequently or most frequently used in the genes of a vertebrate of interest, such as a mouse or human, for enhanced expression in the cells of that vertebrate. Various species exhibit specific biases toward certain codons for specific amino acids. Typically, codon optimization does not change the amino acid sequence of the original translated protein. Optimized codons can be determined, for example, using Aptagen's Gene Forge® codon optimization and custom gene synthesis platform (Aptagen, Inc., 2190 Fox Mill Rd. Suite 300, Herndon, Va. 20171) or another public database. In some embodiments, the nucleic acid encoding the antibody or fusion protein is optimized for human expression and / or is a human or humanized antibody, or antigen-binding fragment thereof, as known in the art.
[0205] In some embodiments, the antibody or fusion protein expressed by the ceDNA vector is a therapeutic antibody or fusion protein, including a therapeutic activating antibody or fusion protein or a therapeutic neutralizing (e.g., blocking or inhibiting) antibody or fusion protein.
[0206] The transgene expressed by the ceDNA vector for producing the antibody or fusion protein disclosed herein encodes an antibody or fusion protein. Antibodies and fusion proteins are well known in the art and can bind to any protein of interest, including, but not limited to, ligands, receptors, toxins, hormones, enzymes, or cell surface proteins, or pathogen or viral proteins or antigens, as well as pre- and post-translationally modified proteins such as glycoproteins or sumoylated proteins (e.g., anti-SUMO2 / 3 antibodies). Antibodies also include antibodies that bind to any antigen, including, but not limited to, nucleic acids, such as DNA (e.g., anti-dsDNA antibodies) and RNA (e.g., anti-RNA-binding antibodies). In some embodiments, the antibody or fusion protein produced by the ceDNA vector disclosed herein is a neutralizing antibody or fusion protein. Exemplary target genes and proteins of interest are described in detail in the sections on uses and treatments herein. Antibodies, fusion proteins, and variants thereof, and / or active fragments thereof for use in treating, preventing, and / or ameliorating one or more symptoms of a disease, dysfunction, injury, and / or disorder are encompassed for use in ceDNA vectors for producing the antibodies or fusion proteins disclosed herein. Exemplary therapeutic genes are described herein in the section entitled "Methods of Treatment."
[0207] There are many structural features of ceDNA vectors for producing antibodies or fusion proteins that distinguish them from plasmid-based expression vectors. ceDNA vectors may have one or more of the following characteristics: lack of original (i.e., uninserted) bacterial DNA, lack of a prokaryotic replication origin, be self-contained (i.e., do not require any sequences other than the two ITRs containing the Rep binding and terminal resolution sites (RBS and TRS), and do not require any exogenous sequences between the ITRs), have ITR sequences that form hairpins, and lack bacterial-type DNA methylation, or indeed any other methylation that would be considered abnormal by a mammalian host. Generally, it is preferred that the vector does not contain any prokaryotic DNA, although it is contemplated that some prokaryotic DNA may be inserted as exogenous sequences, such as, for example, promoter or enhancer regions. Another important feature that distinguishes ceDNA vectors from plasmid expression vectors is that ceDNA vectors are single-stranded linear DNA with closed ends, whereas plasmids are always double-stranded DNA.
[0208] The ceDNA vectors for producing antibodies or fusion proteins produced by the methods provided herein preferably have a linear, continuous, rather than discontinuous, structure, as determined by restriction enzyme digestion assays (Figure 4D). A linear, continuous structure is believed to be more stable against attack by cellular endonucleases and less likely to recombine and cause mutagenesis. Therefore, a ceDNA vector with a linear, continuous structure is a preferred embodiment. Continuous, linear, single-stranded, intramolecularly duplexed ceDNA vectors may lack sequences encoding AAV capsid proteins, with the termini covalently linked. These ceDNA vectors are structurally distinct from plasmids (including the ceDNA plasmids described herein), which are circular, double-stranded nucleic acid molecules of bacterial origin. While the complementary strands of a plasmid can be separated following denaturation to produce two nucleic acid molecules, a ceDNA vector, although having complementary strands, is a single DNA molecule and therefore remains a single molecule even when denatured. In some embodiments, the ceDNA vectors described herein, unlike plasmids, can be produced without the DNA base methylation of prokaryotic cell types. Thus, ceDNA vectors and ceDNA-plasmids differ both in terms of their structure (in particular, linear vs. circular) and the methods used to produce and purify these different entities (see below), as well as in terms of their DNA methylation, which is of prokaryotic cell type in the case of ceDNA-plasmids and eukaryotic cell type in the case of ceDNA-vectors.
[0209] There are several advantages to using ceDNA vectors for producing the antibodies or fusion proteins described herein over plasmid-based expression vectors, including, but not limited to: 1) Plasmids contain bacterial DNA sequences and are subject to prokaryotic cell-specific methylation, such as 6-methyladenosine and 5-methylcytosine methylation, whereas capsid-free AAV vector sequences are of eukaryotic origin and are not subject to prokaryotic cell-specific methylation. As a result, capsid-free AAV vectors are less likely to induce inflammation and immune responses compared to plasmids. 2) Plasmids require the presence of resistance genes during the production process, whereas ceDNA vectors do not. 3) Circular plasmids are not delivered to the nucleus upon introduction into cells and require overloading to bypass degradation by cellular nucleases, whereas ceDNA vectors contain viral cis-elements, i.e., ITRs, that confer resistance to nucleases and can be designed to be targeted and delivered to the nucleus. We hypothesize that the minimal defining elements essential for ITR function are a Rep binding site (RBS, 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 60) for AAV2) and a terminal resolution site (TRS, 5'-AGTTGG-3' (SEQ ID NO: 64) for AAV2), plus a variable palindromic sequence that allows hairpin formation. 4) ceDNA vectors do not have the excessive representation of CpG dinucleotides often found in prokaryotic-derived plasmids that reportedly bind members of the Toll-like family of receptors and elicit T cell-mediated immune responses. In contrast, transduction with the capsid-free AAV vectors disclosed herein can use a variety of delivery reagents and efficiently target cells and tissue types that are difficult to transduce with conventional AAV virions.
[0210] IV.ITRs As disclosed herein, a ceDNA vector for producing an antibody or fusion protein comprises a transgene or heterologous nucleic acid sequence positioned between two inverted terminal repeat (ITR) sequences, which may be an asymmetric ITR pair or a symmetric or substantially symmetric ITR pair, as these terms are defined herein. The ceDNA vector disclosed herein may comprise ITR sequences selected from: (i) at least one WT ITR and at least one modified AAV inverted terminal repeat (ITR) (e.g., an asymmetric modified ITR), (ii) two modified ITRs (e.g., an asymmetric modified ITR) in which the mod-ITR pair has a different three-dimensional spatial configuration relative to each other, or (iii) a symmetric or substantially symmetric WT-WT ITR pair in which each WT-ITR has the same three-dimensional spatial configuration, or (iv) a symmetric or substantially symmetric modified ITR pair in which each mod-ITR has the same three-dimensional spatial configuration, and the disclosed method may further comprise a delivery system, such as, but not limited to, a liposomal nanoparticle delivery system.
[0211] In some embodiments, the ITR sequences can be derived from viruses of the Parvoviridae family, which includes two subfamilies: Parvovirinae, which infect vertebrates, and Densovirinae, which infect insects. The Parvovirinae subfamily (also referred to as parvoviruses) includes the Dependovirus family, whose members, under most conditions, require co-infection with a helper virus, such as an adenovirus or a herpesvirus, for productive infection. The Dependovirus family includes adeno-associated viruses (AAVs), which typically infect humans (e.g., serotypes 2, 3A, 3B, 5, and 6) or primates (e.g., serotypes 1 and 4), as well as related viruses that infect other warm-blooded animals (e.g., bovine, canine, equine, and ovine adeno-associated viruses). Parvoviruses and other members of the Parvoviridae family are generally described in Kenneth I. Berns, "Parvoviridae: The Viruses and Their Replication," Chapter 69 in FIELDS VIROLOGY (3d Ed. 1996).
[0212] ITRs are exemplified in the specification, and the example herein is the AAV2 WT-ITR, but one of skill in the art will recognize that ITRs from any known parvovirus, e.g., dependovirus, such as AAV (e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV5, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAV-DJ, and AAV-DJ8 genomes, see e.g., NCBI: NC002077; NC001401; NC001729; NC001829; NC006152; NC006260; NC006261), chimeric ITRs, or ITRs from any synthetic AAV, as described above. In some embodiments, AAV can infect warm-blooded animals, such as avian (AAAV), bovine (BAAV), canine, equine, and ovine adeno-associated viruses. In some embodiments, the ITRs are derived from B19 parvovirus (GenBank accession number NC000883), minute virus of mice (MVM) (GenBank accession number NC001510), goose parvovirus (GenBank accession number NC001701), or snake parvovirus 1 (GenBank accession number NC006148). In some embodiments, the 5'WT-ITR can be derived from one serotype and the 3'WT-ITR can be derived from a different serotype, as discussed herein.
[0213] Those skilled in the art will recognize that ITR sequences have the general structure of a double-stranded Holliday junction, typically a T- or Y-shaped hairpin structure (see, e.g., Figures 2A and 3A). Each wild-type ITR is formed by two palindromic arms or loops (B-B' and C-C') embedded in a larger palindromic arm (A-A'), and a single-stranded D sequence (the order of these palindromic sequences defines the flip or flop orientation of the ITR). See, for example, structural analysis and sequence comparison of ITRs from different AAV serotypes (AAV1-AAV6). Grimm et al., J. Virology, 2006;80(1);426-439; Yan et al., J. Virology, 2005;364-379; Duan et al., Virology 1999;261;8-14. Based on the exemplary AAV2 ITR sequences provided herein, those skilled in the art can easily determine the WT-ITR sequence from any AAV serotype for use in a ceDNA vector or ceDNA-plasmid. For example, see Grimm et al., J. Virology, 2006;80(1);426-439, for a comparison of the ITR sequences from different AAV serotypes (AAV1 to AAV6, as well as avian AAV (AAAV) and bovine AAV (BAAV)). This shows the percent identity of the left ITR of AAV2 to the left ITRs from other serotypes: AAV-1 (84%), AAV-3 (86%), AAV-4 (79%), AAV-5 (58%), AAV-6 (left ITR) (100%), and AAV-6 (right ITR) (82%).
[0214] A. Symmetric ITR pair In some embodiments, a ceDNA vector for producing an antibody or fusion protein described herein comprises, in the 5' to 3' direction, a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest (e.g., an expression cassette described herein), and a second AAV ITR, wherein the first ITR (5'ITR) and the second ITR (3'ITR) are symmetrical or substantially symmetrical with respect to each other; i.e., the ceDNA vector may comprise ITR sequences with a symmetrical three-dimensional spatial organization, such that their structures are the same shape in geometric space or have the same A, C-C', and B-B' loops in three-dimensional space. In such embodiments, the symmetrical or substantially symmetrical ITR pair may be a modified ITR (e.g., a mod-ITR) that is not a wild-type ITR. A mod-ITR pair may have one or more modifications from the wild-type ITR and have the same sequence that is the reverse complement (inverted) of each other. In alternative embodiments, the modified ITR pair is substantially symmetric as defined herein, i.e., the modified ITR pair may have different sequences but may have corresponding or the same symmetrical three-dimensional shapes.
[0215] (i) Wild-type ITR In some embodiments, the symmetric or substantially symmetric ITRs are wild-type (WT-ITR) as described herein. That is, both ITRs have wild-type sequences, but are not necessarily WT-ITRs of the same AAV serotype. That is, in some embodiments, one WT-ITR can be derived from one AAV serotype, and the other WT-ITR can be derived from a different AAV serotype. In such embodiments, the WT-ITR pair is substantially symmetric as defined herein, that is, they can have one or more conservative nucleotide modifications while maintaining a symmetrical three-dimensional spatial configuration.
[0216] Thus, as disclosed herein, a ceDNA vector comprises a transgene or heterologous nucleic acid sequence located between two adjacent wild-type inverted terminal repeat (WT-ITR) sequences, which are reverse-complementary (inverted) to each other, or alternatively, are substantially symmetrical to each other. That is, the WT-ITR pair has a symmetrical three-dimensional spatial configuration. In some embodiments, the wild-type ITR sequence (e.g., AAV WT-ITR) comprises a functional Rep binding site (RBS, e.g., 5'-GCGCGCTCGCTCGCTC-3' for AAV2, SEQ ID NO: 60) and a functional terminal resolution site (TRS, e.g., 5'-AGTT-3', SEQ ID NO: 62).
[0217] In one aspect, a ceDNA vector for producing an antibody or fusion protein can be obtained from a vector polynucleotide encoding a heterologous nucleic acid operably positioned between two wild-type inverted terminal repeats (WT-ITRs) (e.g., AAV WT-ITRs). That is, both ITRs have wild-type sequences, but are not necessarily WT-ITRs of the same AAV serotype. That is, in some embodiments, one WT-ITR can be derived from one AAV serotype, and the other WT-ITR can be derived from a different AAV serotype. In such embodiments, the WT-ITR pair is substantially symmetrical as defined herein, i.e., they can have one or more conservative nucleotide modifications while maintaining a symmetrical three-dimensional spatial configuration. In some embodiments, the 5'WT-ITR is derived from one AAV serotype, and the 3'WT-ITR is derived from the same or a different AAV serotype. In some embodiments, the 5'WT-ITR and 3'WT-ITR are mirror images of each other, i.e., they are symmetrical. In some embodiments, the 5'WT-ITR and the 3'WT-ITR are from the same AAV serotype.
[0218] WT ITRs are well known. In one embodiment, the two ITRs are derived from the same AAV2 serotype. In certain embodiments, WT ITRs from other serotypes can be used. There are several homologous serotypes, such as AAV2, AAV4, AAV6, and AAV8. In one embodiment, closely homologous ITRs (e.g., ITRs with similar loop structures) can be used. In another embodiment, more diverse AAV WT ITRs, such as AAV2 and AAV5, can be used, and in yet another embodiment, a substantially WT ITR can be used, i.e., it has the basic loop structure of the WT but has some conservative nucleotide changes that do not change or affect its properties. When using WT-ITRs derived from the same virus serotype, one or more regulatory sequences can also be used. In certain embodiments, the regulatory sequence is a regulatory switch that allows for the adjustment of the activity of the ceDNA, for example, the expression of the encoded antibody or fusion protein.
[0219] In some embodiments, one aspect of the technology described herein relates to a ceDNA vector for the production of an antibody or fusion protein, wherein the ceDNA vector comprises at least one heterologous nucleotide sequence operably positioned between two wild-type inverted terminal repeats (WT-ITRs), where the WT-ITRs can be from the same serotype, different serotypes, or can be substantially symmetrical with respect to each other (i.e., have a symmetrical three-dimensional spatial organization such that their structures are the same shape in geometric space, or have the same A, C-C', and B-B' loops in three-dimensional space). In some embodiments, the symmetric WT-ITRs comprise functional terminal resolution sites and Rep binding sites. In some embodiments, the heterologous nucleic acid sequence encodes a transgene, and the vector is not in a viral capsid.
[0220] In some embodiments, the WT-ITRs are the same but are reverse complements of each other. For example, the sequence AACG in the 5' ITR can be CGTT (i.e., the reverse complement) of the corresponding site in the 3' ITR. In one example, the 5' WT-ITR sense strand comprises the sequence ATCGATCG, and the corresponding 3' WT-ITR sense strand comprises the sequence [ka] (i.e., the reverse complement of ATCGATCG). In some embodiments, the WT-ITR ceDNA further comprises a terminal resolution site and a replication protein binding site (RPS) (sometimes referred to as a replication protein binding site), e.g., a Rep binding site.
[0221] Exemplary WT-ITR sequences for use in ceDNA vectors for the production of antibodies or fusion proteins containing WT-ITRs are shown in Table 7 herein, which shows pairs of WT-ITRs (5'WT-ITR and 3'WT-ITR).
[0222] As an illustrative example, the present disclosure provides a ceDNA vector for the production of an antibody or fusion protein comprising a promoter, with or without a regulatory switch, operably linked to a transgene (e.g., a gene editing sequence), wherein the ceDNA lacks a capsid protein and is (a) produced from a ceDNA-plasmid (see, e.g., Figures 1F-1G) encoding WT-ITRs, each WT-ITR having the same number of intramolecularly duplexed base pairs in its hairpin secondary configuration (preferably excluding any AAA or TTT terminal loop deletions in this configuration compared to these reference sequences), and (b) identified as ceDNA using the assay for identification of ceDNA by agarose gel electrophoresis under native and denaturing conditions of Example 1.
[0223] In some embodiments, adjacent WT-ITRs are substantially symmetrical to each other. In this embodiment, the 5'WT-ITR can be derived from one serotype of AAV, and the 3'WT-ITR can be derived from a different serotype of AAV, so that the WT-ITRs are not identical reverse complements. For example, the 5'WT-ITR can be derived from AAV2, and the 3'WT-ITR can be derived from a different serotype (e.g., AAV1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12). In some embodiments, the WT-ITRs can be selected from two different parvoviruses selected from any of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, snake parvovirus (e.g., royal python parvovirus), bovine parvovirus, caprine parvovirus, avian parvovirus, canine parvovirus, equine parvovirus, shrimp parvovirus, porcine parvovirus, or insect AAV. In some embodiments, such a combination of WT-ITRs is a combination of WT-ITRs from AAV2 and AAV6. In one embodiment, substantially symmetric WT-ITRs, when inverted relative to the other ITR, are at least 90% identical, at least 95% identical, at least 96%...97%...98%...99%...99.5%, and all points in between, and have the same symmetrical three-dimensional spatial configuration. In some embodiments, WT-ITR pairs are substantially symmetric because they have symmetric three-dimensional spatial configurations, e.g., the same three-dimensional configuration of the A, C-C', B-B', and D arms. In one embodiment, a substantially symmetric WT-ITR pair is inverted relative to the other and is at least 95% identical to each other, at least 96%...97%...98%...99%...99.5%, and all points in between, wherein one WT-ITR retains a Rep binding site (RBS) and terminal resolution site (trs) of 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 60).In some embodiments, a substantially symmetric WT-ITR pair is inverted relative to each other and is at least 95% identical to each other, at least 96%...97%...98%...99%...99.5%, and all points in between, where one WT-ITR retains a Rep binding site (RBS) and terminal resolution site (trs) of 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 60), in addition to a variable palindromic sequence that allows for hairpin secondary structure formation. Homology can be determined by standard means known in the art, such as BLAST (Basic Local Alignment Search Tool), BLASTN, with default settings.
[0224] In some embodiments, the structural element of an ITR can be any structural element involved in the functional interaction of an ITR with a large Rep protein (e.g., Rep78 or Rep68). In certain embodiments, the structural element provides selectivity for the interaction of an ITR with a large Rep protein, i.e., determines, at least in part, which Rep protein functionally interacts with the ITR. In other embodiments, the structural element physically interacts with a large Rep protein when the Rep protein is bound to the ITR. Each structural element can be, for example, the secondary structure of the ITR, the nucleotide sequence of the ITR, the space between two or more elements, or any combination of the above. In one embodiment, the structural element is selected from the group consisting of A and A' arms, B and B' arms, C and C' arms, D arm, Rep binding site (RBE) and RBE' (i.e., complementary RBE sequences), and terminal resolution site (trs).
[0225] By way of example only, Table 6 shows exemplary WT-ITR combinations.
[0226] Table 6: Exemplary combinations of WT-ITRs from the same or different serotypes, or different parvoviruses. The order shown does not indicate ITR position; for example, "AAV1, AAV2" specifies that the ceDNA can contain a WT-AAV1 ITR at the 5' position and a WT-AAV2 ITR at the 3' position, or vice versa, a WT-AAV2 ITR at the 5' position and a WT-AAV1 ITR at the 3' position. Abbreviations: AAV serotype 1 (AAV1), AAV serotype 2 (AAV2), AAV serotype 3 (AAV3), AAV serotype 4 (AAV4), AAV serotype 5 (AAV5), AAV serotype 6 (AAV6), AAV serotype 7 (AAV7), AAV serotype 8 (AAV8), AAV serotype 9 (AAV9), AAV serotype 10 (AAV10), AAV serotype 11 (AAV11), or AAV serotype 12 (AAV12); AAVrh8, AAVrh10, AAV-DJ, and AAV-DJ8 genomes (e.g., NCBI: NC002077; NC001401; NC NC001729; NC001829; NC006152; NC006260; NC006261), ITRs from warm-blooded animals (avian AAV (AAAV), bovine AAV (BAAV), canine, equine, and ovine AAV), ITRs from B19 parvovirus (GenBank accession number: NC000883), minute virus of mice (MVM) (GenBank accession number: NC001510); goose: goose parvovirus (GenBank accession number: NC001701); snake: snake parvovirus 1 (GenBank accession number: NC006148). [Table 6-1] [Table 6-2] [Table 6-3]
[0227] By way of example only, Table 7 shows the sequences of exemplary WT-ITRs from several different AAV serotypes. [Table 7]
[0228] In some embodiments, the nucleotide sequence of the WT-ITR sequence may be modified (e.g., by modifying 1, 2, 3, 4, 5 or more nucleotides, or any range therein), whereby the modification is a substitution of a complementary nucleotide, e.g., G for C and vice versa, T for A and vice versa.
[0229] In certain embodiments of the invention, a ceDNA vector for the production of an antibody or fusion protein does not have a WT-ITR consisting of a nucleotide sequence selected from any of SEQ ID NOs: 1, 2, 5-14. In alternative embodiments of the invention, when a ceDNA vector has a WT-ITR comprising a nucleotide sequence selected from any of SEQ ID NOs: 1, 2, 5-14, the adjacent ITR is also WT, and the ceDNA comprises a regulatory switch, e.g., as disclosed herein and in International Application No. PCT / US18 / 49996 (see, e.g., Table 11 of PCT / US18 / 49996). In some embodiments, a ceDNA vector for the production of an antibody or fusion protein comprises a regulatory switch as disclosed herein and the selected WT-ITR having a nucleotide sequence selected from any of the group consisting of SEQ ID NOs: 1, 2, 5-14.
[0230] The ceDNA vectors for producing antibodies or fusion proteins described herein may contain a WT-ITR structure that retains operable RBE, trs, and RBE' portions. Figures 2A and 2B, using wild-type ITRs for illustrative purposes, show one possible mechanism for engineering the trs site within the wild-type ITR portion of a ceDNA vector. In some embodiments, the ceDNA vectors for producing antibodies or fusion proteins contain one or more functional WT-ITR polynucleotide sequences that include a Rep-binding site (RBS, 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 60) for AAV2) and a terminal resolution site (TRS, 5'-AGTT (SEQ ID NO: 62)). In some embodiments, at least one WT-ITR is functional. In alternative embodiments, where the ceDNA vectors for producing antibodies or fusion proteins contain two WT-ITRs that are substantially symmetrical to each other, at least one WT-ITR is functional and at least one WT-ITR is non-functional.
[0231] B. Common modified ITRs (mod-ITRs) of ceDNA vectors containing asymmetric or symmetric ITR pairs As discussed herein, ceDNA vectors for antibody or fusion protein production can contain symmetric or asymmetric ITR pairs. In either case, one or both ITRs can be modified ITRs, the difference being that in the first case (i.e., symmetric mod-ITR), the mod-ITRs have the same three-dimensional spatial organization (i.e., have the same A-A', C-C', and B-B' arm organization), whereas in the second case (i.e., asymmetric mod-ITR), the mod-ITRs have a different three-dimensional spatial organization (i.e., have a different A-A', C-C', and B-B' arm organization).
[0232] In some embodiments, the modified ITR is an ITR that is modified by deletion, insertion, and / or substitution compared to a wild-type ITR sequence (e.g., an AAV ITR). In some embodiments, at least one of the ITRs of the ceDNA vector comprises a functional Rep binding site (RBS; e.g., 5'-GCGCGCTCGCTCGCTC-3', SEQ ID NO: 60, for AAV2) and a functional terminal resolution site (TRS; e.g., 5'-AGTT-3', SEQ ID NO: 62). In one embodiment, at least one of the ITRs is a non-functional ITR. In one embodiment, each of the different or modified ITRs is not a wild-type ITR from a different serotype.
[0233] While specific alterations and mutations of ITRs are described in detail herein, in the context of ITRs, "altered" or "mutated" or "modified" refers to nucleotides that have been inserted, deleted, and / or substituted relative to the wild-type, reference, or original ITR sequence. An altered or mutated ITR may be an engineered ITR. As used herein, "engineered" refers to an aspect that has been manipulated by the hand of man. For example, a polypeptide is considered "engineered" when at least one aspect of the polypeptide, e.g., its sequence, has been manipulated by the hand of man and is different from the aspect in which it occurs in nature.
[0234] In some embodiments, the mod-ITRs can be synthetic. In one embodiment, the synthetic ITRs are based on ITR sequences from two or more AAV serotypes. In another embodiment, the synthetic ITRs do not contain AAV-based sequences. In yet another embodiment, the synthetic ITRs preserve the ITR structure described above but contain little or no AAV-origin sequences. In some aspects, the synthetic ITRs may preferentially interact with wild-type Rep or Rep of a particular serotype, or in some cases, are not recognized by wild-type Rep but are recognized only by mutant Rep.
[0235] A skilled artisan can determine corresponding sequences in other serotypes by known means. For example, determine whether there are changes in the A, A', B, B', C, C', or D regions and determine the corresponding region in another serotype. BLAST® (Basic Local Alignment Search Tool) or other homology alignment programs can be used in their default settings to determine corresponding sequences. The present invention further provides populations and multiple ceDNA vectors containing mod-ITRs from combinations of different AAV serotypes. That is, one mod-ITR can be derived from one AAV serotype and the other mod-ITR can be derived from a different serotype. Without being bound by theory, in one embodiment, one ITR may be derived from or based on an AAV2 ITR sequence, and the other ITR of the ceDNA vector may be derived from or based on any one or more ITR sequences of AAV serotype 1 (AAV1), AAV serotype 4 (AAV4), AAV serotype 5 (AAV5), AAV serotype 6 (AAV6), AAV serotype 7 (AAV7), AAV serotype 8 (AAV8), AAV serotype 9 (AAV9), AAV serotype 10 (AAV10), AAV serotype 11 (AAV11), or AAV serotype 12 (AAV12).
[0236] Any parvovirus ITR can be used for modification as an ITR or as a basic ITR. Preferably, the parvovirus is a dependovirus. More preferably, it is AAV. The serotype selected can be based on the tissue tropism of the serotype. AAV2 has broad tissue tropism, AAV1 preferentially targets neurons and skeletal muscle, and AAV5 targets neurons, retinal pigment epithelium, and photoreceptors. AAV6 preferentially targets skeletal muscle and lung. AAV8 preferentially targets liver, skeletal muscle, heart, and pancreatic tissue. AAV9 preferentially targets liver, skeletal, and lung tissue. In one embodiment, the modified ITR is based on the AAV2 ITR.
[0237] More specifically, the ability of a structural element to functionally interact with a specific large Rep protein can be altered by modifying the structural element. For example, the nucleotide sequence of the structural element can be modified compared to the wild-type sequence of the ITR. In one embodiment, structural elements of the ITR (e.g., the A arm, A' arm, B arm, B' arm, C arm, C' arm, D arm, RBE, RBE', and trs) can be removed and replaced with wild-type structural elements from a different parvovirus. For example, the replacement structure can be from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, snake parvovirus (e.g., royal python parvovirus), bovine parvovirus, caprine parvovirus, avian parvovirus, canine parvovirus, equine parvovirus, shrimp parvovirus, porcine parvovirus, or insect AAV. For example, the ITRs can be AAV2 ITRs, with the A or A' arms or RBE replaced with structural elements from AAV5. In another example, the ITRs can be AAV5 ITRs, with the C or C' arms, RBE, and trs replaced with structural elements from AAV2. In another example, the AAV ITRs can be AAV5 ITRs, with the B and B' arms replaced with the AAV2 ITR B and B' arms.
[0238] By way of example only, Table 8 shows exemplary modifications (e.g., deletions, insertions, and / or substitutions) of at least one nucleotide in a region of a modified ITR, where X indicates the modification (e.g., deletion, insertion, and / or substitution) of at least one nucleic acid in that section relative to the corresponding wild-type ITR. In some embodiments, any modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in any of the C and / or C' and / or B and / or B' regions retains three consecutive T nucleotides (i.e., TTT) in at least one terminal loop. For example, if the modification results in either a single-arm ITR (e.g., a single C-C' arm or a single B-B' arm), or a modified C-B' arm or C'-B arm, or a two-arm ITR with at least one truncated arm (e.g., a truncated C-C' arm and / or a truncated B-B' arm), at least the single arm, or at least one of the arms of the two-arm ITR (one arm may be truncated), retains three consecutive T nucleotides (i.e., TTT) in at least one terminal loop. In some embodiments, the truncated C-C' arm and / or the truncated B-B' arm has three consecutive T nucleotides (i.e., TTT) in the terminal loop. [Table 8]
[0239] In some embodiments, mod-ITRs for use in ceDNA vectors for producing antibodies or fusion proteins comprise an asymmetric or symmetric mod-ITR pair disclosed herein and may include any one of the modification combinations shown in Table 8, as well as a modification of at least one nucleotide in any one or more of the regions selected from A' and C, C and C', C' and B, B and B', and B' and A. In some embodiments, any modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in the C or C' or B or B' region still preserves the terminal loop of the stem-loop. In some embodiments, any modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide between C and C' and / or B and B' retains three consecutive T nucleotides (i.e., TTT) in at least one terminal loop. In alternative embodiments, any modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide between C and C' and / or between B and B' preserves three consecutive A nucleotides (i.e., AAA) in at least one terminal loop. In some embodiments, modified ITRs for use herein may include any one of the combinations of modifications shown in Table 8, as well as a modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in any one or more of the regions selected from A', A, and / or D. For example, in some embodiments, modified ITRs for use herein may include any one of the combinations of modifications shown in Table 8, as well as at least one modification (e.g., deletion, insertion, and / or substitution) in the A region. In some embodiments, modified ITRs for use herein may include any one of the combinations of modifications shown in Table 8, as well as a modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in the A' region.In some embodiments, modified ITRs for use herein may include any one of the combinations of modifications shown in Table 8, as well as a modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in the A and / or A' region. In some embodiments, modified ITRs for use herein may include any one of the combinations of modifications shown in Table 8, as well as a modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in the D region.
[0240] In one embodiment, the nucleotide sequence of a structural element can be modified (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more nucleotides, or any range therein) to produce a modified structural element. In one embodiment, specific modifications to the ITRs are exemplified herein (e.g., SEQ ID NOS: 3, 4, 15-47, 101-116, or 165-187) or shown in Figures 7A-7B of PCT / US2018 / 064242, filed December 6, 2018 (e.g., SEQ ID NOS: 97-98, 101-103, 105-108, 111-112, 117-134, 545-54 of PCT / US2018 / 064242). In some embodiments, the ITRs may be modified (e.g., by modifying 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more nucleotides, or any range therein). In other embodiments, the ITRs can have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more sequence identity to one of the modified ITRs of SEQ ID NOs: 3, 4, 15-47, 101-116, or 165-187, or to the RBE-containing sections of the A-A' arm and the C-C' and B-B' arms set forth in SEQ ID NOs: 3, 4, 15-47, 101-116, or 165-187, or Tables 2-9 of International Application No. PCT / US18 / 49996 (i.e., SEQ ID NOs: 110-112, 115-190, 200-468), which are incorporated by reference herein in their entirety.
[0241] In some embodiments, modified ITRs can include, for example, removal or deletion of all of a particular arm, e.g., all or part of the A-A' arm, or all or part of the B-B' arm, or all or part of the C-C' arm, or removal of 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs forming the stem of a loop, so long as a final loop capping the stem (e.g., a single arm) is still present (see, e.g., ITR-21 in Figure 7A of PCT / US2018 / 064242, filed December 6, 2018). In some embodiments, modified ITRs can include removal of 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs from the B-B' arm. In some embodiments, the modified ITR can include the removal of 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs from the C-C' arm (see, e.g., ITR-1 in Figure 3B or ITR-45 in Figure 7A of PCT / US2018 / 064242, filed December 6, 2018). In some embodiments, the modified ITR can include the removal of 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs from the C-C' arm and the removal of 1, 2, 3, 4, 5, 6, 7, 8, 9, or more base pairs from the B-B' arm. Any combination of base pair removal is contemplated; for example, six base pairs in the C-C' arm and two base pairs in the B-B' arm can be removed. As an illustrative example, Figure 3B shows an exemplary modified ITR having at least seven base pairs deleted from each of the C and C' portions, a substitution of a nucleotide in the loop between the C and C' regions, and a deletion of at least one base pair from each of the B and B' regions, such that the modified ITR comprises two arms in which at least one arm (e.g., C-C') is truncated. In some embodiments, the modified ITR also comprises a deletion of at least one base pair from each of the B and B' regions, such that the B-B' arm is also truncated relative to the WT ITR.
[0242] In some embodiments, the modified ITRs may have a 1-50 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotide deletion relative to the full-length wild-type ITR sequence. In some embodiments, the modified ITRs may have a 1-30 nucleotide deletion relative to the full-length WT ITR sequence. In some embodiments, the modified ITRs have a 2-20 nucleotide deletion relative to the full-length wild-type ITR sequence.
[0243] In some embodiments, the modified ITRs do not contain any nucleotide deletions in the RBE-containing portions of the A or A' regions so as not to interfere with DNA replication (e.g., binding to the RBE by Rep proteins or nicking at the terminal resolution site). In some embodiments, modified ITRs encompassed for use herein have one or more deletions in the B, B', C, and / or C regions described herein.
[0244] In some embodiments, a ceDNA vector for the production of an antibody or fusion protein comprising a symmetric or asymmetric ITR pair comprises a regulatory switch as disclosed herein and at least one selected modified ITR having a nucleotide sequence selected from any of the group consisting of SEQ ID NOs: 3, 4, 15-47, 101-116, or 165-187.
[0245] In another embodiment, the structure of the structural element may be modified. For example, the structural element may have a change in stem height and / or the number of nucleotides in the loop. For example, the stem height may be about 2, 3, 4, 5, 6, 7, 8, or 9 nucleotides or more, or any range therein. In one embodiment, the stem height may be about 5 nucleotides to about 9 nucleotides and may functionally interact with Rep. In another embodiment, the stem height may be about 7 nucleotides and may functionally interact with Rep. In another example, the loop may have a length of 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or more, or any range therein.
[0246] In another embodiment, the number of GAGY-binding sites or GAGY-related binding sites in an RBE or extended RBE can be increased or decreased. In one example, an RBE or extended RBE can contain 1, 2, 3, 4, 5, 6, or more GAGY-binding sites, or any range therein. Each GAGY-binding site can independently be the exact GAGY sequence or a sequence similar to GAGY, so long as the sequence is sufficient to bind to the Rep protein.
[0247] In another embodiment, the spacing between two elements (such as, but not limited to, an RBE and a hairpin) can be altered (e.g., increased or decreased) to alter functional interactions with a large Rep protein. For example, the spacing can be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 nucleotides or more, or any range therein.
[0248] The ceDNA vectors for the production of antibodies or fusion proteins described herein may contain ITR structures that are modified relative to the wild-type AAV2 ITR structure disclosed herein, while still retaining operable RBE, trs, and RBE' portions. Figures 2A and 2B show one possible mechanism for engineering the trs portion within the wild-type ITR structure of a ceDNA vector for the production of antibodies or fusion proteins. In some embodiments, the ceDNA vectors for the production of antibodies or fusion proteins contain one or more functional ITR polynucleotide sequences, including a Rep-binding site (RBS, 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 60) for AAV2) and a terminal resolution site (TRS, 5'-AGTT (SEQ ID NO: 62)). In some embodiments, at least one ITR (wild-type or modified ITR) is functional. In an alternative embodiment, in which a ceDNA vector for the production of an antibody or fusion protein comprises two modified ITRs that are different or asymmetric from each other, at least one modified ITR is functional and at least one modified ITR is non-functional.
[0249] In some embodiments, modified ITRs (e.g., left or right ITRs) of ceDNA vectors for producing antibodies or fusion proteins described herein have modifications in the loop arm, cleavage arm, or spacer. Exemplary sequences of ITRs with modifications in the loop arm, cleavage arm, or spacer are listed in Table 2 (i.e., SEQ ID NOS: 135-190, 200-233); Table 3 (e.g., SEQ ID NOS: 234-263); Table 4 (e.g., SEQ ID NOS: 264-293); Table 5 (e.g., SEQ ID NOS: 294-318 herein); Table 6 (e.g., SEQ ID NOS: 319-468); and Tables 7-9 (e.g., SEQ ID NOS: 101-110, 111-112, 115-134) or Table 10A or 10B (e.g., SEQ ID NOS: 9, 100, 469-483, 484-499) of International Application No. PCT / US18 / 49996, which are incorporated herein by reference in their entireties.
[0250] In some embodiments, modified ITRs for use in ceDNA vectors for the production of antibodies or fusion proteins comprising asymmetric or symmetric mod-ITR pairs are selected from any of those set forth in Tables 2, 3, 4, 5, 6, 7, 8, 9, and 10A-10B of International Application No. PCT / US18 / 49996, which is incorporated herein by reference in its entirety, or a combination thereof.
[0251] Additional exemplary modified ITRs for use in ceDNA vectors for the production of antibodies or fusion proteins comprising asymmetric or symmetric mod-ITR pairs in each of the above classes are shown in Tables 9A and 9B. The predicted secondary structures of the right-modified ITRs in Table 9A are shown in Figure 7A of International Application No. PCT / US2018 / 064242, filed December 6, 2018, and the predicted secondary structures of the left-modified ITRs in Table 9B are shown in Figure 7B of International Application No. PCT / US2018 / 064242, filed December 6, 2018, which is incorporated herein by reference in its entirety.
[0252] Tables 9A and 9B show exemplary right- and left-modified ITRs. [Table 9A-1] [Table 9A-2]
[0253] [Table 9B-1] [Table 9B-2]
[0254] In one embodiment, a ceDNA vector for producing an antibody or fusion protein comprises, from 5' to 3', a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest (e.g., an expression cassette described herein), and a second AAV ITR, wherein the first ITR (5'ITR) and the second ITR (3'ITR) are asymmetric with each other. That is, they have different three-dimensional spatial configurations. In an exemplary embodiment, the first ITR can be a wild-type ITR and the second ITR can be a mutant or modified ITR, or vice versa, where the first ITR can be a mutant or modified ITR and the second ITR can be a wild-type ITR. In some embodiments, the first ITR and the second ITR are both mod-ITRs, but have different sequences or modifications, and therefore are not the same modified ITR but have different three-dimensional spatial configurations. In other words, a ceDNA vector with asymmetric ITRs may contain ITRs in which any changes in one ITR relative to the WT-ITR are not reflected in the other ITR, or, if the asymmetric ITRs have a modified asymmetric ITR pair, they may have different sequences and different three-dimensional shapes relative to each other. Exemplary asymmetric ITRs in ceDNA vectors for producing antibodies or fusion proteins and for use in generating ceDNA-plasmids are shown in Tables 9A and 9B.
[0255] In alternative embodiments, a ceDNA vector for producing an antibody or fusion protein comprises two symmetric mod-ITRs. That is, both ITRs have the same sequence but are reverse complements (inverted) of each other. In some embodiments, a symmetric mod-ITR pair comprises at least one or any combination of deletions, insertions, or substitutions compared to the wild-type ITR sequence from the same AAV serotype. The additions, deletions, or substitutions of the symmetric ITRs are the same but are reverse complements of each other. For example, an insertion of three nucleotides into the C region of the 5' ITR is reflected by an insertion of three reverse complements into the corresponding section of the C' region of the 3' ITR. For illustrative purposes only, if the addition is AACG in the 5' ITR, the addition is CGTT in the 3' ITR at the corresponding site. For example, if the 5' ITR sense strand is [ka] and between G and A [ka] With the addition of the sequence [ka] (SEQ ID NO: 51). The corresponding 3'ITR sense strand is [ka] ( [ka] (the reverse complement of T and C) [ka] (i.e., the reverse complement of AACG) [ka] (SEQ ID NO: 49)( [ka] (reverse complement of SEQ ID NO: 51).
[0256] In alternative embodiments, the modified ITR pair is substantially symmetrical as defined herein, i.e., the modified ITR pair may have different sequences but have corresponding or identical symmetrical three-dimensional shapes. For example, one modified ITR may be derived from one serotype, and the other modified ITR may be derived from a different serotype, but they have the same mutation (e.g., nucleotide insertion, deletion, or substitution) in the same region. In other words, for illustrative purposes only, the 5'-modified ITR may be derived from AAV2 and have a deletion in the C region, and the 3'-modified ITR may be derived from AAV5 and have a corresponding deletion in the C' region. Provided that the 5'-modified ITR and the 3'-modified ITR have the same or symmetrical three-dimensional spatial configuration, they are encompassed in the use of the modified ITR pair herein.
[0257] In some embodiments, a substantially symmetric mod-ITR pair has the same A, C-C', and B-B' loops in three-dimensional space. For example, if the modified ITR of a substantially symmetric mod-ITR pair has a deletion of the C-C' arm, the cognate mod-ITR has a corresponding deletion of the C-C' loop and has a similar three-dimensional structure of the remaining A and B-B' loops that are the same shape in geometric space as the cognate mod-ITR. By way of example only, substantially symmetric ITRs can have a symmetric spatial organization such that their structures are the same shape in geometric space. This can occur, for example, when a GC pair is modified to, for example, a CG pair, or vice versa, or when an AT pair is modified to a TA pair, or vice versa. Thus, [ka] A modified 5'ITR as (SEQ ID NO: 51), and [ka] (SEQ ID NO: 49) as a modified 3' ITR (i.e., [ka] (SEQ ID NO: 51)) and for example, [ka] (SEQ ID NO: 50) (where the G in the addition is modified to a C), these modified ITRs are still symmetrical, and the substantially symmetrical 3' ITR would be obtained without modifying the T in the addition to the corresponding a, [ka] (SEQ ID NO: 49) In some embodiments, the modified ITR pair has symmetric stereochemistry, such that the modified ITR is substantially symmetric.
[0258] Table 10 shows exemplary symmetrically modified ITR pairs (i.e., left-modified ITRs and symmetrically right-modified ITRs) for use in ceDNA vectors for the production of antibodies or fusion proteins. The bold (red) portions of the sequences identify the partial ITR sequences (i.e., the sequences of the A-A', C-C', and B-B' loops) that are also shown in Figures 31A-46B. These exemplary modified ITRs can include the RBE GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 60), the spacer ACTGAGGC (SEQ ID NO: 69), the spacer complement GCCTCAGT (SEQ ID NO: 70), and the RBE' (i.e., the complement to the RBE) GAGCGAGCGAGCGCGC (SEQ ID NO: 71). [Table 10-1] [Table 10-2] [Table 10-3] [Table 10-4]
[0259] In some embodiments, a ceDNA vector for the production of an antibody or fusion protein comprising an asymmetric ITR pair may comprise an ITR having modifications corresponding to any of the modifications in the ITR sequences or ITR subsequences set forth in any one or more of Tables 9A-9B herein, or the sequences shown in Figures 7A-7B of International Application No. PCT / US2018 / 064242, filed December 6, 2018 (incorporated herein in its entirety), or disclosed in Tables 2, 3, 4, 5, 6, 7, 8, 9, or 10A-10B of International Application No. PCT / US18 / 49996, filed September 7, 2018 (incorporated herein by reference in its entirety).
[0260] V. Exemplary ceDNA Vectors As described above, the present disclosure relates to recombinant ceDNA expression vectors and ceDNA vectors encoding antibodies or fusion proteins for the production of antibodies or fusion proteins, comprising any one of the above-described asymmetric ITR pairs, symmetric ITR pairs, or substantially symmetric ITR pairs. In certain embodiments, the present disclosure relates to recombinant ceDNA vectors for the production of antibodies or fusion proteins having flanking ITR sequences and a transgene, wherein the ITR sequences are asymmetric, symmetric, or substantially symmetric with respect to each other as defined herein, and the ceDNA further comprises a nucleotide sequence of interest (e.g., an expression cassette comprising the nucleic acid of the transgene) located between the flanking ITRs, wherein the nucleic acid molecule lacks a viral capsid protein-encoding sequence.
[0261] The ceDNA expression vector for producing an antibody or fusion protein may be any ceDNA vector that can be conveniently subjected to recombinant DNA procedures, comprising the nucleotide sequence(s) described herein, provided that at least one ITR is altered. The ceDNA vector for producing an antibody or fusion protein of the present disclosure is compatible with the host cell into which the ceDNA vector is introduced. In certain embodiments, the ceDNA vector may be linear. In certain embodiments, the ceDNA vector may exist as an extrachromosomal entity. In certain embodiments, the ceDNA vector of the present disclosure may contain element(s) that allow integration of the donor sequence into the genome of the host cell. As used herein, "transgene" and "heterologous nucleotide sequence" are synonymous and encode an antibody or fusion protein, as described herein.
[0262] 1A-1G, schematic diagrams of the functional components of two non-limiting plasmids useful for generating ceDNA vectors for antibody or fusion protein production are shown. Figures 1A, 1B, 1D, and 1F show the constructs of ceDNA vectors for antibody or fusion protein production or the sequences of the corresponding ceDNA plasmids. The ceDNA vectors are capsid-free and can be derived from a plasmid encoding, in this order, a first ITR, an expressible transgene cassette, and a second ITR, where the first and second ITR sequences are asymmetric, symmetric, or substantially symmetric with respect to each other, as defined herein. The ceDNA vectors for antibody or fusion protein production are capsid-free and can be derived from a plasmid encoding, in this order, a first ITR, an expressible transgene (protein or nucleic acid), and a second ITR, where the first and second ITR sequences are asymmetric, symmetric, or substantially symmetric with respect to each other, as defined herein. In some embodiments, the expressible transgene cassette optionally includes an enhancer / promoter, one or more homology arms, a donor sequence, a post-transcriptional regulatory element (e.g., a WPRE, e.g., SEQ ID NO: 67), and a polyadenylation and termination signal (e.g., a BGH polyA, e.g., SEQ ID NO: 68).
[0263] Figure 5 is a gel confirming the production of ceDNA from multiple plasmid constructs using the methods described in the Examples. The ceDNA is confirmed by the characteristic banding pattern in the gel, as discussed above with respect to Figure 4A and in the Examples.
[0264] A. Regulatory Elements The ceDNA vectors for producing antibodies or fusion proteins described herein, which contain asymmetric or symmetric ITR pairs as defined herein, may further contain specific combinations of cis-regulatory elements. Cis-regulatory elements include, but are not limited to, promoters, riboswitches, insulators, mir regulatory elements, post-transcriptional regulatory elements, tissue- and cell-type-specific promoters, and enhancers. In some embodiments, the ITRs can act as promoters for transgenes, such as antibodies or fusion proteins. In some embodiments, the ceDNA vectors for producing antibodies or fusion proteins described herein contain additional components for regulating the expression of transgenes, such as regulatory switches described herein, which regulate the expression of transgenes or kill switches that can kill cells containing ceDNA vectors encoding antibodies or antigen-binding fragments thereof. Regulatory elements, including regulatory switches, that can be used in the present invention are more fully discussed in International Application No. PCT / US18 / 49996, which is incorporated herein by reference in its entirety.
[0265] In embodiments, the second nucleotide sequence comprises a regulatory sequence and a nucleotide sequence encoding a nuclease. In certain embodiments, the gene regulatory sequence is operably linked to the nucleotide sequence encoding the nuclease. In certain embodiments, the regulatory sequence is suitable for controlling expression of the nuclease in the host cell. In certain embodiments, the regulatory sequence comprises a suitable promoter sequence capable of directing transcription of a gene operably linked to a promoter sequence, such as a nucleotide sequence encoding a nuclease(s) of the present disclosure. In certain embodiments, the second nucleotide sequence comprises an intron sequence linked to the 5' end of the nucleotide sequence encoding the nuclease. In certain embodiments, an enhancer sequence is provided upstream of the promoter to increase the efficiency of the promoter. In certain embodiments, the regulatory sequence comprises an enhancer and a promoter, and the second nucleotide sequence comprises an intron sequence upstream of the nucleotide sequence encoding the nuclease, wherein the intron comprises one or more nuclease cleavage site(s), and the promoter is operably linked to the nucleotide sequence encoding the nuclease.
[0266] ceDNA vectors for the production of antibodies or fusion proteins, produced synthetically or using the cell-based production methods described in the Examples herein, may further comprise specific combinations of cis-regulatory elements, such as the WHP post-transcriptional regulatory element (WPRE) (e.g., SEQ ID NO: 67) and BGH polyA (SEQ ID NO: 68). Suitable expression cassettes for use in expression constructs are not limited by packaging constraints imposed by viral capsids.
[0267] (i) Promoter: Those skilled in the art will understand that promoters used in ceDNA vectors for production of the antibodies or fusion proteins disclosed herein should be appropriately tailored to the particular sequences they promote.
[0268] Expression cassettes in ceDNA vectors for antibody or fusion protein production can contain promoters that can affect overall expression levels as well as cell specificity. In the case of transgene expression, such as antibody or antigen-binding fragment expression, they can contain highly active viral immediate-early promoters. The expression cassette can contain a tissue-specific eukaryotic promoter to restrict transgene expression to specific cell types and reduce toxic effects and immune responses resulting from unregulated ectopic expression. In some embodiments, the expression cassette can contain a synthetic regulatory element, such as the CAG promoter (SEQ ID NO: 72). The CAG promoter contains (i) a cytomegalovirus (CMV) early enhancer element, (ii) the promoter, the first exon and first intron of the chicken β-actin gene, and (iii) the splice acceptor of the rabbit β-globulin gene. Alternatively, the expression cassette may contain the alpha-1-antitrypsin (AAT) promoter (SEQ ID NO:73 or SEQ ID NO:74), the liver-specific (LP1) promoter (SEQ ID NO:75 or SEQ ID NO:76), or the human elongation factor-1 alpha (EF1a) promoter (e.g., SEQ ID NO:77 or SEQ ID NO:78). In some embodiments, the expression cassette comprises one or more constitutive promoters, such as the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with an RSV enhancer), or the cytomegalovirus (CMV) immediate early promoter (optionally with a CMV enhancer, e.g., SEQ ID NO:79). Alternatively, an inducible promoter, the transgene's native promoter, a tissue-specific promoter, or various promoters known in the art can be used.
[0269] Suitable promoters, including those described above, may be derived from viruses and therefore may be referred to as viral promoters, or they may be derived from any organism, including prokaryotes or eukaryotes. Suitable promoters can be used to direct the expression of any RNA polymerase (e.g., pol Expression can be driven by SV40 early promoter, mouse mammary tumor virus long terminal sequence (LTR) promoter, adenovirus major late promoter (Ad MLP); herpes simplex virus (HSV) promoter, cytomegalovirus (CMV) promoter, such as the CMV immediate early promoter region (CMVIE), Rous sarcoma virus (RSV) promoter, human U6 micronucleus promoter (U6, e.g., SEQ ID NO: 80) (Miyagishi et al., Nature Biotechnology 20, 497-500 (2002)), enhanced U6 promoter (e.g., Xia et al., Nucleic Acids Res. 2003 Sep. 1; 31 (17)), human H1 promoter (H1) (e.g., SEQ ID NO: 81 or SEQ ID NO: 155), CAG promoter, human alpha1-antitypsin (HAAT) promoter (e.g., SEQ ID NO: 82), and the like. In certain embodiments, these promoters are modified at their downstream intron-containing ends to contain one or more nuclease cleavage sites, hi certain embodiments, the DNA containing the nuclease cleavage site(s) is exogenous to the promoter DNA.
[0270] In one embodiment, the promoter used is the native promoter of the gene encoding the therapeutic protein.The promoter and other regulatory sequences of each gene encoding the therapeutic protein are known and characterized.The promoter region used may further include one or more additional regulatory sequences (e.g., native), such as enhancers (e.g., SEQ ID NO:79 and SEQ ID NO:83), including the SV40 enhancer (SEQ ID NO:126).
[0271] In some embodiments, the promoter may be a promoter from a human gene, such as human ubiquitin C (hUbC), human actin, human myosin, human hemoglobin, human muscle creatine, or human metallothionein. The promoter may also be a natural or synthetic tissue-specific promoter, for example, a liver-specific promoter, for example, human alpha 1-antitypic syn (HAAT). In one embodiment, delivery to the liver may be achieved using endogenous ApoE-specific targeting of a composition comprising a ceDNA vector to hepatocytes via the low-density lipoprotein (LDL) receptor present on the surface of hepatocytes.
[0272] Non-limiting examples of suitable promoters for use in accordance with the present invention include, for example, the CAG promoter (SEQ ID NO: 72), the HAAT promoter (SEQ ID NO: 82), the human EF1-α promoter (SEQ ID NO: 77), or the EF1a promoter (SEQ ID NO: 78), the IE2 promoter (e.g., SEQ ID NO: 84), and the rat EF1-α promoter (SEQ ID NO: 85), the mEF1 promoter (SEQ ID NO: 59), or the 1E1 promoter fragment (SEQ ID NO: 125).
[0273] (ii) Polyadenylation sequence: A sequence encoding a polyadenylation sequence can be included in a ceDNA vector for antibody or fusion protein production to stabilize the mRNA expressed from the ceDNA vector and to aid in nuclear transport and translation. In one embodiment, the ceDNA vector does not contain a polyadenylation sequence. In other embodiments, a ceDNA vector for antibody or fusion protein production contains at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 45, at least 50, or more adenine dinucleotides. In some embodiments, the polyadenylation sequence comprises about 43 nucleotides, about 40-50 nucleotides, about 40-55 nucleotides, about 45-50 nucleotides, about 35-50 nucleotides, or any range therebetween. As shown in Figures 10A-10G, the polyadenylation sequence can be located 3' to the transgene encoding the antibody or antibody fragment. In some embodiments, a ceDNA vector for the production of an antibody or fusion protein encoding a complete IgG or antibody may contain an IRES (internal ribosome entry site) sequence (SEQ ID NO: 190), for example, when the IRES sequence is located 3' to the polyadenylation sequence, thereby enabling a second transgene (e.g., antibody or antigen-binding fragment) located 3' to the first transgene to be translated and expressed by the same ceDNA vector, enabling the ceDNA vector to express a complete antibody (see, e.g., Figure 10B).
[0274] Expression cassettes can include polyadenylation sequences known in the art or variations thereof, such as naturally occurring sequences isolated from bovine BGHpA (e.g., SEQ ID NO: 68) or viral SV40pA (e.g., SEQ ID NO: 86), or synthetic sequences (e.g., SEQ ID NO: 87). Some expression cassettes can also include an SV40 late polyA signal upstream enhancer (USE) sequence. In some embodiments, a USE can be used in combination with SV40pA or a heterologous polyA signal.
[0275] The expression cassette may also contain post-transcriptional elements to increase transgene expression. In some embodiments, the woodchuck hepatitis virus (WHP) post-transcriptional regulatory element (WPRE) (e.g., SEQ ID NO: 67) is used to increase transgene expression. Other post-transcriptional processing elements, such as the post-transcriptional elements from the thymidine kinase gene of herpes simplex virus or hepatitis B virus (HBV), can be used. A secretory sequence can be linked to the transgene, for example, the VH-02 and VK-A26 sequences, e.g., SEQ ID NO: 88 and SEQ ID NO: 89.
[0276] (iii). Nuclear localization sequence In some embodiments, the ceDNA vector for producing an antibody or fusion protein comprises one or more nuclear localization sequences (NLSs), for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs. In some embodiments, the one or more NLSs are located at or near the amino terminus, at or near the carboxy terminus, or a combination thereof (e.g., one or more NLSs at the amino terminus and / or one or more NLSs at the carboxy terminus). When multiple NLSs are present, each can be selected independently from the other NLSs, such that a single NLS is present in multiple copies and / or in combination with one or more other NLSs present in one or more copies. Non-limiting examples of NLSs are shown in Table 11. [Table 11]
[0277] B. Additional Components of ceDNA Vectors The ceDNA vector for producing the antibody or fusion protein of the present disclosure may include nucleotides encoding other components for gene editing. For example, to select specific gene targeting events, a protective shRNA can be embedded in a microRNA and inserted into a recombinant ceDNA vector designed for site-specific integration into a highly active locus, such as the albumin locus. Such an embodiment is described in Nygaard et al., "A universal system to select gene-modified hepatocytes in vivo," Gene Therapy, June 2014. This may provide a system for in vivo selection and expansion of genetically modified hepatocytes in any genetic background, as described in [PubMed], 8, 2016. The ceDNA vectors of the present disclosure may contain one or more selectable markers that allow for the selection of transformed, transfected, transduced, etc. cells. A selectable marker is a gene whose product provides biocide or viral resistance, resistance to heavy metals, prototrophy for auxotrophs, NeoR, etc. In certain embodiments, a positive selectable marker, such as NeoR, is incorporated into the donor sequence. A negative selectable marker can be incorporated downstream of the donor sequence; for example, a nucleic acid sequence encoding the negative selectable marker, HSV-tk, can be incorporated into the nucleic acid construct downstream of the donor sequence.
[0278] C. Adjustment switch A molecular regulatory switch is one that generates a measurable change in state in response to a signal. Such regulatory switches can be usefully combined with the ceDNA vectors for antibody or fusion protein production described herein to control the expression output for antibody or fusion protein production from the ceDNA vector. In some embodiments, the ceDNA vectors for antibody or fusion protein production include a regulatory switch that serves to fine-tune antibody or antigen-binding fragment expression. For example, it can serve as a biocontainment function for the ceDNA vector. In some embodiments, the switch is an "on / off" switch designed to start or stop (i.e., shut down) antibody or antigen-binding fragment expression in the ceDNA vector in a controllable and regulatable manner. In some embodiments, the switch can include a "kill switch" that, once activated, can instruct cells containing the ceDNA vector to undergo programmed cell death. Exemplary regulatory switches included for use in ceDNA vectors for antibody or fusion protein production can be used to regulate transgene expression and are discussed more fully in International Application No. PCT / US18 / 49996, incorporated herein by reference in its entirety.
[0279] (i) Binary Adjustment Switch In some embodiments, ceDNA vectors for producing antibodies or fusion proteins contain regulatory switches that can help controllably regulate the expression of the antibody or antigen-binding fragment. For example, the expression cassette located between the ITRs of the ceDNA vector can additionally contain a regulatory region, such as a promoter, cis-element, repressor, enhancer, etc., operably linked to the antibody or antigen-binding fragment, which is regulated by one or more cofactors or exogenous agents. By way of example only, the regulatory region can be regulated by a small molecule switch or an inducible or repressible promoter. Non-limiting examples of inducible promoters are hormone-inducible or metal-inducible promoters. Other exemplary inducible promoter / enhancer elements include, but are not limited to, the RU486-inducible promoter, the ecdysone-inducible promoter, the rapamycin-inducible promoter, and the metallothionein promoter.
[0280] (ii) small molecule regulatory switches Various small molecule-based regulatory switches known in the art can be combined with the ceDNA vectors for the production of antibodies or fusion proteins disclosed herein to form a ceDNA vector controlled by the regulatory switch. In some embodiments, the regulatory switch is an orthogonal ligand / nuclear receptor pair, such as retinoid receptor mutants / LG335 and GRQCIMFI (with an artificial promoter controlling the expression of an operably linked transgene, such as those disclosed in Taylor, et al., BMC Biotechnology 10 (2010): 15); an engineered steroid receptor, such as a modified progesterone receptor with a C-terminal truncation that cannot bind progesterone but binds RU486 (mifepristone) (U.S. Patent No. 5,364,791); the ecdysone receptor from Drosophila and its ecdysteroid ligands (Saez, et al., PNAS, 97 (26) (2000), 14512-14517), or Sando R 3 rd; Nat Methods. 2013, 10(11):1085-8. In some embodiments, the regulatory switch for controlling the transgene expressed by the ceDNA vector is a prodrug activation switch, such as those disclosed in U.S. Patent Nos. 8,771,679 and 6,339,070.
[0281] (iii) "Passcode" adjustment switch In some embodiments, the regulatory switch may be a "passcode switch" or "passcode circuit." A passcode switch allows for fine-tuning of the control of transgene expression from a ceDNA vector when certain conditions occur. That is, a combination of conditions must be present for transgene expression and / or repression to occur. For example, at least conditions A and B must occur for transgene expression to occur. A passcode regulatory switch may be any number of conditions, e.g., at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or more conditions must be present for transgene expression to occur. In some embodiments, at least two conditions (e.g., conditions A and B) must occur, and in some embodiments, at least three conditions must occur (e.g., conditions A, B, and C or A, B, and D). By way of example only, conditions A, B, and C must be present for gene expression from a ceDNA with a passcode "ABC" regulatory switch to occur. Conditions A, B, and C may be as follows: Condition A is the existence of pathology or disease, condition B is hormonal response, and condition C is response to the expression of transgene.For example, if transgene edits defective EPO gene, condition A is the existence of chronic kidney disease (CKD), condition B occurs when the subject has hypoxia in the kidney, and condition C is the insufficient erythropoietin-producing cell (EPC) mobilization in the kidney, or alternatively, the insufficient HIF-2 activation.Once oxygen level increases or reaches a desired EPO level, transgene will be turned off again and then turned back on until the three conditions occur.
[0282] In some embodiments, the passcode regulatory switches or "passcode circuits" included for use in ceDNA vectors contain hybrid transcription factors (TFs) to expand the range and complexity of environmental signals used to define biological containment conditions. In contrast to dead-man switches, which trigger cell death in the presence of predetermined conditions, "passcode circuits" allow cell survival or transgene expression in the presence of specific "passcodes" and can be easily reprogrammed to allow transgene expression and / or cell survival only when a given environmental condition or passcode is present.
[0283] Any and all combinations of the regulatory switches disclosed herein, such as small molecule switches, nucleic acid-based switches, small molecule-nucleic acid hybrid switches, post-transcriptional transgene-regulated switches, post-translational regulated radiation-controlled switches, hypoxia-mediated switches, and other regulatory switches disclosed herein and known to those skilled in the art, can be used in the passcode regulatory switches disclosed herein. Regulatory switches encompassed for use are also discussed in the review article Kis et al., JR Soc Interface. 12:20141000 (2015) and summarized in Table 1 of Kis. In some embodiments, regulatory switches for use in the passcode system can be selected from any or combinations of the switches disclosed in Table 11 of International Patent Application No. PCT / US18 / 49996, which is incorporated herein by reference in its entirety.
[0284] (iv) Nucleic acid-based regulatory switches for controlling transgene expression In some embodiments, the regulatory switch for controlling the antibody or antigen-binding fragment expressed by ceDNA is based on a nucleic acid-based regulatory mechanism.Exemplary nucleic acid regulatory mechanisms are known in the art and are envisioned for use.For example, such mechanisms include riboswitches, such as those disclosed in US2009 / 0305253, US2008 / 0269258, US2017 / 0204477, WO2018 / 026762A1, U.S. Patent No. 9,222,093, and European Patent Application No. EP288071, and those disclosed in the review by Villa JK et al., Microbiol Spectr.2018 May;6(3).Metabolite-responsive transcriptional biosensors are also included, such as those disclosed in WO2018 / 075486 and WO2017 / 147585. Other mechanisms known in the art that can be used include silencing transgenes by siRNA or RNAi molecules (for example, miR, shRNA).For example, ceDNA vectors can contain regulatory switches that code for RNAi molecules that are complementary to the part of the transgene that is expressed by ceDNA vectors.When such RNAi is expressed by ceDNA vectors, transgenes (for example, antibodies or antigen-binding fragments) are silenced by complementary RNAi molecules; and when RNAi is not expressed when transgenes are expressed by ceDNA vectors, transgenes (for example, antibodies or antigen-binding fragments) are not silenced by RNAi.
[0285] In some embodiments, the regulatory switch is a tissue-specific self-inactivating regulatory switch, e.g., as disclosed in US2002 / 0022018, whereby the regulatory switch purposefully switches off transgene expression in sites where expression of the transgene (e.g., antibody or antigen-binding fragment) would otherwise be detrimental. In some embodiments, the regulatory switch is a recombinase reversible gene expression system, e.g., as disclosed in US2014 / 0127162 and U.S. Patent No. 8,324,436.
[0286] (v).Post-transcriptional and post-translational regulatory switches. In some embodiments, the regulatory switch for controlling the antibody or antigen-binding fragment expressed by the ceDNA vector is a post-transcriptional modification system.For example, such a regulatory switch can be an aptazyme riboswitch that is sensitive to tetracycline or theophylline, as disclosed in US2018 / 0119156, GB2011 / 07768, WO2001 / 064956A3, EP2707487, and Beilstein et al., ACS Synth.Biol.,2015,4(5),pp 526-534, Zhong et al., Elife.2016 Nov 2;5.pii:e18858.In some embodiments, it is assumed that a person skilled in the art can code both a transgene and an inhibitory siRNA that contains a ligand-sensitive (off-switch) aptamer, the end result of which is a ligand-sensitive on-switch.
[0287] (vi) Other exemplary adjustment switches Any known regulatory switch can be used in the ceDNA vector to control the gene expression of the antibody or antigen-binding fragment expressed by the ceDNA vector, including those triggered by environmental changes. Additional examples include, but are not limited to, the BOC method of Suzuki et al., Scientific Reports 8;10051(2018), genetic code expansion and non-physiological amino acids, radiation-controlled or ultrasound-controlled on / off switches (see, for example, Scott S et al., Gene Ther. 2000 July;7(13):1121-5, U.S. Patent Nos. 5,612,318, 5,571,797, 5,770,581, 5,817,636, and WO1999 / 025385A1). In some embodiments, the regulatory switch is controlled by an implantable system, e.g., as disclosed in U.S. Pat. No. 7,840,263, US2007 / 0190028A1, and gene expression is controlled by one or more forms of energy, including electromagnetic energy, that activate a promoter operably linked to a transgene in a ceDNA vector.
[0288] In some embodiments, the regulatory switch envisioned for use in the ceDNA vector is a hypoxia-mediated or stress-activated switch, such as those disclosed in WO1999 / 060142A2, U.S. Patent Nos. 5,834,306, 6,218,179, 6,709,858, US2015 / 0322410, Greco et al., (2004) Targeted Cancer Therapies 9, S368, as well as FROG, TOAD, and NRSE elements, and conditionally inducible silence elements (e.g., hypoxia response element (HRE), inflammatory response element (IRE), and shear stress activation element (SSAE) disclosed in U.S. Patent No. 9,394,526). Such embodiments are useful for turning on the expression of transgenes from ceDNA vectors after ischemia or in ischemic tissues and / or tumors.
[0289] (iv) Kill Switch Other embodiments described herein relate to ceDNA vectors for producing the antibodies or fusion proteins described herein, which include a kill switch. The kill switch disclosed herein can cause cells containing the ceDNA vector to be killed or undergo programmed cell death as a means of permanently removing the introduced ceDNA vector from a subject's system. It will be understood by those skilled in the art that the use of a kill switch in a ceDNA vector for producing an antibody or fusion protein is typically coupled with targeting of the ceDNA vector to a limited number of cells that the subject can tolerately lose, or to a cell type (e.g., cancer cells) for which apoptosis is desired. In all aspects, the "kill switch" disclosed herein is designed to result in rapid and robust cell killing of cells containing the ceDNA vector in the absence of an input survival signal or other specified condition. In other words, the kill switch encoded by the ceDNA vector for producing the antibodies or fusion proteins described herein can restrict cell survival of cells containing the ceDNA vector to an environment defined by a specific input signal. Such kill switches serve as a biocontainment function when it is desirable to remove an antibody or antigen-binding fragment-expressing ceDNA vector from a subject or to ensure that the encoded antibody or antigen-binding fragment is not expressed.
[0290] Other kill switches known to those of skill in the art are encompassed for use in the ceDNA vectors for production of the antibodies or fusion proteins disclosed herein, e.g., those disclosed in US2010 / 0175141, US2013 / 0009799, US2011 / 0172826, US2013 / 0109568, as well as the kill switches disclosed in Jusiak et al, Reviews in Cell Biology and molecular Medicine;2014;1-56, Kobayashi et al., PNAS,2004;101;8419-9, Marchisio et al., Int. Journal of Biochem and Cell Biol.,2011;43;310-319, and Reinshagen et al., Science Translational Medicine,2018,11.
[0291] Thus, in some embodiments, a ceDNA vector for antibody or fusion protein production can include a kill-switch nucleic acid construct comprising a nucleic acid encoding an effector toxin or reporter protein, where expression of the effector toxin (e.g., death protein) or reporter protein is controlled by a predetermined condition. For example, the predetermined condition can be the presence of an environmental substance, e.g., an exogenous substance, without which the cell will by default express the effector toxin (e.g., death protein) and be killed. In an alternative embodiment, the predetermined condition is the presence of two or more environmental substances, e.g., the cell will survive only if two or more necessary exogenous substances are provided, and in the absence of either, the cell containing the ceDNA vector will be killed.
[0292] In some embodiments, ceDNA vectors for antibody or fusion protein production are modified to incorporate a kill switch that destroys cells containing the ceDNA vector, effectively terminating the in vivo expression of the transgene expressed by the ceDNA vector (e.g., full-length antibody, Fab, scAb). Specifically, the ceDNA vector is further engineered to express a switch protein that does not function in mammalian cells under normal physiological conditions. Only upon administration of a drug or environmental condition that specifically targets this switch protein are cells expressing the switch protein destroyed, thereby terminating expression of the therapeutic protein or peptide. For example, it has been reported that cells expressing HSV-thymidine kinase can be killed by administering drugs such as ganciclovir and cytosine deaminase. See, for example, Dey and Evans, "Suicide Gene Therapy by Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK)," in Targets in See Gene Therapy, edited by You (2011), and Beltinger et al., Proc. Natl. Acad. Sci. USA 96(15):8699-8704 (1999). In some embodiments, the ceDNA vector can include an siRNA kill switch called DISE (death by excision induced survival gene) (Murmann et al., Oncotarget. 2017;8:84643-84658. Induction of DISE in ovarian cancer cells in vivo).
[0293] VI. Detailed Methods for the Production of ceDNA Vectors A. General production Certain methods for producing ceDNA vectors for producing antibodies or fusion proteins comprising asymmetric or symmetric ITR pairs as defined herein are described in Section IV of International Application No. PCT / US18 / 49996, filed September 7, 2018, which is incorporated herein by reference in its entirety. In some embodiments, ceDNA vectors for producing antibodies or fusion proteins as disclosed herein can be produced using insect cells, as described herein. In alternative embodiments, ceDNA vectors for producing antibodies or fusion proteins as disclosed herein can be produced synthetically, and in some embodiments, by cell-free methods, as disclosed in International Application No. PCT / US19 / 14122, filed January 18, 2019, which is incorporated herein by reference in its entirety.
[0294] As described herein, in one embodiment, a ceDNA vector for producing an antibody or fusion protein can be obtained, for example, by a process comprising: a) incubating a population of host cells (e.g., insect cells) harboring a polynucleotide expression construct template (e.g., ceDNA-plasmid, ceDNA-bacmid, and / or ceDNA-baculovirus) under conditions effective to induce production of the ceDNA vector in the host cells in the presence of Rep proteins, and for a time period sufficient for the host cells to lack viral capsid-encoding sequences; and b) harvesting and isolating the ceDNA vector from the host cells. The presence of Rep proteins induces replication of the vector polynucleotide with modified ITRs to produce the ceDNA vector in the host cells. However, viral particles (e.g., AAV virions) are not expressed. Therefore, there are no size limitations, such as those naturally imposed by AAV or other viral vectors.
[0295] The presence of a ceDNA vector isolated from a host cell can be confirmed by digesting the DNA isolated from the host cell with a restriction enzyme that has a single recognition site on the ceDNA vector and analyzing the digested DNA material on a non-denaturing gel to confirm the presence of a characteristic linear, continuous DNA band compared to linear, discontinuous DNA.
[0296] In yet another aspect, the present invention provides the use of host cell lines that stably integrate a DNA vector polynucleotide expression template (ceDNA template) into their own genome in the production of non-viral DNA vectors, for example, as described in Lee, L. et al. (2013) Plos One 8(8):e69879. Preferably, Rep is added to the host cells at an MOI of about 3. When the host cell line is a mammalian cell line, such as HEK293 cells, the cell line may have a stably integrated polynucleotide vector template, and a second vector, such as a herpesvirus, may be used to introduce Rep proteins into the cells, allowing for excision and amplification of ceDNA in the presence of Rep and a helper virus.
[0297] In one embodiment, the host cells used to generate ceDNA vectors for the production of antibodies or fusion proteins described herein are insect cells, and baculovirus is used to deliver both the polynucleotide encoding the Rep protein and the non-viral DNA vector polynucleotide expression construct template for ceDNA, e.g., as described in Figures 4A-4C and Example 1. In some embodiments, the host cells are engineered to express the Rep protein.
[0298] The ceDNA vector is then harvested and isolated from the host cells. The time for harvesting the ceDNA vector described herein from the cells can be selected and optimized to achieve high-yield production of the ceDNA vector. For example, the harvest time can be selected taking into account cell viability, cell morphology, cell growth, etc. In one embodiment, the cells are grown under sufficient conditions and harvested after a sufficient amount of time has passed since baculovirus infection to produce the ceDNA vector, but before a portion of the cells begin to die due to the toxicity of the baculovirus. The DNA vector can be isolated using a plasmid purification kit such as the Qiagen Endo-Free Plasmid Kit. Other methods developed for plasmid isolation can also be adapted for DNA vectors. Generally, any nucleic acid purification method can be employed.
[0299] DNA vector can be purified by any means known to those skilled in the art for DNA purification.In one embodiment, ceDNA vector is purified as DNA molecule.In another embodiment, ceDNA vector is purified as exosome or microparticle.
[0300] The presence of a ceDNA vector for the production of an antibody or fusion protein can be confirmed by digesting the vector DNA isolated from the cells with a restriction enzyme that has a single recognition site on the DNA vector, and analyzing both the digested and undigested DNA material using gel electrophoresis to confirm the presence of characteristic linear, continuous DNA compared to linear, discontinuous DNA. Figures 4C and 4D show one embodiment for identifying the presence of a closed-ended ceDNA vector produced by the processes herein.
[0301] B.ceDNA Plasmid A ceDNA-plasmid is a plasmid used in the later production of a ceDNA vector for the production of an antibody or fusion protein. In some embodiments, a ceDNA-plasmid can be constructed using known techniques to provide at least (1) a 5'ITR sequence, (2) an expression cassette containing cis-regulatory elements, such as a promoter, an inducible promoter, a regulatory switch, an enhancer, and the like, and (3) a modified 3'ITR sequence (the 3'ITR sequence is asymmetric relative to the 5'ITR sequence) as operably linked components in the transcription direction. In some embodiments, the expression cassette flanked by ITRs contains a cloning site for introducing an exogenous sequence. The expression cassette replaces the rep and cap coding regions of the AAV genome.
[0302] In one aspect, a ceDNA vector for antibody or fusion protein production is derived from a plasmid, referred to herein as a "ceDNA-plasmid," that encodes, in that order, a first adeno-associated virus (AAV) inverted terminal repeat (ITR), an expression cassette containing a transgene, and a mutated or modified AAV ITR, wherein the ceDNA-plasmid lacks the AAV capsid protein coding sequence. In an alternative embodiment, a ceDNA-plasmid encodes, in that order, a first (or 5') modified or mutated AAV ITR, an expression cassette containing a transgene, and a second (or 3') modified AAV ITR, wherein the ceDNA-plasmid lacks the AAV capsid protein coding sequence, and the 5' and 3' ITRs are symmetrical with respect to each other. In an alternative embodiment, the ceDNA-plasmid encodes, in that order, a first (or 5') modified or mutated AAV ITR, an expression cassette containing a transgene, and a second (or 3') mutated or modified AAV ITR, wherein the ceDNA-plasmid lacks the AAV capsid protein coding sequence, and the 5' and 3' modified ITRs have the same modifications (i.e., they are reverse complementary or symmetrical to each other).
[0303] In further embodiments, the ceDNA-plasmid system lacks viral capsid protein coding sequences (i.e., it lacks not only the AAV capsid gene but also the capsid gene of other viruses). Additionally, in certain embodiments, the ceDNA-plasmid also lacks the AAV Rep protein coding sequence. Thus, in preferred embodiments, the ceDNA-plasmid lacks functional AAV cap and AAV rep genes (GG-3' in the case of AAV2) as well as a variable palindrome sequence that allows hairpin formation.
[0304] The ceDNA-plasmids of the present invention can be generated using the native nucleotide sequence of the genome of any AAV serotype known in the art. In one embodiment, the ceDNA-plasmid backbone is derived from the AAV1, AAV2, AAV3, AAV4, AAV5, AAV5, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAV-DJ, and AAV-DJ8 genomes. See, for example, Kotin and Smith, The Springer, available at NCBI:NC002077, NC001401, NC001729, NC001829, NC006152, NC006260, NC006261, URLs maintained by Springer. Index of Viruses (www web address: oesys.springer.de / viruses / database / mkchapter.asp?virID=42.04) (Note - references to a URL or database refer to the URL or database contents as of the effective filing date of this application). In a specific embodiment, the ceDNA-plasmid backbone is derived from the AAV2 genome. In another specific embodiment, the ceDNA-plasmid backbone is a synthetic backbone engineered to include 5' and 3' ITRs from one of these AAV genomes.
[0305] The ceDNA-plasmid may optionally contain a selectable or selectable marker for use in establishing a ceDNA vector-producing cell line. In one embodiment, the selectable marker may be inserted downstream (i.e., 3') of the 3' ITR sequence. In another embodiment, the selectable marker may be inserted upstream (i.e., 5') of the 5' ITR sequence. Suitable selectable mar...
Claims
[Claim 1] A capsid-free closed-end DNA (ceDNA) vector, comprising: A ceDNA vector comprising at least one heterologous nucleotide sequence between flanking inverted terminal repeats (ITRs), the at least one heterologous nucleotide sequence encoding at least one antibody and / or fusion protein.
